

References

- Abbeck D, Ring J, editors. Atopisches Ekzem im Kindesalter. Neurodermitis – das zeitgemäße Management. Darmstadt: Steinkopff; 2002.
- Abels C, Brocks E. Therapie des atopischen Ekzems. *Hautarzt*. 2006;57:711–25.
- Adachi J, Endo K, Fukuzumi T, Tanigawa N, Aoki T. Increasing incidence of streptococcal impetigo in atopic dermatitis. *J Dermatol Sci*. 1998;17:45–53.
- Ader R, Felton D, Cohen N, editors. Psychoneuroimmunology. 3rd ed. London: Academic Press; 1991.
- Aetios von Amida. Aetii medici Graeci contractae ex veteribus medicinae tetrabiblos. Basel; 1542.
- Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, Klotz M, Werfel T, Herz U, et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. *J Allergy Clin Immunol*. 2004;113:565–7.
- Akdis M, Akdis C. IgE class switching and cellular memory. *Nat Immunol*. 2012;13:312–4.
- Akdis M, Simon HU, Weigl L, Kreyden O, Blaser K, Akdis CA. Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. *J Immunol*. 1999;163:466–75.
- Akdis C, Akdis M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. *Curr Opin Immunol*. 2000;12:641–6.
- Akdis CA, Blaser K, Akdis M. Genes of tolerance. *Allergy*. 2004;59:897–913.
- Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T, European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *J Allergy Clin Immunol*. 2006;118:152–69. Review. Erratum *J Allergy Clin Immunol* 2006;118:724.
- Akhavan A, Rudikoff D. The treatment of atopic dermatitis with immunosuppressive agents. *Clin Dermatol*. 2003;21:225–40.
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006;124:783–801.
- Alessandrini F, Schulz H, Takenaka S, et al. Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung. *J Allergy Clin Immunol*. 2006;117:824–30.
- Alexander F. Psychosomatische Medizin. Berlin: De Gruyter; 1971.
- Alfvén T, Braun-Fahrlander C, Brunekreef B, von Mutius E, Riedler J, Scheynius A, et al. Allergic disease and atopic sensitization in children related to farming and anthroposophic lifestyle – the PARSIFAL Study. *Allergy*. 2006;61:414–21.
- Alm JS, Swartz J, Lilja G, Scheynius A, Pershagen G. Atopy in children of families with an anthroposophic lifestyle. *Lancet*. 1999;353:1485–8.
- Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. *Br J Dermatol*. 2004;151 Suppl 70:3–27.
- Aly R. Bacteriology of atopic dermatitis. *Acta Dermatol Venereol Suppl*. 1980;92:16–8.
- Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. *Arch Dermatol*. 1977;113:780–2.
- Amon U, Menz U, Wolff HH. Investigations on plasma levels of mast cell mediators in acute atopic dermatitis. *J Dermatol Sci*. 1994;7:63–7.
- Andersson AC, Lindberg M, Loden M. The effect of two urea-containing creams on dry eczematous skin in atopic patients. I. Expert, patient and instrumental evaluation. *J Dermatolog Treat*. 1999;10(3):165–9.
- Anonymous. Alphaderm (“Crème aus dem Jenseits”). Erhältlich bei: Commings, POB 1143, D-33748 Schloss Holte-Stukenbrok; 1992.
- Arbeitsgemeinschaft Neurodermitisschulung, 2005: Qualitätsmanagement in der Neurodermitisschulung von Kindern und Jugendlichen sowie ihren Eltern (über: www.neurodermitisschulung.de).
- Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *J Invest Dermatol*. 2007;127:808–16.

- Armstrong NC, Ernst E. The treatment of eczema with Chinese herbs: a systematic review of randomized clinical trials. *Br J Clin Pharmacol*. 1999;48:262–4.
- Arshad SH. Exposure to indoor allergens in the development of asthma and allergy. *Curr Allergy Asthma Rep*. 2003;3:115–20.
- Artik S, Ruzicka T. Complementary therapy for atopic eczema and other allergic skin diseases. *Dermatol Ther*. 2003;16:150–63.
- Asher M, Montefort S, Björkstén B, et al. Group IPTS. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and two repeat multicountry cross-sectional surveys. *Lancet*. 2006;368:733–43.
- Ashida Y, Denda M, Hirao T. Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. *J Invest Dermatol*. 2001;116:261–5.
- Atherton DJ, Sewell M, Soothill JF, Wells RS, Chilvers CE. A double-blind controlled crossover trial of an antigen-avoidance diet in atopic eczema. *Lancet*. 1978;1:401–3.
- Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy with vitamin D₃ analogues, corticosteroids and their two compound formulations. *JDDG*. 2014;12:667–82.
- Augustin M, Zschocke I, Buhrke U. Attitudes and prior experience with respect to alternative medicine among dermatological patients: the Freiburg questionnaire on attitudes to naturopathy (FAN). *Forsch Komplementarmed*. 1999a;6:26–9.
- Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Lebensqualität bei Hauterkrankungen: Vergleich verschiedener Lebensqualitäts-Fragebögen bei Psoriasis und atopischer Dermatitis. *Hautarzt*. 1999b;50:715–22.
- Augustin M, Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U. Validation and clinical results of the FLQA-d, a Quality of Life Questionnaire for patients with chronic skin disease. *Dermatol Psychosom*. 2000;1–7.
- Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin Immunol*. 2013;132:110–7.
- Bager P, Arved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T, Petersen HW, Kristensen B, Thamsborg S, Roepstorff A, Kapel C, Melbye M. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. *J Allergy Clin Immunol*. 2010;125:123–30.
- Bair B, Dodd J, Heidelberg K, Krach K. Cataracts in atopic dermatitis: a case presentation and review of the literature. *Arch Dermatol*. 2011;147:585–9.
- Bandmann HJ. Ekzem und ekzematoide Dermatitiden im Kindesalter. In: Miescher G, Storck H, editors. *Handbuch der Haut- und Geschlechtskrankheiten* 8I. (Johansson), *Ergänzungswerk v. A. Marchionini*. Bd II/1, *Entzündliche Dermatosen*. Berlin: Springer; 1962. p. 320–68.
- Bannister MJ, Freeman S. Adult-onset atopic dermatitis. *Australas J Dermatol*. 2000;41:225–8.
- Barbarot S, Bernier C, Deleuran M, De Raeve L, Eichenfield L, El Hachem M, et al. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. *Pediatr Dermatol*. 2013;30:199–206.
- Bard S, Paravisini A, Avilés-Izquierdo JA, Fernandez-Cruz E, Sánchez-Ramón S. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. *Arch Dermatol*. 2008;144:1662–3.
- Bauer CP. Hypoallergene Babyahrung und Atopieprävention. In: Behr-Völtzer C, Hamm M, Vieluf D, Ring J, editors. *Diät bei Nahrungsmittelallergien und -intoleranzen*. 4th ed. Munich: Urban & Vogel; 2008. p. 59–65.
- Bauer CP. Hausstaubmilbenallergie-Aspekte zur Sensibilisierung und Allergenreduktion. *Pädiatr Allergologie Klin Prax*. 1985;1:6–13.
- Baur X, Aschauer H, Dewair M, et al. Relationship between primary structures and allergenicity of asthma-inducing insect proteins (chironomid hemoglobins). *Chest*. 1982;82:254–9.
- Baurecht H, Irvine AD, Novak N, et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. *J Allergy Clin Immunol*. 2007;120:1406–12.
- Beck J. *Praxis der kognitiven Therapie*. Weinheim: Psychologische Verlags Union; 1999.
- Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med*. 2014;371:130–9.
- Becker D, Langer E, Seemann M, Seemann G, Fell I, Saloga J, Grabbe S, von Stebut E. Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. *PLoS One*. 2011;6:e20566.
- Bedi M, Shenefelt P. Herbal therapy in dermatology. *Arch Dermatol*. 2002;138:232–42.
- Beetham WP. Atopic cataracts. *Arch Ophthalmol*. 1940;24:21–37.
- Behne MJ, Barry NP, Hanson KM, Aronchik I, Clegg RW, Gratton E, Feingold K, Holleran WM, Elias PM, Mauro TM. Neonatal development of the stratum corneum pH gradient: localization and mechanisms leading to emergence of optimal barrier function. *J Invest Dermatol*. 2003;120(6):998–1006.
- Behrendt H, Becker WM. Localization, release and bioavailability of pollen allergens: the influence of environmental factors. *Curr Opin Immunol*. 2001;13:709–15.
- Behrendt H, Ring J. Histamine, antihistamines and atopic eczema. *Clin Exp Allergy*. 1990;20 Suppl 4:25–30.
- Behrendt H, Ring J. Genetik und Umwelteinflüsse in der. In: Heptt W, Bachert C, editors. *Epidemiologie von Allergien*. Stuttgart: Thieme; 2011. p. 1–12.
- Behrendt H, Krämer U, Dolgner R, Hinrichs J, Willer H, Hagenbeck H, Schlipkötter HW. Elevated levels of total serum IgE in East German children: atopy, parasites, or pollutants? *Allergo J*. 1993;2:31–40.

- Behrendt H, et al. Der Rat von Sachverständigen für Umweltfragen (SRU). Sondergutachten: Umwelt und Gesundheit. Stuttgart: Metzler-Peschel; 1999.
- Behrens T, Taeger D, Maziak W, Duhme H, Rzehak P, Weiland SK, Keil U. Self-reported traffic density and atopic disease in children. Results of the ISAAC Phase III survey in Muenster, Germany. *Pediatr Allergy Immunol.* 2004;15:331–9.
- Behr-Völtzer C, Hamm M, Vieluf D, Ring J, editors. Diät bei Nahrungsmittelallergien und –intoleranzen. 4th ed. Munich: Urban und Vogel; 2008.
- Belloni B, Ziai M, Lim A, Lemerrier B, Sbornik M, Weidinger S, Andres C, Schnopp C, Ring J, Hein R, Ollert M, Mempel M. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. *J Allergy Clin Immunol.* 2007;120:1223–5.
- Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. *Br J Dermatol.* 2001;144(3):638–9.
- Benveniste J, Ducot B, Spira A. Memory of water revisited. *Nature.* 1994;370:322.
- Benveniste J, Arnoux B, editors. Platelet-activating factor and structurally related ether-lipids. *Inserm Symp* 23. Amsterdam: Elsevier; 1981.
- Bergmann KC, Ring J, editors. History of allergy. Basel: Karger; 2014.
- Bergmann RL, Bergmann KE, Lau-Schadendorf S, et al. Atopic diseases in infancy. The German multicenter atopy study (MAS-90). *Pediatr Allergy Immunol.* 1994;5:19–25.
- Bergstresser PR, Takashima A, editors. Gamma-delta T cells. *Chemical Immunology* 1979. Basel: Karger; 2001.
- Bernard A. Eczéma et gastrite hypertrophique. *J Sc Méd Lille.* 1953;71:219–22.
- Berth-Jones J, Graham-Brown RA. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. *Lancet.* 1993;341:1557–60.
- Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis randomized double blind, parallel group study. *BMJ.* 2003;326:1367.
- Besnier E. Première note et observations préliminaires pour servir d'introduction à l'étude diathésique. *Ann Dermatol Syphiligr.* 1892;4:634.
- Besnier E. *La Pratique Dermatologique*, Vol 2; 1901. p. 3
- Beyer K, Wahn U. Is atopic dermatitis predictable? *Pediatr Allergy Immunol.* 1999;10:7–10.
- Bharati A, Yesudian PD. Positivity of iron studies in pruritus of unknown origin. *J Eur Acad Dermatol Venereol.* 2008;22:616–8.
- Bhavani Meduri N, Vanderriff T, Rasmussen H, Jacobs H. Phototherapy in the management of atopic dermatitis: a systemic review. *Photodermatol Photoimmunol Photomed.* 2007;23:106–22.
- Bieber T. Atopic dermatitis. *N Engl J Med.* 2008;358:1483–94.
- Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. *Allergy.* 2012;67:1475–82.
- Bieber T. Many ways lead to Rome – a glance at the multiple immunological pathways underlying atopic dermatitis. *Allergy.* 2013;68:957–8.
- Bieber T, Leung DM, editors. Atopic dermatitis. New York: Marcel Dekker; 2002.
- Bieber T, Ring J. Terfenadin und Kraftfahrzeugführung. Eine placebokontrollierte Doppelblindstudie zum Einfluss verschiedener Antihistaminika auf das Fahrverhalten. *Med Klin.* 1987;82:683–6.
- Bieber T, Rieger A, Neuchrist C, Prinz JC, Rieber EP, Boltz-Nitulescu G, Scheiner O, Kraft D, Ring J, Stingl G. Induction of FCεR2/CD23 on human epidermal Langerhans-cells by human recombinant IL4 and IFN. *J Exp Med.* 1992;170:309–14.
- Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, Hanau D, de la Salle C. Human Langerhans cells express the high affinity receptor for IgE (FCεR1). *J Exp Med.* 1995;175:1285–90.
- Biedermann T. Dissecting the role of infections in atopic dermatitis. *Acta Derm Venereol.* 2006;86:99–109. Review.
- Bienenstock J, Kunze W, Forsythe P. Microbiota and the gut-brain axis. *Nutr Rev.* 2015;73 Suppl 1:28–31. doi:10.1093/nutrit/nuv019.
- Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, et al. Standardization of food challenges in patients with immediate reactions to foods – position paper from the European Academy of Allergy and Clinical Immunology. *Allergy.* 2004;59:690–7.
- Bisgaard H, Simpson A, Palmer CN, Bønnelykke K, Mclean I, Mukhopadhyay S, et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. *PLoS Med.* 2008;5, e131.
- Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. *Br J Dermatol.* 2011;166:853–60.
- Björkstén B. Allergy priming in early life. *Lancet.* 1999;353:167–8.
- Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. *J Allergy Clin Immunol.* 2001;108:516–20.
- Blaser K, editor. T cell regulation in allergy, asthma and atopic skin disease. Basel: Karger; 2008.
- Blumenthal F, Jaffe K. Ekzem und Idiosynkrasie. Berlin: Karger; 1933.
- Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F, Gelmetti C. Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. *J Eur Acad Dermatol Venereol.* 2009;23:751–9.
- Bockelbrink A, Heinrich J, Schäfer I, Zutavern A, Borte M, Herbarth O, Schaaf B, von Berg A, Schäfer T, for the LISA Study Group. Atopic eczema in children: another harmful sequel of divorce. *Allergy.* 2006;61:1397–402.
- Bode HH. Dwarfism following long-term topical corticosteroid therapy. *JAMA.* 1980;244:813–4.

- Bode U, Ring J, Neubert U. Intrakutantestungen und bakteriologische Untersuchungen bei Patienten mit atopischem Ekzem. *Allergologie*. 1982;5:259–61.
- Boehncke WH, Zollner TM. Die Rolle bakterieller Superantigene in der Pathophysiologie der Haut. *Hautarzt*. 1999;50:91–7.
- Boettger MK, Bär K-J, Dohrmann A, Müller H, Mertins L, Brockmeyer NH, Agelink MW. Increased vagal modulation in atopic dermatitis. *J Dermatol Sci*. 2009;53:55–9.
- Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DYM. Effects of cefuroxime axetil on *Staphylococcus aureus* colonization and superantigen production in atopic dermatitis. *J Allergy Clin Immunol*. 2001;108:651–2.
- Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, Heinz V, Kreilinger D, Spielberger BD, Schimke-Marques LF, Sawalle-Belohradsky J, Belohradsky BH, Przybilla B, Schaub B, Wollenberg A, Renner ED. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. *Allergy*. 2014;69:943–53.
- Borelli S. Untersuchungen zur Psychosomatik des Neurodermitikers. *Hautarzt*. 1950;1:250–6.
- Borelli S. Probleme der Klimatherapie bei Dermatosen. *MünchMed Wschr*. 1969;35:1709–17.
- Borelli S. Climate therapy of skin diseases. *Ther Umsch*. 1972;29:610–6.
- Borelli S. Die Dermatologische Klinik und Poliklinik am Biederstein der Technischen Universität München und die Deutsche Klinik Alexanderhaus Davos. Munich: Lindner; 1995.
- Borelli S, Chlebarov S. Änderungen der Histamin-Reagibilität der Haut nach Hochgebirgs-Klimabehandlung. *MünchMed Wschr*. 1966;11:592–6.
- Borelli S, Schnyder UW. Neurodermitis constitutionalis atypica. II. Ätiologie, Pathophysiologie, Pathogenese, Therapie. In: Miescher G, Storck H, editors. *Handbuch der Haut- und Geschlechtskrankheiten, Entzündliche Dermatosen I*, vol. 2/1. Berlin/Göttingen/Heidelberg: Springer; 1962. p. 254–319.
- Borelli S, Michailov P, Ene-Popescu C. Die Veränderungen der allergisch-mediatorischen Reaktivität bei Neurodermitis-constitutionalis-Kranken nach Höhenklimatherapie. *Hautarzt*. 1967;18:456–8.
- Bork K, Hoede N. Juvenile papulöse Dermatitis. *Hautarzt*. 1978;29:216–9.
- Bornhoevd EC, Schuller E, Bieber T, Wollenberg A. Immunsuppressive Makrolide und ihr Einsatz in der Dermatologie. *Hautarzt*. 2000;51:646–54.
- Bos JD. Atopiform dermatitis. *Br J Dermatol*. 2002;147:426–9.
- Bos JD, Van Leent EJ, Sillevs Smitt JH. The millennium criteria for the diagnosis of atopic dermatitis. *Exp Dermatol*. 1998;7:132–9.
- Bosse KA. Psychosomatische Gesichtspunkte bei der Betreuung atopischer Ekzematiker. *Z Hautkr*. 1990;65:543–5.
- Bosse KA, Gieler U, editors. *Seelische Faktoren bei Hautkrankheiten*. Bern: Huber; 1987.
- Bourke JF, Berth-Jones J, Holder J, Graham-Brown RA. A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses. *Br J Dermatol*. 1996;134:777–9.
- Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiological studies. *Am J Respir Crit Care Med*. 2007;175:822–8.
- Boralevi F, Saint Aroman M, Delarue A, Raudsepp H, Kaszuba A, Bylaite M, Tiplica GS. Long-term emollient therapy improves xerosis in children with atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2014;28:1456–62.
- Bovet D, Staub AM. Action protectrice des éthers-phénoliques au cours de l'intoxication histaminique. *C R Soc Biol Paris*. 1934;124:547–9.
- Bozek A, Fisher A, Filipowska B, Mazur B, Jarzab J. Clinical features and immunological markers of atopic dermatitis in elderly patients. *Int Arch Allergy Immunol*. 2012;157:372–8.
- Bradley M, Soderhall C, Wahlgren CF, Luthman H, Nordenskjöld M, Kockum I. The Wiskott-Aldrich syndrome gene as a candidate gene for atopic dermatitis. *Acta Derm Venereol*. 2001;81:340–2.
- Braun-Fahrländer C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. *N Engl J Med*. 2002;347:869–77.
- Braun-Fahrländer C, Gassner M, Grize L, et al., SCARPOL TEAM. No further increase in asthma, hay fever and atopic sensitisation in adolescents living in Switzerland. *Eur Respir J*. 2004;23:407–13.
- Braun-Falco O, Korting HC. Syndets in the treatment of atopic eczema. In: Ruzicka T, Ring J, Przybilla B, editors. *Handbook of atopic eczema*. Berlin/Heidelberg/New York: Springer; 1991. p. 356–63.
- Braun-Falco O, Ring J. Zur Therapie des atopischen Ekzems. *Hautarzt*. 1984;35:447–54.
- Braun-Falco O, Ryckmanns F, Heilgemeir GP, Ring J. Zum Syndrom: Unkämmbare Haare. *Hautarzt*. 1982;33:366–72.
- Breit R. Neurodermitis (Dermatitis atypica) im Kindesalter. *Z Hautkrankh*. 1997;2(Suppl):72–82.
- Bremmer MS, Bremmer SF, Baig-Lewis S, Simpson EL. Are biologics safe in the treatment of atopic dermatitis? *J Am Acad Dermatol*. 2009;61:666–76.
- Brennkmeijer EE, Schram ME, Leeftang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. *Br J Dermatol*. 2008;158:754–65.
- Bresser H. Allergietestung mittels Elektroakupunktur nach Dr. Voll. *Hautarzt*. 1993;46:408–9.
- Breuer K, Kapp A. Stationäre medizinische Rehabilitation bei erwachsenen Patienten mit atopischer Dermatitis. *Hautarzt*. 2006;57:592–602.
- Broberg A, Augustsson A. Atopic dermatitis and melanocytic naevi. *Br J Dermatol*. 2000;142:306–9.
- Broberg A, Faergemann J. Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomized study. *Acta Derm Venereol*. 1995;75:46–9.
- Brockow K, Ring J. Nahrungsmittel als Auslöser einer Anaphylaxie. *Allergologie*. 2008;31:286–92.

- Brockow K, Abeck D, Ring J. Die systemische Therapie im Behandlungskonzept des atopischen Ekzems. *Hautarzt*. 1999a;50:323–9.
- Brockow K, Grabenhorst P, Abeck D, et al. Effect of gentian violet, corticosteroid and tar preparations in *Staphylococcus-aureus*-colonized atopic eczema. *Dermatology*. 1999b;199:231–6.
- Brocq L. L'eczéma considéré comme une réaction cutanéé. *Ann Dermatol Syph*. 1903;4:172.
- Brocq L. Conception générale des dermatoses, nouvelle note sur leur classification. *Ann Dermatol Syphilol*. 1927;8:65.
- Bruijnzeel-Koomen CA, Mudde GC, Bruijnzeel PL. The presence of IgE molecules on epidermal Langerhans cells in atopic dermatitis and their significance for its pathogenesis. *Allerg Immunol (Paris)*. 1989;90 Suppl 1:51–6.
- Bruijnzeel PL, Kuijper PH, Kapp A, Warringa RA, Betz S, Bruijnzeel-Koomen CA. The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis. *Clin Exp Allergy*. 1993;23:97–109.
- Bruijnzeel-Koomen CAFM, Van Wichem DF, Spry CJF, Venge P, Bruynzeel PLB. Active participation of eosinophils in patch test reactions to inhalant allergens in patients with atopic dermatitis. *Br J Dermatol*. 1988;118:229–38.
- Büchau AS, MacLeod DT, Morizane S, Kotol PF, Hata T, Gallo RL. Bcl-3 acts as an innate immune modulator by controlling antimicrobial responses in keratinocytes. *J Invest Dermatol*. 2009;129:2148–55.
- Buckley RH, Becker WG. Abnormalities in the regulation of human IgE synthesis. *Immunol Rev*. 1978;41:288–314.
- Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. *Allergy*. 2010;65:805–21.
- Buhl R, Hanf G, Soler M, Bensch G, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. *Eur Resp J*. 2002;20:1088–94.
- Buhles N, Wehrmann J, Amon K. Dermatologische stationäre Rehabilitation bei atopischer Dermatitis Erwachsener. *J Deutsch Derm Ges*. 2003;3:238–41.
- Bunikowski R, Mielke M, Skarabis H, et al. Prevalence and role of serum IgE antibodies to the *Staphylococcus aureus*-derived superantigens SEA and SEB in children with atopic dermatitis. *J Allergy Clin Immunol*. 1999;103:119–24.
- Bunikowski R, Staab D, Kussebi F, Brautigam M, Weidinger G, Renz H, Wahn U. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. *Pediatr Allergy Immunol*. 2001;12:216–23.
- Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. *J Allergy Clin Immunol*. 2008;121:1344–50.
- Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. *Psychother Psychosom*. 2001;70:6–16.
- Buslau M, Thaci D. Atopic dermatitis: borage oil for systemic therapy. *Z Dermatol*. 1996;182:131–6.
- Busse WW, Lantis SOH. Decrease H2 histamine granulocyte response in atopic eczema. *J Invest Dermatol*. 1979;73:184–9.
- Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? *J Allergy Clin Immunol*. 2006;118:1292–8.
- Bussmann C, Weidinger S, Novak N. Genetics of atopic dermatitis. *JDDG*. 2011;9:670–6.
- Butler JM, Ebert M, Chan M, Stevens SR, Szobieszczuk D, Hanifin JM. Basophil histamine release in atopic dermatitis and its relationship to disordered cyclic nucleotide metabolism. *Acta Derm Venereol [Suppl] (Stockh)*. 1985;114:55–61.
- Camargo Jr CA, Ganmaa D, Sidbury R, Erdenedelger K, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. *J Allergy Clin Immunol*. 2014;134:831–5.
- Cap F. Bemerkungen eines Physikers zur Bioresonanz. *Allergologie*. 1995;18:235–7.
- Caputo R, Vanotti P, Bertani E. Netherton's syndrome in two adult brothers. *Arch Dermatol*. 1984;120:220–2.
- Carlsson CP, Wallengren J. Therapeutic and experimental therapeutic studies on acupuncture and itch: review of the literature. *J Eur Acad Dermatol Venereol*. 2010;24:1013–6.
- Caruso C, Gaeta F, Valluzzi RL, Romano A. Omalizumab efficacy in a girl with atopic eczema. *Allergy*. 2010;65:278–9.
- Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. *Int J Immunopathol*. 2006;19:237–40.
- Cavani A, Albanese C, Traidl C, Sebastiani S, Girolomoni G. Effector and regulatory T cells in allergic contact dermatitis. *Trends Immunol*. 2001;22:118–20.
- Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. *J Invest Dermatol*. 1993;100:681–4.
- Charman CR, Williams HC. Outcome measures of disease severity in atopic eczema. *Arch Dermatol*. 2000;136:763–9.
- Chatzi L, Torrent M, Romieu I, Garcia-Esteban R, Ferrer C, Vioque J, Kogevinas M, Sunyer J. Mediterranean diet in pregnancy is protective for wheeze and atopy in childhood. *Thorax*. 2008;63:507–13.
- Chen W, Mempel M, Schober W, Behrendt H, Ring J. Gender differences, sex hormones and immediate hypersensitivity. *Allergy*. 2008;63:1418–27.
- Cheng H-M, Chiang L-C, Jan Y-M, Chen G-W. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. *Int Arch Allergy Immunol*. 2011;155:141–8.

- Chida Y, Hamer M, Steptow A. A bidirectional relationship between psychosocial factors and atopic disorders: A systematic review and metaanalysis. *Psychosom Med*. 2008;70:102–16.
- Christiansen JV, Gadborg E, Kleiter I, et al. Efficacy of bufexamac cream in skin diseases. A double-blind multicentre trial. *Dermatologica*. 1977;154:177–84.
- Church MK. Non-H1-receptor effects of antihistamines. *Clin Exp Allergy*. 1999;29 Suppl 3:39–48.
- Coca AF. Familial non-reaginic food allergy. Springfield: Charles C Thomas; 1943.
- Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. *J Immunol*. 1923;8:163–82.
- Coca AF, Grove E. Studies in hypersensitiveness. XIII. A study of the atopic reagins. *J Immunol*. 1925;10:445.
- Coffmann RL, von der Weid T. Multiple passways for the initiation of T helper 2 (Th2) responses. *J Exp Med*. 1997;185:373–5.
- Colcha W, Leuschner J, Leuschner F. The adverse effects of dark sulfonated shale oil following local and systemic administration. *Arzneimittelforschung*. 1994;44:844–9.
- Colver GB, Mortimer PS, Millard PR. The “dirty neck” – a reticulate pigmentations in atopics. *Clin Exp Dermatol*. 1987;12:1–4.
- Conroy MC, Adkinson NF, Lichtenstein LM. Measurement of IgE in human basophils; relation to serum IgE and anti-IgE-induced histamine release. *J Immunol*. 1977;118:1317–24.
- Cookson WO, Moffatt MF. The genetics of atopic dermatitis. *Curr Opin Allergy Immunol*. 2002;2:283–387.
- Cookson WOCM, Young RP, Sandford A, et al. Maternal inheritance of atopic IgE responsiveness chromosome 11q. *Lancet*. 1992;340:381–4.
- Cookson WO, Ubhi B, Lawrence R, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. *Nat Genet*. 2001;27:372–3.
- Corbo GM, Ferrante E, Macciochi B, Foresi A, De Angelis V, Fabbri L, Ciappi G. Bronchial hyperresponsiveness in atopic dermatitis. *Allergy*. 1989;44:595–8.
- Cork MJ. The importance of skin barrier function. *J Dermatol Treat*. 1997;8:S7–13.
- Cork MJ, Robinson D, Vasilopoulos Y, Ferguson A, Moustafa M, Mac Gowan A, Ward SJ, Tazi-Ahmini R. Predisposition to sensitive skin and atopic eczema. *Community Pract*. 2005;78:440–2.
- Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, MacGowan AL, Tazi-Ahmini R, Ward SJ. Epidermal barrier dysfunction in atopic dermatitis. *J Invest Dermatol*. 2009;129:1892–908.
- Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H₄ receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. *J Invest Dermatol*. 2010;130:1023–33.
- Cox L, Platts-Mills TA, Finegold I et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force. Report onomalizumab-associated anaphylaxis. *J Allergy Clin Immunol*. 2007;120:1373–7.
- Cramer C, Ranft U, Ring J, Möhrenschrager M, Behrendt H, Oppermann H, Wilhelm M, Krämer U. Allergic sensitization and disease in mother-child pairs from Germany: role of early childhood environment. *Int Arch Allergy Immunol*. 2007;143:282–9.
- Cramer R, Faith A, Hemmann S, Jaussi R, Ismail C, Menz G, Blaser K. Humoral and cell-mediated autoimmunity in allergy to *Aspergillus fumigatus*. *J Exp Med*. 1996;184:265–70.
- Czarnecka-Operacz M, Silny W. Specific immunotherapy in atopic dermatitis – four-year treatment in different age and airborne allergy type subgroups. *Acta Dermatovenerol Croat*. 2006;14(4):230–40.
- Czerny A. Die exsudative Diathese. *Jb Kinderheilk*. 1905;61:3–199.
- Dale HH, Laidlaw BP. The physiological action of β -Imidazolylethylamine. *J Physiol*. 1910;41:318.
- Darsow U, Sbornik M, Rombold S, Katzer K, von Krempelhuber A, Chaplin P, Baedeker N, Sobek V, Vollmar J, Rösch S, von Sonnenburg F, Behrendt H, Ring J. Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. (in prep).
- Darsow U, Ring J. Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. *Clin Exp Dermatol*. 2000;25:544–51.
- Darsow U, Vieluf U, Ring J. The atopy patch test: an increased rate of reactivity in patients who have an air-exposed pattern of atopic eczema. *Br J Dermatol*. 1996;135:182–6.
- Darsow U, Mautner VF, Bromm B, Scharein E, Ring J. Der Eppendorfer Juckreizfragebogen. *Hautarzt*. 1997a;48:730–3.
- Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumor necrosis factor- α) at the dermal-epidermal junction. *Br J Dermatol*. 1997b;137:415–7.
- Darsow U, Vieluf U, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. Atopy Patch Test Study Group. *J Am Acad Dermatol*. 1999;40:187–93.
- Darsow U, Drzezga A, Frisch M, Munz F, Weilke F, Bartenstein P, Schwaiger M, Ring J. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. *J Invest Dermatol*. 2000;115:1029–33.
- Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic using the “Eppendorf Itch Questionnaire”. *Int Arch Allergy Immunol*. 2001;124:326–31.
- Darsow U, Forer I, Ring J. Spezifische Hyposensibilisierung bei atopischem Ekzem. *Allergologie*. 2005;28:53–61.
- Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza A-M, Giusti F, Lübke J, Seidenari S, Ring J. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2010;24:317–28.
- Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. *Curr Allergy Asthma Rep*. 2011;11:277–83.

- Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza A-M, Giusti F, Lübke J, Seidenari S, Ring J, for the European Task Force on Atopic Dermatitis/EADV Eczema Task Force. Difficult to control atopic dermatitis. *WAO J.* 2013;6:1–5.
- David TJ. Short stature in children with atopic eczema. *Acta Derm Venereol Suppl.* 1989;144:41–4.
- David TJ, Cambridge GC. Bacterial infection and atopic eczema. *Arch Dis Child.* 1986;61:20–3.
- David TJ, Waddington E, Stanton RHJ. Nutritional hazards of elimination diets in children with atopic eczema. *Arch Dis Child.* 1984;59:323–5.
- David TJ, Wells FE, Sharpe TC, Gibbs AC, Devlin J. Serum levels of trace metals in children with atopic eczema. *Br J Dermatol.* 1990;122:485–9.
- Dawe RS. Ultraviolet A1 phototherapy. *Br J Dermatol.* 2003;148:626–37.
- De Benedetto A, Qualia CM, Baroody FM, Beck LA. Filaggrin expression in oral, nasal and esophageal mucosa. *J Invest Dermatol.* 2008;128:1594–7.
- De Benedetto A, Agnihotri R, McGirt LY, Bankova LG, Beck L. Atopic dermatitis: a disease caused by innate immune defects? *J Invest Dermatol.* 2009;129:14–30.
- de Weck AL. What can we learn from the allergic zoo? *Int Arch Allergy Immunol.* 1995;107:13–8.
- de Weck A. Memories: failures and dreams, One life, many dreams, vol. 1. Berlin: Pro Business; 2008.
- De Weert J, Timmerman L, Kint A. Alopecia areata and atopy. *Dermatologica.* 1984;168:224–9.
- Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. *Int J Dermatol.* 2014;53:1037–41.
- Degos R. *Dermatologie.* Paris: Flammarion; 1953.
- Deleuran M, Ellingsen AR, Paludan K, Schou C, Thestrup-Pedersen K. Purified Der p1 and p2 patch tests in patients with atopic dermatitis: evidence for both allergenicity and proteolytic irritancy. *Acta Derm Venereol.* 1998;78:241–3.
- Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. *J Am Acad Dermatol.* 2008;59(2):234–44. doi:10.1016/j.jaad.2008.04.006. Epub 11 June 2008.
- Devillers ACA, de Waard-van der Spek FB, Mulder PGH, Oranje AP. Treatment of refractory atopic dermatitis using “wet-wrap” dressings and diluted corticosteroids: results of standardized treatment in both children and adults. *Dermatology.* 2002;204:50–5.
- Devos SA, van der Valk PG. The relevance of skin prick tests for *Pityrosporum ovale* in patients with head and neck dermatitis. *Allergy.* 2000;55:1056–8.
- Diebschlag W, Diebschlag B. *Hausstauballergien. Gesundheitliche und hygienische Aspekte.* 2nd ed. Munich: Herbert Utz; 2000.
- Diepgen TL. Atopic dermatitis – the role of social factors. *J Am Acad Dermatol.* 2001;45:44–8.
- Diepgen TL. Early treatment of the atopic child study group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatr Allergy Immunol.* 2002;13:278–86.
- Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. In: Kamerva L, Elsner P, Wahlberg JE, Maibach HI, editors. *Handbook of occupational dermatology.* Berlin: Springer; 2000. p. 3–16.
- Diepgen TL, Fartasch M, Hornstein OP. Kriterien zur Beurteilung der atopischen Hautdiathese. *Dermatosen.* 1991;39:79–83.
- Diepgen T, Fartasch M, Ring J, Scheewe S, Staab D, Szczepanski R, Werfel T, Wahn U, Gieler U. Neurodermitisschulung. *Hautarzt.* 2003;54:946–51.
- Diepgen TL, Andersen KE, Brandao FM, Bruze M, Bruynzeel DP, Frosch P, Goncalo M, Goossens A, Le Coz CJ, Rustemeyer T, White IR, Agner T. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. *Br J Dermatol.* 2009;160:323–58.
- Dieris-Hirche J, Gieler U, Kupfer JP, Milch WE. Suizidgedanken, Angst und Depression bei erwachsenen Neurodermitikern. *Hautarzt.* 2009;60:641–6.
- Diezel W, Gruner S, Anhalt GJ. ATPase positive epidermal Langerhans cells: inhibition of ATPase by ammonium bituminosulfonate (Ichthyol) and pix lithanthracis. *Hautarzt.* 1992;43:22–4.
- Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006–2011. *J Eur Acad Dermatol Venereol.* 2015;29:1071–81.
- Dittmar HC, Pflieger D, Schempp CM, Schöpf E, Simon JC. Vergleichsstudie Solebäder plus UVA/B versus UVA/B Monotherapie bei Patienten mit subakuter atopischer Dermatitis. *Hautarzt.* 1999;50:649–53.
- Dondi A, Ricci L, Neri I, Ricci G, Patrizi A. The switch from non-IgE-associated to IgE-associated atopic dermatitis occurs early in life. *Allergy.* 2013;68:259–60.
- Dorsch W, Ring J. Komplementärverfahren oder sogenannte Alternativmethoden in der Allergologie. *Allergo J.* 2002;11:163–70.
- Dorsch W, Sitzmann FC, editors. *Naturheilkunde in der Kinderheilkunde.* 2nd ed. Stuttgart: Hippokrates; 2001.
- Dorsch W, Ring J, Reimann HY, Geiger R. Mediator studies in skin blister fluids from parents with dual skin reactions. *J Allerg Clin Immunol.* 1982;70:236–44.
- Droitcourt C, Touboul GC, Ezzedine K, Cario-André M, de Verneuil H, Colin J, Taïeb A. A prospective study of filaggrin null mutations in keratoconus patients with or without atopic disorders. *Dermatology.* 2011;222:336–41.
- Drzimalla K, Wagner SA, Disch R, Borelli S. Longterm results after high-altitude climatotherapy in Davos – a follow-up study. *Präv Rehab.* 1999;11:18–27.
- Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, Brough HA, Phippard D, Basting M, Feeny M, Turcanu V, Sever ML, Gomez Lorenzo M, Plaut M, Lack G, LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. *N Engl J Med.* 2015;372(9):803–13. doi:10.1056/NEJMoa1414850. Epub 23 Feb 2015.

- Dubowitz V. Familial low birth weight dwarfism with an unusual facies and skin eruption. *J Med Genet.* 1965;2:12–7.
- Dunstan JA, Mori TA, Barden A, Beilin LJ, Holt PG, Calder PC, Taylor AL, Prescott SL. Effects of n-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. *Eur J Clin Nutr.* 2004;58:429–37.
- Dupré MMA, Christol B, Bonafe JL. La dermatite du toboggan (variant de “frictional lichenoid eruption in children”). *Bull Soc Fr Dermatol Syphiligr.* 1974;81:203–5.
- Dupré AS, Christol B, Bonafe JL, Lassere J. Orf and atopic dermatitis. *Br J Dermatol.* 1981;105:103–4.
- Dutoit G, Kats Y, Sasieni P, et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. *J Allergy Clin Immunol.* 2008;22:984–91.
- Eberlein B, Eicke C, Reinhardt H-W, Ring J. Adjuvante Therapie mit einer N-Palmitoylethanolamin-haltigen Creme bei Kindern mit atopischem Ekzem (ATOPA-Studie). *Akt Dermatol.* 2009a;35:339–41.
- Eberlein B, Gulyas AF, Schultz K, Lecheler J, Flögel S, Wolfmeyer C, Thiessen K, Jakob T, Schuster T, Hollweck R, Ring J, Behrendt H. Domestic allergens and endotoxin in three hospitals offering in-patient rehabilitation for allergic disease in the alpine mountain climate of Bavaria – The AURA study. *Int J Hyg Environ Health.* 2009b;212:21–6.
- Eberlein-König B, Spiegl A, Przybilla B. Change of skin roughness due to lowering air humidity in a climate chamber. *Acta Derm Venereol.* 1996;76:447–9.
- Eberlein-König B, Przybilla B, Kühnl P, Pechak J, Gebefügi I, Kleinschmidt J, Ring J. Influence of airborne nitrogen dioxide or formaldehyde on parameters of skin function and cellular activation in patients with atopic eczema and control subjects. *J Allergy Clin Immunol.* 1998;101:141–3.
- Eberlein-König B, Schäfer T, Huss-Marp J, Darsow U, Möhrenschrager M, Herbert O, Abeck D, Krämer U, Behrendt H, Ring J. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. *Acta Derm Venereol.* 2000;80(3):188–91.
- Edgren G. Prognose und Erblichkeitsmomente bei Eczema infantum. Eine klinisch-statistische Untersuchung von Allergieerscheinungen. *Acta Paediatr Scand.* 1943;30 Suppl 2:1–204.
- Ege MJ, Herzum I, Büchele G, et al., Protection Against Allergy Study Rural Environments (PASTURE) Study group. Prenatal exposure to a farm environment modifies atopic sensitization at birth. *J Allergy Clin Immunol.* 2008a;122:407–12.
- Ege MJ, Herzum I, Büchele G, Krauss-Etschmann S, Lauener RP, Roponen M, et al. Prenatal exposure to a farm environment modifies atopic sensitization at birth. *J Allergy Clin Immunol.* 2008b;122:407–12.
- Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase which may be involved in desquamation. *J Invest Dermatol.* 1993;101:200–4.
- Egle UT, König U, Dorsch W. Zur pathogenetischen Bedeutung früher psychosozialer Einflussfaktoren bei atopischer Dermatitis. *Allergologie.* 2002;25:291–9.
- Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis. A comparison of psychological and dermatological approaches to relapse prevention. *J Consult Clin Psychol.* 1995;63:624–35.
- Ehlken B, Möhrenschrager M, Kugland B, Berger K, Quednau K, Ring J. Krankheitskostenstudie bei Patienten mit atopischem Ekzem in Deutschland. *Hautarzt.* 2005;56:1144–51.
- Ehnert B, Lau-Schadendorf S, Weber A, Buettner P, Schou C, Wahn U. Reducing domestic dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. *J Allergy Clin Immunol.* 1992;90:135–8.
- Ehrlich P. Beiträge zur Kenntnis der der Anilinfärbungen und ihrer Verwendung in der mikroskopischen Technik. *Arch mikr Anat.* 1877;13:263, T-XXI, 5.
- Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M. Safety and efficacy of pimecrolimus (ASM 981) cream 1 % in the treatment of mild and moderate atopic dermatitis in children and adolescents. *J Am Acad Dermatol.* 2002;46:495–504.
- Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. *Pediatrics.* 1998;101:E8.
- Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. *Adv Lipid Res.* 1991;24:1–26.
- Ellinghaus D, Baurecht H, Esparza-Gordillo J, Rodríguez E, Matanovic A, Marenholz I, Hübner N, Schaarschmidt H, Novak N, Michel S, Maintz L, Werfel T, Meyer-Hoffert U, Hotze M, Prokisch H, Heim K, Herder C, Hirota T, Tamari M, Kubo M, Takahashi A, Nakamura Y, Tsoi LC, Stuart P, Elder JT, Sun L, Zuo X, Yang S, Zhang X, Hoffmann P, Nöthen MM, Fölster-Holst R, Winkelmann J, Illig T, Boehm BO, Duerr RH, Büning C, Brand S, Glas J, McAleer MA, Fahy CM, Kabesch M, Brown S, McLean WH, Irvine AD, Schreiber S, Lee YA, Franke A, Weidinger S. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. *Nat Genet.* 2013;45:808–12.
- Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz DR, Lebowitz M, Stevens SR, Whitaker-Worth DL, Cheng JW. Cost of atopic dermatitis and eczema in the United States. *J Am Acad Dermatol.* 2002;46:361–70.
- Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y, Eichenfield LF, Ferrandiz C, Gian-netti A, Hanifin J, Koo JY, Leung D, Lynde C, Ring J, Ruiz-Maldonado R, Saurat JH. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strat-egies. *Br J Dermatol.* 2003;148 Suppl 63:3–10.

- Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. *Br J Dermatol*. 2010;162:587–93.
- Elsner I, Kapp A. Regulation and modulation of eosinophil effector functions. *Allergy*. 1999;54:15–26.
- Emerson RM, Charman CR, Williams HC. The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. *Br J Dermatol*. 2000;142:288–97.
- Enders F, Przybilla B, Ring J, Burg G, Braun-Falco O. Epikutantestung mit einer Standardreihe. *Hautarzt*. 1988;39:779–86.
- Engman MF, Weiss RS, Engman ME. Eczema and environment. *Med Clin North Am*. 1936;20:651–63.
- Engst R, Vocks E. Hochgebirgsklimatherapie bei Dermatosen und Allergien. Wirkmechanismen, Ergebnisse und Einflüsse auf immunologische Parameter. *Rehabilitation*. 2000;39:215–22.
- Enk AH, Katz SI. Early events in the induction phase of contact sensitivity. *J Invest Dermatol*. 1992;99:9–41.
- Ernst E, Barnes J. Are homeopathic remedies effective for delayed-onset muscle soreness? A systemic review of placebo-controlled trials. *Perfusion*. 1998;11:4–8.
- Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind A, Ruschendorf F, Patone G, Rohde K, Marenholz I, Schulz F, Kerscher T, Hubner N, Wahn U, Schreiber S, Franke A, Vogler R, Heath S, Baurecht H, Novak N, Rodriguez E, Illig T, Lee-Kirsch MA, Ciechanowicz A, Kurek M, Piskackova T, Macek M, Lee YA, Ruether A. A common variant on chromosome 11q13 is associated with atopic dermatitis. *Nat Genet*. 2009;41:596–601.
- European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD Index. Consensus report of the European task force on atopic dermatitis. *Dermatology*. 1993;186:23, 31.
- Ewing CI, Ashcroft C, Gibbs AC, Jones GA, Connor PJ, David TJ. Flucloxacilin in the treatment of atopic dermatitis. *Br J Dermatol*. 1998;138:1022–9.
- Exl BM, Deland U, Secretin MC, Preysch U, Wall M, Shmerling DH. Improved general health status in an unselected infant population following an allergen-reduced dietary intervention programme: the ZUFF-STUDY-PROGRAMME. Part II: infant growth and health status to age 6 months. *Zug-FrauenFeld*. *Eur J Nutr*. 2000;39:145–56.
- Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. *Allergy*. 2013;68:974–82.
- Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, Ring J, Traidl-Hoffmann C. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. *J Invest Dermatol*. 2008;128:3640–5.
- Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H, Ring J, Traidl-Hoffmann C, Albanesi C. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. *J Allergy Clin Immunol*. 2009a;123:59–66.
- Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. *J Clin Invest*. 2009b;119:3573–85.
- Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, Grosber M, Pfab F, Schmidt-Weber CB, Mempel M, Hein R, Ring J, Cavani A, Eyerich K. Mutual antagonism of T cells causing psoriasis and atopic eczema. *N Engl J Med*. 2011;365(3):231–8.
- Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. *J Asthma*. 2014;51(7):669–76.
- Falk ES. Ketotifen in the treatment of atopic dermatitis. Results of a double-blind study. *Rev Eur Sci Med Pharmacol*. 1993;15(2):63–6.
- Falsh-Magnusson K, Kjellmann NI. Allergy prevention by maternal elimination diet during late pregnancy – a 5-year follow-up of a randomized study. *J Allergy Clin Immunol*. 1992;89:709–13.
- Farahmand S, Tien L, Hui X, Maibach HI. Measuring transepidermal water loss: a comparative in vivo study of condenser-chamber, unventilated-chamber and open-chamber systems. *Skin Res Technol*. 2009;15:392–8.
- Farin E, Gerdes N, Jäckel WH, Follert P, Klein K, Glattacker M. “Qualitätsprofile” von Rehabilitationskliniken als Modell der Qualitätsmessung in Einrichtungen des Gesundheitswesens. *Gesundh ökon Qual Manag*. 2003;8:191–204.
- Fartasch M, Diepgen TL, Hornstein OP. Atopic dermatitis – ichthyosis vulgaris – hyperlinear palms – an ultrastructural study. *Dermatologica*. 1989;178:202–5.
- Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. *Br J Dermatol*. 1975;93:303–12.
- Ferguson JE, Chalmers RJ, Rowlands DJ. Reversible dilated cardiomyopathy following treatment of atopic eczema with Chinese herbal medicine. *Br J Dermatol*. 1997;136:592–3.
- Ferié J, Dinkela A, Mbata M, Idindili B, Schmid-Grendelmeier P, Hatz C. Skin disorders among school children in rural Tanzania and an assessment of therapeutic needs. *Trop Doct*. 2006;36:219–21.
- Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. *Br J Dermatol*. 1996a;135:509–15.
- Finlay AY. Measures of the effect of severe atopic dermatitis on quality of life. *J Eur Acad Dermatol Venereol*. 1996b;7:149–59.
- Finlay AY. Quality of life measurement in dermatology: a practical guide. *Br J Dermatol*. 1997;136:305–14.
- Finlay AY, Khan GK. *Dermatology Life Quality Index (DLQI)*: a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19:210–6.
- Fisher MS, Kripke ML. Systemic alteration induced by UV light irradiation. *PNAS*. 1977;74:1688–92.
- Flohr C, Nagel G, Weinmayer G, Kleiner A, Strachan DP, Williams HC. Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema:

- lessons from the International Statistic of Asthma and Allergies in Childhood (ISAAC) phase two. *Br J Dermatol.* 2011;165:1280–9.
- Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. *J Allergy Clin Immunol.* 2013;132:774–774.e776.
- Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. *Allergy.* 2014;69:3–16.
- Fölster-Holst R, Kiene P, Brodersen JP, Christophers E. Dermatitis papulosa juvenilis. *Hautarzt.* 1996;47:129–31.
- Fölster-Holst R, Weichenthal M, Steinsland K, Polzhofer G, Christophers E. Eczema infantum and its prognosis. *Acta Derm Venereol.* 2004;84:410–2.
- Fölster-Holst R, Müller F, Schnopp N, Abeck D, Kreiselmaier I, Lenz T, von Rügen U, Schrezenmair J, Christophers E, Weichenthal M. Prospective, randomized controlled trial on *Lactobacillus rhamnosus* in infants with moderate to severe atopic dermatitis. *Br J Dermatol.* 2006a;155(6):1256–61.
- Fölster-Holst R, Pape M, Buss YL, et al. Low prevalence of the intrinsic form of atopic dermatitis among adult patients. *Allergy.* 2006b;61:629–33.
- Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcεpsilonRI. *Cutis.* 2007;80(1):38–40.
- Frei R, Lauener RP, Cramer R, et al. Microbiota and dietary interactions: an update to the hygiene hypothesis? *Allergy.* 2012;67:451–61.
- Freitag G, Hoppner T. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. *Curr Med Res Opin.* 1997;13:529–37.
- Friedländer MH. Ocular allergy. In: Middleton E, Reed CE, Ellis EF, editors. *Allergy: principle and practice.* 3rd ed. St Louis: Mosby; 1988.
- Frosch PJ. *Hautirritation und empfindliche Haut.* Berlin: Rosse; 1985.
- Frosch PJ, Schwanitz HJ, Macher E. A double blind trial of h1 and h2 receptor antagonists in the treatment of atopic dermatitis. *Arch Dermatol Res.* 1984;276(1):36–40.
- Fuchs F, Hentschel G. Höhenklimatherapeutische Möglichkeiten und Erfahrungen bei Neurodermitis-Kranken auf dem Fichtelberg. *Z Meteorol.* 1959;13:116.
- Fuhrmann T, Smith N, Tausk F. Use of complementary and alternative medicine among adults with skin disease: updated results from a national survey. *J Am Acad Dermatol.* 2010;63(6):1000–5.
- Fujita H, Shemer A, Suarez-Farinas M, Johnson-Huang LM, Tintle S, Cardinale I, et al. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. *J Allergy Clin Immunol.* 2011;128:574–82.
- Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, Koga T. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. *Br J Dermatol.* 2003;148(1):128–33.
- Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H. JAPANESE E6005 Study Investigators Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. *J Dermatol.* 2014;41:577–85.
- Galli S, editor. *Anaphylaxis.* Novartis Foundation symposium 157. Chichester: Wiley; 2004.
- Galli SJ, Kalesnikoff J, Grimaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. *Annu Rev Immunol.* 2005;23:749–86.
- Gamble RG, Dellavalle RT. Ion-exchange water softener use and eczema. *Arch Dermatol.* 2011;147:1208–10.
- Garg N, Silverberg JI. Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention. *Ann Allergy Asthma Immunol.* 2014;112:525–32.
- Garritsen FM, Brouwer MW, Limpens J, Spuls PL. Photo(chemo)therapy in the management of atopic dermatitis: an updated systemic review with implications for practice and research. *Br J Dermatol.* 2014;170:501–13.
- Garritsen FM, ter Haar NM, Spuls PL. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic. *Br J Dermatol.* 2013;168:688–91.
- Gassner-Bachmann M, Wüthrich B. Bauernkinder leiden selten an Heuschnupfen und Asthma. *Dtsch Med Wochenschr.* 2000;125:924–31.
- Gauger A, Mempel M, Schekatz A, Schäfer T, Ring J, Abeck D. Silver-coated textiles reduce *Staphylococcus aureus* colonization in patients with atopic eczema. *Dermatology.* 2003;207:15–21.
- Gauger A, Fischer S, Mempel M, Schaefer T, Foelster-Holst R, Abeck D, Ring J. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. *J Eur Acad Dermatol Venereol.* 2006;20(5):534–41. Erratum *J Eur Acad Dermatol Venereol.* 2006;20(6):771.
- Gdalevich M, Mimouni D, David M, Mimouni M. Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. *J Am Acad Dermatol.* 2001;45:520–7.
- Gebert N, Hümmelink R, Könning J, et al. Efficacy of a self-management program for childhood asthma – a prospective controlled study. *Patient Educ Couns.* 1998;35:213–20.
- Gehring W. Gezielter Einsatz von Vehikeln und Basistherapie. In: Korting HC, Sterry W, editors. *Therapeutische Verfahren in der Dermatologie. Dermatika und Kosmetika.* Berlin/Wien: Blackwell Wissenschafts-Verlag; 2001. p. 93–100.
- Gehring W, Gloor M. Behandlung der Neurodermitis atopica mit einer W/O Emulsion mit und ohne Hydrocortison – Ergebnisse einer klinisch und methodisch kontrollierten randomisierten Doppelblindstudie. *Z Hautkr.* 1996;71:554–60.
- Gehring W, Wenz J, Gloor M. Influence of topically applied ceramide/phospholipid mixture on the barrier function of intact skin, atopic skin and experi-

- mentally induced barrier damage. *Int J Cosmet Sci.* 1997;19:143–56.
- Gelfand HH, Cinder JC, Grant SF, Soiffer M. Evaluation of histamine-gamma globulin (histaglobin) in the treatment of various allergic conditions. *Ann Allergy.* 1963;21:150–5.
- Gelmetti C. Skin cleansing in children. *J Eur Acad Dermatol Venereol.* 2001;15 Suppl 1:12–5.
- Gelmetti C, Wollenberg A. Atopic dermatitis – all you can do from the outside. *Br J Dermatol.* 2014;170:19–24.
- George AO. Atopic eczema in Nigeria. *Int J Dermatol.* 1989;28:237–9.
- Gfesser M, Abeck D, Rügemer J, Schreiner V, Stüb F, Disch R, Ring J. The early phase of epidermal barrier regeneration is faster in patients with atopic eczema. *Dermatology.* 1997;195:332–6.
- Giannetti A, Fantini F, Cimitan A, Pincelli C. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. *Acta Derm Venereol.* 1992;176:90–2.
- Gibbs NK, Norval M. Photoimmunosuppression: a brief overview. *Photodermatol Photoimmunol Photomed.* 2013;29:57–64.
- Gieler U. Die Sprache der Haut. 3rd ed. Düsseldorf: Walter; 2006.
- Gieler U, Ehlers A, Höhler T, Burkhard G. Die psychosoziale Situation der Patienten mit endo-genem Ekzem. *Hautarzt.* 1990;41:416–23.
- Gieler U, Bräuer J, Freiling G. Neurodermitis-Schulung. Ein neuer, psychosomatisch orientierter Behandlungsansatz. In: *Jahrbuch der medizinischen Psychologie (Bd.9). "Hauterkrankungen aus psychologischer Sicht"*. Göttingen: Hogrefe Verlag; 1992.
- Gieler U, Hohmann M, Niemeier V, Kupfer J, Stangler U, Ehlers A. Cost evaluation in atopic eczema. *J Dermatol Treat.* 1999;10 Suppl 1:15–20.
- Gieler U, Ring J, Wahn U. Neurodermitisschulung. *Dt Ärztebl.* 2001;98:3202–9.
- Girolomoni G, Sebastiani S, Albanesi C, Cavani A. T-cell subpopulations in the development of atopic and contact allergy. *Curr Opin Immunol.* 2001;13:733–7.
- Gläser R, Meyer-Hoffert U, Harder J, Cordes J, Wittersheim M, Kobliakova J, Fölster-Holst R, Proksch E, Schröder JM, Schwarz T. The Antimicrobial Protein Psoriasin (S100A7) is Upregulated in Atopic Dermatitis and after Experimental Skin Barrier Disruption. *J Invest Dermatol.* 2009a;129:641–9.
- Gläser R, Navid F, Schuller W, Jantschitsch C, Harder J, Schröder J, Schwarz A, Schwarz T. UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo. *J Allergy Clin Immunol.* 2009b;123:1117–23.
- Gleich GJ. The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? *J Allergy Clin.* 1982;70:160–9.
- Gloor M. Sebaceous gland activity in atopic eczema. In: Ruzicka T, Ring J, Przybilla B, editors. *Handbook of atopic eczema.* Berlin/Heidelberg/New York: Springer; 1991. p. 287–95.
- Gloor M, Gehring W. Effects of emulsions on the stratum corneum barrier and hydration (in German). *Hautarzt.* 2003;54:324–30.
- Gloor M, Schermer W, Gehring G. Ist eine Kombinationsbehandlung von Harnstoff und Glycerin in Externagrundlagen sinnvoll? *Z Hautkr.* 1997;72:509–14.
- Goldblum RW, Piper WN. Artificial lichenification produced by a scratching machine. *J Invest Dermatol.* 1954;22:405.
- Gondo A, Saeki N, Tokuda Y. Challenge reactions in atopic dermatitis after percutaneous entry of mite antigen. *Br J Dermatol.* 1986;115:485–93.
- Granstein RB, Askari M. Cutaneous cells in activation of immunology actions: further characterization. *J Invest Dermatol.* 1986;97:141–9.
- Grewe M. Hyposensibilisierung bei atopischem Ekzem. *Allergo J.* 2000;9:351–357.
- Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. *J Invest Dermatol.* 2000;114:1108–12.
- Grootendorst DC, Dahlen SE, Bos J, et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma. *Clin Exp Allergy.* 2001;89:836–43.
- Grüber C, Illi S, Lau S, Nickel R, Forster J, Kamin W, Bauer CP, Wahn V, Wahn U, MAS-90 Study Group. Transient suppression of atopy in early childhood is associated with high vaccination coverage. *Pediatrics.* 2003;111:282–8.
- Grüber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. *Expert Rev Clin Immunol.* 2012;8(1):17–9. doi:10.1586/eci.11.74.
- Grundmann-Kollmann M, Korting HC, Behrens S, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. *Br J Dermatol.* 1999;141:175–6.
- Grundmann-Kollmann M, Kaufmann R, Zollner TM. Treatment of atopic dermatitis with mycophenolate mofetil. *Br J Dermatol.* 2001;145:351–2.
- Guillett G, Guillett MH. Natural history of sensitizations in atopic dermatitis. A 3-year. *Arch Dermatol.* 1992;128:187–92.
- Gupta AK, Chow M. Pimercolism: a review. *J Eur Acad Dermatol Venereol.* 2003;17:493–503.
- Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, et al. Broad defect in epidermal cornification in atopic dermatitis identified through genomic analysis. *J Allergy Clin Immunol.* 2009;124:1235–44.
- Gutzmer R, Langer K, Lisewski M, Mommert S, Rieckborn D, Kapp A, Werfel T. Expression of a function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells. *J Allergy Clin Immunol.* 2002;109:524.
- Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, Werfel T. The histamine H4 receptor is functionally expressed on T(H)2 cells. *J Allergy Clin Immunol.* 2009;123:619–25.
- Haapakoski R, Karisola P, Fyhrquist N, et al. Toll-like receptor activation during cutaneous allergen

- sensitization blocks development of asthma through IFN-gamma-dependent mechanisms. *J Invest Dermatol.* 2013;133:964–72.
- Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. *J Invest Dermatol.* 2003;121:345–53.
- Haeck IM, Knol MJ, ten Berge O, van Velsen SGA, de Bruin-Weller MS, Bruijnzeel-Koomen CAFM. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. *J Am Acad Dermatol.* 2011a;64:1074–84.
- Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. *J Am Acad Dermatol.* 2011b;64:275–81.
- Hafenreffer S. Nosodochium, in quo cutis, eique adaequentium partium, affectus omnes, singulari methodo, et cognoscendi e curandi fidelissime traduntur. Ulm: Kuhnen; 1660. p. 98–102.
- Hahnemann S. Die chronischen Krankheiten, ihre eigentümliche Natur und homöopathische Heilung. Leipzig: Hauk; 1835.
- Halhuber J. Der Kreislaufgesunde und –kranke im Hochgebirgsklima. *Münch Med Wschr.* 1959;26:1118–23.
- Halken S, Hansen KS, Jacobson HP, et al. Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention: a prospective, randomized study. *Pediatr Allergy Immunol.* 2000;11:149–61.
- Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. *J Clin Invest.* 1994;94:870–6.
- Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol.* 2014;134:1293–300.
- Han TY, Kong TS, Kim MH, Chae JD, Lee JH, Son SJ. Vitamin D status and its association with the SCORAD score and serum LL-37 level in Korean adults and children with atopic dermatitis. *Ann Dermatol.* 2015;27:10–14.
- Hanifin JM, Lobitz Jr WC. Newer concepts of atopic dermatitis. *Arch Dermatol.* 1977;113:663–70.
- Hanifin IM, Rajka G. Diagnostic features of atopic dermatitis. *Acta Derm Venereol.* 1980;92(Suppl):44–7.
- Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G, et al. Recombinant interferon gamma therapy for atopic dermatitis. *J Am Acad Dermatol.* 1993;28:189–97.
- Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol.* 2002;147:528–37.
- Hannuksela M, Karvonen J, Husa M, Jokela R, Katajamäki L, Leppisaari M. Ultraviolet light therapy in atopic dermatitis. *Acta Derm Venereol.* 1985;114:137–9.
- Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. *Ann Allergy.* 1993;70:127–33.
- Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. *J Invest Dermatol.* 2000;114(3):587–90.
- Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. *Br J Dermatol.* 2000;143(6):1324–6.
- Happle R. The essence of alternative medicine. A dermatologist's view from Germany. *Arch Dermatol.* 1998;134:1455–60.
- Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. *J Invest Dermatol.* 2000;115:406–13.
- Harari M, Shani J, Seidl V, Hristakieva E. Climatotherapy of atopic dermatitis at the Dead Sea: demographic evaluation and cost-effectiveness. *Int J Dermatol.* 2000;39(1):59–69.
- Harder J, Schröder J, Gläser G. The skin surface as antimicrobial barrier: present concepts and future outlooks. *Exp Dermatol.* 2013;22:1–5.
- Harding NJ, Birch JM, Hepworth SJ, McKinney PA. Atopic dysfunction and risk of central nervous system tumors in children. *Eur J Cancer.* 2008;44:92–9.
- Hardyman MA, Wilkinson E, Martin E, Jayasekera NP, Blume C, Swindle EJ, Gozzard N, Holgate ST, Howarth PA, Davies DE, Collins JE. TNF- α -mediated bronchial barrier disruption and regulation by src family kinase activation. *J Allergy Clin Immunol.* 2013;132:665–75.
- Harper JJ, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. *Br J Dermatol.* 2000;142:52–8.
- Harper J, Oranje A, Prose N, editors. Textbook of pediatric dermatology. Oxford: Blackwell; 2002.
- Hata TR, Audish D, Kotol P, Coda A, Kabigting F, Miller J, et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. *J Eur Acad Dermatol Venereol.* 2014;28:781–9.
- Hattevig G, Sigurs N, Kjellman B. Effects of maternal dietary avoidance during lactation on allergy in children in 10 years of age. *Acta Paediatr.* 1999;88:7–12.
- Hatz HJ. Glucocorticoide. Immunologische Grundlagen, Pharmakologie und Therapierichtlinien. 1st ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 1998.
- Hausen BM, Vieluf IK. Allergiepflanzen – Pflanzenallergene. Ecomed: Landsberg; 1997.
- Hauser C, Saurat JH. Bedeutung der Besiedelung der Haut mit *Staphylococcus aureus*. *Hautarzt.* 1985;36:605–7.
- Hauss H, Proppe A, Matthies C. Vergleichende Untersuchungen zu Behandlung von trockener, juckender Haut mit einer Zubereitung aus Harnstoff und Polidocanol sowie mit einer Linolsäure-haltigen

- Fettcreme. Ergebnisse aus der Praxis. *Dermatosen Beruf Umwelt*. 1993;41(5):184–8.
- Haxthausen H. Interpretation and value of skin tests in atopic dermatitis. *Acta Derm Venereol (Stockh)*. 1957;3:6.
- Hayashida S, Furusho N, Uchi H, Miyazaki S, Eiraku K, Gondo C, Tsuji G, Hachisuka J, Fukagawa S, Kido M, Nakahara T, Moroi Y, Hayashi J, Hagihara A, Furue M. Are lifetime prevalence of impetigo, molluscum and herpes infection really increased in children having atopic dermatitis? *J Dermatol Sci*. 2010;60:173–8.
- Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study. *J Dtsch Dermatol Ges*. 2010;8(12):990–8. doi:10.1111/j.1610-0387.2010.07497.x. [Article in English, German].
- Hemels HGWM. The effect of propranolol on acetylcholine-induced sweat gland response in atopic and non-atopic subjects. *Br J Dermatol*. 1970;83:312.
- Henseler T, Christophers E. Disease concomitance in psoriasis. *J Am Acad Dermatol*. 1995;32:982–6.
- Heratizadeh A, Breuer K, Kapp A, Werfel T. Symptomatische Therapie der atopischen Dermatitis. *Hautarzt*. 2003;54(10):937–45.
- Herbert O. Traditionelle Lebensweise als Schutz vor Allergien? Atopie und atopische Erkrankungen in fünf Dörfern auf Karkar Island Papue Neuguinea. Berlin: VWB; 2009.
- Herbert OC, Barnetson R, Weninger W, Krämer U, Behrendt H, Ring J. Western lifestyle and increased prevalence of atopic diseases: an example from a small Papua New Guinean island. *WAO J*. 2009;2:130–7.
- Herz U, Lacy P, Renz H, Erb K. The influence of infections on the development and severity of allergic disorders. *Curr Opin Immunol*. 2000;12:632–40.
- Herzberg J. Wenig bekannte Formen der Neurodermitis. *Hautarzt*. 1973;24:47–51.
- Hide DW, Matthews S, Matthews L, et al. Effect of allergen avoidance in infancy on allergic manifestations at age two years. *J Allergy Clin Immunol*. 1994;93:842–6.
- Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkès CJ. Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. *Rheumatology (Oxford)*. 2000;39(9):1020–6.
- Hindley D, Galloway G, Murray J, Gardener L. A randomised study of “wet wraps” versus conventional treatment for atopic eczema. *Arch Dis Child*. 2006;91(2):164–8.
- Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, Yamada T, Fujieda S, Tanaka S, Doi S, Miyatake A, Enomoto T, Nishiyama C, Nakano N, Maeda K, Okumura K, Ogawa H, Ikeda S, Noguchi E, Sakamoto T, Hizawa N, Ebe K, Saeki H, Sasaki T, Ebihara T, Amagai M, Takeuchi S, Furue M, Nakamura Y, Tamari M. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. *Nat Genet*. 2012;44(11):1222–6. doi:10.1038/ng.2438. Epub Oct 2012.
- Hjorth N, Clemmenson OJ. Treatment of dermatitis of the head and neck with ketoconazole in patients with type I hypersensitivity for *Pityrosporum orbiculare*. *Semin Dermatol*. 1983;2:26–9.
- Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus beta-methasone in infected or potentially infected eczema. *Pharmatherapeutica*. 1985;4(2):126–31.
- Ho RCM, Giam YC, Enge TP, Mack A, Goa D, Chang NWB, Cheak H, van Bever HP. The influence of childhood atopic dermatitis on health of mothers, and its impact on Asian families. *Pediatr Allergy Immunol*. 2010;21:501–7.
- Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess*. 2000;4:1–191.
- Hoeger PH, Harper JL. Neonatal erythroderma: differential diagnosis and management of the “red baby”. *Arch Dis Child*. 1998;79:186–91.
- Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. *J Allergy Clin Immunol*. 2005;115:459–65.
- Hölscher K. Psychosomatische Aspekte in “Neurodermitis”. Ring J, editor. Ecomed, Landsberg. 1998;29–44.
- Holt PG, Clough JB, Holt BJ, Baron-Hay MJ, Rose AH, Robinson BW, Thomas WR. Genetic ‘risk’ for atopy is associated with delayed postnatal maturation of T-cell competence. *Clin Exp Allergy*. 1992;22:1093–9.
- Hölzle E, Plewig G. Effects of dermatitis, stripping, and steroids on the morphology of corneocytes. A new bioassay. *J Invest Dermatol*. 1977;68:350–6.
- Homey B, Zlotnik A. Chemokines in allergy. *Curr Opin Immunol*. 1999;11:626–34.
- Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. *J Allergy Clin Immunol*. 2006;118:178–89.
- Hönigsmann H. Phototherapy. *J Invest Dermatol*. 2013;133(E1):E18–20. doi:10.1038/skinbio.2013.180.
- Hotze M, Baurecht H, Rodríguez E, Chapman-Rothe N, Ollert M, Fölster-Holst R, Adamski J, Illig T, Ring J, Weidinger S. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. *Allergy*. 2014;69:132–5.
- Høst A, Andrae S, Charkin S, Diaz-Vazquez C, Dreborg S, Eigenmann PA, et al. Allergy testing in children: why, who, when and how? *Allergy*. 2003;58:559–69.
- Høst A, Halken S, Muraro A, et al. Dietary prevention of allergic diseases in infants and small children. *Pediatr Allergy Immunol*. 2008;19:1–4.
- Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, De Benedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol*. 2007;120:150–5.

- Hradetzky S, Werfel T, Rösner LM. Autoallergy in atopic dermatitis. *Allergo J Int.* 2015;24:16–22.
- Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics.* 2009;123:808–14.
- Hubiche T, Ged C, Benard A, Léauté-Labrèze C, McElreavey K, de Verneuil H, Taïeb A, Boralevi S. Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort. *Acta Derm Venereol.* 2007;87:499–505.
- Humpeler E, Skrabal F, Bartsch G. Influence of exposure to moderate altitude on the plasma concentration of cortisol, aldosterone, renin, testosterone, and gonadotropins. *Eur J Appl Physiol.* 1980;45:167–76.
- Hünecke P. Entstellungsgefühle und strukturiertes Video-Feedback – Orientierende Befunde und Überlegungen für einen neuen psychotherapeutischen Ansatz. In: Gieler U, Stangier U, Brähler E, editors. *Hauterkrankungen in psychologischer Sicht. Jahrbuch der medizinischen Psychologie (Bd. 9).* Göttingen: Hofgreffe; 1993.
- Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus. *JAAD.* 2004;50:889–91.
- Hurrelmann K, Hoepner-Stamos F, Palentien C, Setterbulte W, Klaubert K. *Gesundheitsförderung in Grundschulen – Analyse der Ausgangsbedingungen und Implementation von Maßnahmen.* Bielefeld: Universität Bielefeld, Nordrhein-Westfälischer Forschungsverbund Public Health; 1998.
- Hurrelmann K, Klocke A, Melzer W, Ravens-Sieberer U. *Jugendgesundheitsurvey.* Munich: Juventa; 2003.
- Huss-Marp J, Eberlein-König B, Breuer K, Mair S, Ansel A, Darsow U, Krämer U, Mayer E, Gertis K, Ring J, Behrendt H. Influence of short term exposure to airborne Derp 1 and volatile organic compounds on skin barrier function and dermal blood flow in patients with atopic eczema and healthy individuals. *Clin Exp Allergy.* 2007;36:381–9.
- Huss-Marp J, Darsow U, Brockow K, Pfab F, Weichenmeier I, Schober W, Petersson CJ, Borres MP, Ring J, Behrendt H. Can immunoglobulin E-measurement replace challenge tests in allergic rhinoconjunctivitis to grass pollen? *Clin Exp Allergy.* 2011;41(8):1116–24.
- Iamandescu IB. *Psychoneuroallergology.* 2nd ed. Bucarest: Amaltea; 2007.
- Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. *J Eur Acad Dermatol Venereol.* 2010;24:837–9.
- Iikura Y, Naspitz CK, Mikawa H, Talaricofocho S, Baba M, Sole D, Nishima S. Prevention of asthma by ketotifen in infants with atopic dermatitis. *Ann Allergy.* 1992;68:233–6.
- Illi S, Depner M, Genuneit J, Horak E, Loss G, Strunz-Lehner C, Büchele G, Boznanski A, Danielewicz H, Cullinan P, Heederik D, Braun-Fahrländer C, von Mutius E. The GABRIEL advanced studies. *J Allergy Clin Immunol.* 2012;129:1470–7.
- Ikezawa Y, Nakazawa M, Tamura C, et al. Cyclophosphamide decreases the number, percentage and function of CD25+ CD4+ regulatory T cells. *J Dermatol Sci.* 2005;39:105–12.
- Imokawa G. A possible mechanism underlying the ceramide deficiency in atopic dermatitis: expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. *J Dermatol Sci.* 2009;55:1–9.
- Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? *J Invest Dermatol.* 1991;96:523–7.
- IPCC (Intergovernmental Panel on Climate Change). Chapter 8. Human health; 2007.
- ISAAC. Worldwide variations in the prevalence of asthma symptoms: the international study of asthma and allergies in childhood (ISAAC) Steering Committee. *Lancet.* 1998;351:1225–32.
- Ishizaka K, Ishizaka T. Identification of γ E antibodies as carrier of reaginic activity. *J Immunol.* 1967;99:1187–98.
- Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clin Exp Allergy.* 2000;30:1604–10.
- Jablonski NG. The evolution of human skin and skin color. *Ann Rev Anthropol.* 2004;33:585–623.
- Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. *J Am Acad Dermatol.* 2005;52:522–6.
- Jacobsen E. *Progressive relaxation.* Chicago: University Press; 1938.
- Jacquet L. La pratique dermatologique. In: Besnier E, Brocq L, Jacquet L, editors. *La pratique dermatologique.* 1904;5:341.
- Jäger L, Wüthrich B. *Nahrungsmittelallergien und -intoleranzen.* Düstri, München 2001.
- Jaeger T, Rothmaier M, Zander H, Ring J, Gutermuth J, Anliker MD. Acid-coated textiles (pH 5.5–6.5) – a new therapeutic strategy for atopic eczema? *Acta Derm Venereol.* 2015;95(6):659–63. doi:10.2340/00015555-1916.
- Jakob T, Hermann K, Ring J. Eosinophil cationic protein in atopic eczema. *Arch Dermatol Res.* 1991;283:5–6.
- Jakob T, Ring J, Udey MC. Multistep navigation of Langerhans/dendritic cells in and out of the skin. *J Allergy Clin Immunol.* 2001;108:688–96.
- James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. *N Engl J Med.* 1995;332:1262–6.
- Janeway CA, Medzhitov R. Innate immune recognition. *Annu Rev Immunol.* 2002;20:197–216.
- Janmohamed SR, Oranje AP, Devillers AC, Rizopoulos D, van Praag MC, Van Gysel D, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol.* 2014;70:1076–82.
- Jekeler J, Larkö O. Phototherapy for atopic dermatitis with ultraviolet A (UVA), low dose UVB and

- combined UVA and UVB: two paired comparison studies. *Photodermatol Photoimmunol Photomed*. 1991;8:151–6.
- Johansson SGO. Raised levels of a new immunoglobulin (IgND) in asthma. *Lancet*. 1967;2:951–5.
- Johansson SGO, Hourihane JO, Bousquet J, Brujnzeel-Koomen C, Dreborg S, Haahela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wuthrich B, EAACI (the European Academy of Allergology and Clinical Immunology) Nomenclature Task Force. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. *Allergy*. 2001;56:813–24.
- Johansson C, Sandstrom MH, Bartosik J, Sarnhult T, Christiansen J, Zargari A, Back O, Wahlgren CF, Faergemann J, Scheynius A, Tenvall LM. Atopy patch test reactions to *Malassezia* allergens differentiate subgroups of atopic dermatitis patients. *Br J Dermatol*. 2003;148:479–88.
- Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TAE, Ring J, Thien F, Cauwenberge PV, Williams HC. Revised nomenclature for allergy for global use. *Allergy Clin Immunol Int J World Allergy Org*. 2004;17:4–8, (Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003).
- Jones HE, Rinaldi MG, Chai H, Kahn G. Apparent cross-reactivity of airborne molds and the dermatophytic fungi. *J Allergy Immunol*. 1973a;52:346–57.
- Jones HE, Rinhardt JH, Rinaldi MG. A clinical, mycological, and immunological survey for dermatophytosis. *Arch Dermatol*. 1973b;108:61–5.
- Juhlin L, et al. Immunoglobulin E in dermatoses: levels in atopic dermatitis and urticaria. *Arch Dermatol*. 1969;92:17ff.
- Just HL, Deleuran M, Vestergaard C, Deleuran B, Thestrup-Pedersen K. T-cell receptor excision circles (TREC) in CD4+ and CD8+ T-cell subpopulations in atopic dermatitis and psoriasis show major differences in the emission of recent thymic emigrants. *Acta Derm Venereol*. 2008;88:566–72.
- Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T cell and antibody responses by differential expression of H1 and H2 receptors. *Nature*. 2001;413:420–5.
- Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. *J Dermatol Sci*. 2013;70(1):3–11. doi:10.1016/j.jdermsci.2013.02.001. Epub 2013 Feb 15.
- Kabesch M, Peters W, Carr D, et al. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. *J Allergy Clin Immunol*. 2003;111:813–7.
- Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. *J Allergy Clin Immunol*. 2006;117:269–74.
- Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. *Lancet*. 2001;357:1076–9.
- Kantor I, Milbauer J, Posner M, Weinstock IM, Simon A, Thormahlen S. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. *Today Ther Trends*. 1993;11:157–63.
- Kaposi M. *Erkrankungen der Haut*. 2nd ed. Wien; 1891
- Kapp A, Papp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y, for the Flare Reduction in Ekzema with Elidel (Infants) Multicenter Investigator Study Group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. *J Allergy Clin Immunol*. 2002;110:277–84.
- Katagiri K, Arakawa S, Hatano Y, Fujiwara S. Tolerogenic antigen-presenting cells successfully inhibit atopic dermatitis-like skin lesion induced by repeated epicutaneous exposure to ovalbumin. *Arch Dermatol Res*. 2008;300:583–93.
- Katsarou A, Armenaka MC. Atopic dermatitis in older patients: particular points. *J Eur Acad Dermatol Venereol*. 2011;25:12–8.
- Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol*. 2003;148:1212–21.
- Kemeny L, Szabo K. Toll-like receptors link atopic march to the hygiene hypothesis. *J Invest Dermatol*. 2013;133:874–8.
- Kemp AS. Atopic eczema: its social and financial costs. *J Paediatr Child Health*. 1999;35:229–31.
- Kerschenlohr K, Decard S, Darsow U, Ollert M, Wollenberg A. Clinical and immunologic reactivity to aeroallergens in “intrinsic” atopic dermatitis patients. *J Allergy Clin Immunol*. 2003a;111:195–7.
- Kerschenlohr K, Decard S, Przybilla B, Wollenberg A. Atopy patch test reactions show a rapid influx of inflammatory dendritic and patients with intrinsic atopic dermatitis. *J Allergy Clin Immunol*. 2003b;111:869.
- Kilpelainen M, Koskenvuo M, Helenius H, Terho EO. Stressful life events promote the manifestation of asthma and atopic disease. *Clin Exp Allergy*. 2002;32:256–63.
- Kim E, Lee JE, Namkung JH, Kim PS, Kim S, Shin ES, Cho EY, Yang JM. Single nucleotide polymorphisms and the haplotype in the DEFBI gene are associated with atopic dermatitis in a Korean population. *J Dermatol Sci*. 2009;54:25–30.
- Kim KW, Myers RA, Lee JH, Igartua C, Lee KE, Kim YH, Kim EJ, Yoon D, Lee JS, Hirota T, Tamari M, Takahashi A, Kubo M, Choi JM, Kim KE, Nicolae DL, Ober C, Sohn MH. Genome-wide association study of recalcitrant atopic dermatitis in Korean children. *J Allergy Clin Immunol*. 2015;136(3):678–684. e4. doi:10.1016/j.jaci.2015.03.030. Epub 2015 Apr 30.

- Kimura T, Miyazawa H. The 'butterfly' sign in patients with atopic dermatitis: evidence for the role of scratching in the development of skin manifestations. *J Acad Dermatol.* 1989;21:579–80.
- Kini SP, De Long LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. *Arch Dermatol.* 2011;147:312–9.
- Kissling S, Wüthrich B. Verlauf der atopischen Dermatitis nach dem Kleinkindesalter. *Hautarzt.* 1993;44:569–73.
- Kitamura K, Takahashi Y, Sasagawa S. (in Japanese). *Jpn J Dermatol.* 1950;60:59.
- Kjellmann NIM. Atopic disease in seven-year-old children. Incidence in relation to family history. *Acta Paediatr Scand.* 1977;66:465–71.
- Kleijnen J, Knipschild P, ter Riet G. Clinical trials in homeopathy. *Br Med J.* 1991;302:316–23.
- Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol.* 1999;135:1522–5.
- Kleine-Tebbe J, Lepp U, Niggemann B, et al. In-vitro-Diagnostik von Nahrungsmittelallergien. Leitlinie von DGAKI, ÅDA, GPA, SGAI, ÖGAI. *Allergo J.* 2009;18:132–46, (AWMF-Leitlinienregister Nr. 061/008, www.awmf-online.de).
- Kneipp S. *Meine Wasser-Kur.* 50th ed. Kempten: Kösel'sche Buchhandlung; 1984.
- Knobler RM. Photophoresis – extracorporeal irradiation of 8-MOP containing blood – a new therapeutic modality. *Blood.* 1987;54:247–50.
- Kobayashi H, Mizuno N, Teramae H, Kutsuna H, Ueoku S, Onoyama J, Yamanaka K, Fujita N, Ishii M. The effects of Hochu-ekki-to in patients with atopic dermatitis resistant to conventional treatment. *Int J Tissue React.* 2004;26:113–7.
- Koblenzer CS. Itching and the atopic skin. *J Allergy Clin Immunol.* 1999;104:109–13.
- Kodama A, Horikawa T, Suzuki T, Ajiki W, Takashima T, Harada S, Ichihashi M. Effects of stress on atopic dermatitis: investigations in patients after the great Hanshin earthquake. *J Allergy Clin Immunol.* 1999;104:173–6.
- Kofler H, Ulmer H, Mechter E, Falk M, Fritsch PO. Bioresonanz bei Pollinose: Eine vergleichende Untersuchung zur diagnostischen und therapeutischen Wertigkeit. *Allergologie.* 1996;19:114–22.
- Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. *Eur J Immunol.* 1998;28:769–79.
- Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res.* 2012;22:850–9.
- Korting GW. *Zur Pathogenese des endogenen Ekzems.* Stuttgart: Thieme; 1954.
- Korting HC. Äußerliche Dermatotherapie. In: Braun-Falco O, Plewig G, Wolff HH, editors. *Dermatologie und Venerologie.* 4th ed. Berlin: Springer; 1995. p. 1488–529.
- Kowalczick L, Kleinheinz A, Weichenthal M, Ring J. Low-dose versus medium-dose UVA1 treatment in severe atopic eczema. *Acta Derm Venereol.* 1995;75:43–5.
- Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy and/or lactation for preventing or treating atopic disease in the child. *Cochrane Database Syst Rev* 2003;(4):CD000133.
- Krämer U, Link E, Behrendt H, Ring J. Trends und Risikofaktoren von Asthma und allergischen Erkrankungen bei Kindern und Jugendlichen in Deutschland. *Miriam-Studie Augsburg.* 1996; 2001(01 EE 9501/2):1–27.
- Krämer U, Altmann L, Behrendt H, Dolgner R, Islam MS, Kaysers HG, Ring J, Stiller-Winkler R, Turfeld M, Weishoff-Houben M, Willer H, Winneke G. Comparison of the influence of socioeconomic factors on air pollution health effects in West and East Germany. In: Jantunen H, editor. *Socioeconomic and cultural factors in air pollution epidemiology, Air pollution epidemiology report series, vol. 8.* Bruxelles: EU; 1997. p. 41–9.
- Krämer U, Behrendt H, Dolgner R, Ranft U, Ring J, Willer H, Schlipkötter HW. Airway disease and allergies in East and West German children during the first 5 years after reunification: time trends and the impact of sulphur dioxide and total suspended particles. *Int J Epidemiol.* 1999a;28:865–73.
- Krämer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy in later childhood. *Lancet.* 1999b;353:450–4.
- Krämer U, Oppermann H, Ranft U, Schäfer T, Ring J, Behrendt H. Veränderungen in den Prävalenzen von allergischen Erkrankungen bei sechsjährigen Kindern aus Ost- und Westdeutschland seit 1991. *Allergo J.* 1999c;8:305–9.
- Kramer MS, Chalmers B, Hodnett ED, et al. Promotion of breastfeeding intervention trial (PROBIT): a randomized trial in the Republic of Belarus. *JAMA.* 2001;285:413–20.
- Krämer U, Link E, Oppermann H, et al. Die Schulanfängerstudie in West- und Ostdeutschland (SA-WO). Trends von Allergien und Sensibilisierungen 1991–2000. *Gesundheitswesen.* 2002;64:657–63.
- Krämer U, Lemmen CH, Behrendt H, Link E, Schäfer T, Gostomzyk J, Scherer G, Ring J. The effect of environmental tobacco smoke on eczema and allergic sensitization in children. *Br J Dermatol.* 2004;150:111–8.
- Krämer U, Weidinger S, Darsow U, Möhrenschrager M, Ring J, Behrendt H. Seasonality in symptom severity influenced by temperature or grass pollen: results of a panel study in children with eczema. *J Invest Dermatol.* 2005;124:514–23.
- Krämer U, Schmitz R, Ring J, Behrendt H. What can reunification of East and West Germany tell us about the cause of the allergy epidemic? *Clin Exp Allergy.* 2015;45(1):94–107. doi:10.1111/cea.12458.
- Kreft B, Wohlrab J, Fischer M, Uhlig H, Skolziger R, Marsch WC. Analyse des Serumzinkspiegels bei

- Patienten mit atopischer Dermatitis, Psoriasis vulgaris und Hautgesunden. *Hautarzt*. 2000;51:931–4.
- Krönauer C, Eberlein-König B, Ring J, Behrendt H. Influence of UVB, UVA and UVA1 irradiation on histamine release from human basophils and mast cells in vitro in the presence and absence of antioxidants. *Photochem Photobiol*. 2003;77(5):531–4.
- Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D, Solinger A, Padula S, Scholl P. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*. 2015;136(1):116–124.e7. doi:10.1016/j.jaci.2015.01.018. Epub 2015 Mar 11.
- Krutmann J, Hönigsmann H. *Handbuch der dermatologischen Phototherapie und Photodiagnostik*. Berlin/Heidelberg: Springer; 1997.
- Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E. High-dose UVA-1 therapy in the treatment of patients with atopic dermatitis. *J Am Acad Dermatol*. 1992;26:225–30.
- Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sönnichsen N, Czech W, Kapp A, Stege H, Grewe M, Schöpf E. High-dose UVA 1 therapy for atopic dermatitis: results of a multicenter trial. *J Am Acad Dermatol*. 1998;38:589–93.
- Krutmann J, Morita A, Chung JH. Sun exposure: What molecular photodermatology tells us about its good and bad sides. *J Invest Dermatol*. 2012;132:976–84.
- Kuehr J. *Asthma und Allergien bei Kindern. Studien in Süddeutschland*. *Allergologie*. 1999;22:48–53.
- Kukutsch NA. *Darstellung und Diskussion alternativer/komplementärer diagnostischer und/oder therapeutischer Konzepte im Hinblick auf atopische Erkrankungen*. Dissertation, Universität Hamburg, 1997
- Kunz B, Ring J. Clinical features and diagnostic criteria of atopic dermatitis. In: Harper J, Oranje A, Prose N, editors. *Textbook of pediatric dermatology*. Oxford: Blackwell Science; 2000. p. 199–215.
- Kunz B, Ring J, Überla K. Frequency of contact dermatitis and contact sensitization in preschool children. *Arch Derm Res*. 1990;281:544.
- Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Täieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. *Dermatology*. 1997;195:10–9.
- Kunz B, Lüdtke R, Leeber N, Ring J. Test-retest-reliability and validity of the kinesiology muscle test. *Complement Ther Med*. 2001;9:141–5.
- Kwiek B, Novak N. Immunosuppressants as treatment for atopic dermatitis. In: Pawankar R et al., editors. *Allergy frontiers: therapy and prevention*. Berlin/New York: Springer; 2010. p. 291–310.
- La Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double-blind study of cetirizine in atopic eczema in children. *Ann Allergy*. 1994;73(2):117–22.
- Lack G, Fox D, Northstone K, Golding J, Avon Longitudinal Study of Parents and Children Study Team. Factors associated with development with peanut allergy in childhood. *N Engl J Med*. 2003;348:977–85.
- Lacour M, Hauser C. The role of microorganisms in atopic dermatitis. *Clin Rev Allergy*. 1993;11:491–522.
- Langan SM, Silcocks P, Williams HC. What causes flares of eczema in children? *Br J Dermatol*. 2009;161:640–6.
- Langeland T, Fagertum HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. *Allergy*. 1994;49(1):22–6.
- Langer H, Hauswald B. Langzeitstudie über die Therapie der Rhinopathia pollinosa mittels Akupunktur bzw. Laserakupunktur Erfahrungsheilkunde. 1992;4:262–7.
- Langerhans P. Über die Nerven der menschlichen Haut. *Arch Pathol Anatom*. 1868;44:325–37
- Langeveld-Wildschut EG, Riedl H, Thepen T, Bihari IC, Bruijnzeel PL, Bruijnzeel-Koomen CA. Modulation of the atopy patch test reaction by topical corticosteroids and tar. *J Allergy Clin Immunol*. 2000;106:737–43.
- Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cells responses: lineages, plastic and kinetics. *Curr Opin Immunol*. 2001;13:291.
- Lara-Corrales I, Gomez G, De Los RC, Pope E. Vitamin D in patients dermatitis: a randomized, double-blinded, placebo-controlled study preliminary analysis. *Pediatr Dermatol*. 2013;30:638.
- Larkö O, Swanbeck G. Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. *Acta Derm Venereol*. 1982;62(6):507–12.
- Lau S, Falkenhorst G, Weber A, et al. High mite-allergen exposure increases the risk of sensitization in atopic children and young adults. *J Allergy Clin Immunol*. 1989;84:718–25.
- Lauffer F, Ring J. Target oriented therapy – emerging specific drugs for atopic dermatitis. *Emerging Drugs*, 2016.
- Lee YA, Wahn U, Kehrer R, et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. *Nat Genet*. 2000;26:470473.
- Lee YL, Su HJ, Scheu HM, Yu HS, Guo YL. Traffic-related air pollution, climate, and prevalence of eczema in Taiwanese school children. *J Invest Dermatol*. 2008;128:2412–20.
- Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, Doan S, Marmouz F, Demoly P, Delgado L. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. *Allergy*. 2012;67:1327–37.
- Leung DY. Role of *Staphylococcus aureus* in atopic dermatitis. In: Bieber T, Leung DYM, editors. *Atopic dermatitis*. New York: Marcel Dekker; 2002. p. 401–18.
- Leung DY. Infection in atopic dermatitis. *Curr Opin Pediatr*. 2003;15:399–404.
- Leung AK, Barber KA. Managing childhood atopic dermatitis. *Adv Ther*. 2003;20:129–37.
- Leung DY, Bieber T. Atopic dermatitis. *Lancet*. 2003;361:151.
- Leung DY, Hirsch RL, Schneider L, et al. Thymopentin therapy reduces the clinical severity of atopic dermatitis. *J Allergy Clin Immunol*. 1990;85:927–33.

- Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, Hanifin JM, Sampson HA. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. *J Clin Invest.* 1993;92:1374–80.
- Leung DY, Sampson HA, Yunginger JW, Burks Jr AW, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan Jr WR. Effect of anti-IgE therapy in patients with peanut allergy. *N Engl J Med.* 2003;348:986.
- Leutgeb C, Bandmann HJ, Breit R. Handlinienmuster, Ichthyosis vulgaris und Dermatitis atopica. *Arch Dermatol Forsch.* 1972;244:344–56.
- Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. *Br J Dermatol.* 1988;119:189–98.
- Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. *Int J Clin Pract.* 2006;60:1251–8.
- Lewis-Jones MS, Finlay AY, Dykes PJ. The infants' dermatitis quality of life index. *Br J Dermatol.* 2001;144:104–10.
- Leyden JJ, et al. Staphylococcus aureus in the lesions of atopic dermatitis. *Br J Dermatol.* 1975;90:525 ff.
- Lichtenstein LM. The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A 23187. *J Immunol.* 1975;114:1692–9.
- Lim A, Luderschmidt S, Weidinger A, Schnopp C, Ring J, Hein R, Ollert M, Mempel M. The IgE repertoire in PB-MCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias. *J Allergy Clin Immunol.* 2007;120:696–706.
- Lipozencic J, Wolf R. Atopic dermatitis: an update and review of the literature. *Dermatol Clin.* 2007;25:605–12.
- Lob-Corzilius T, Petermann F. Asthmaschulung – Wirksamkeit bei Kindern und Jugendlichen. Beltz: Weinheim; 1997.
- Lobitz WC, Campbell CJ. Physiologic studies in atopic dermatitis (disseminated neurodermitits) I. The local cutaneous response to intradermally injected acetylcholine and epinephrine. *Arch Dermatol Syphil.* 1953;67:575.
- Loden M, Anderson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). *Br J Dermatol.* 1999a;140:264–7.
- Loden M, Andersson AC, Lindberg M. The effect of two urea-containing creams on dry, eczematous skin in atopic patients. II Adverse effects. *J Dermatolog Treat.* 1999b;10(3):171–5.
- Lonne-Rahm SB, Rickberg H, El-Nour H, Mårin P, Azmitia EC, Nordlind K. Neuroimmune mechanisms in patients with atopic dermatitis during chronic stress. *J Eur Acad Dermatol Venereol.* 2008;22:11–8.
- Lord GM. Nephropathy caused by Chinese herbs in the UK. *Lancet.* 1999;354:481–2.
- Lü ZR, Park TH, Lee ES, Kim KJ, Park D, Park YD, Yang JM. Dysregulated genes of extrinsic type of atopic dermatitis: 34 K microarray and interactomic analyses. *J Dermatol Sci.* 2009;53:146–50.
- Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. *Hautarzt.* 2003;54(5):432–9.
- Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. *J Eur Acad Dermatol Venereol.* 2010;25:251–8.
- Luger TA, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schöpf E, Thestrup-Pedersen K, Van der Valk PGM, Bos J. SDZ ASM981: an emerging new standard for the treatment of atopic dermatitis. *Br J Dermatol.* 2001;144:788–94.
- Luger T, Loske K, Elsner P, et al. Topical skin therapy with glucocorticosteroids – therapeutic index. *J Dtsch Dermatol Ges.* 2004;7:629–34.
- Luger TA, Bieber T, Meurer M, et al. Therapie des atopischen Ekzems mit Calcineurin-Inhibitoren. Leitlinie der Deutschen Dermatologischen Gesellschaft. *J Dtsch Dermatol Ges.* 2005;3:385–91.
- Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, Eigenmann P, Fölster-Holst R, Gelmetti C, Gollnick H, Hamelmann E, Hebert AA, Muraro A, Oranje AP, Paller AS, Paul C, Puig L, Ring J, Siegfried E, Spengel JM, Stingl G, Taieb A, Torrelo A, Werfel T, Wahn U. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. *Pediatr Allergy Immunol.* 2015;26:306–15.
- Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. *J Eur Acad Dermatol Venereol.* 2010;24:43–9.
- Mackie RM, Husain SL. Juvenile plantar dermatosis: a new entity? *Clin Exp Dermatol.* 1976;1:253–60.
- Maeda K, Yamamoto K, Tanaka Y, Anan S, Yoshida H. House dust mite (HDM) antigen in naturally occurring lesions of atopic dermatitis (AD): the relationship between HDM antigen in the skin and HDM antigen-specific IgE antibody. *J Dermatol Sci.* 1992;3:73–7.
- Mailhol C, Lauwers-Cances V, Rancé F, Paul C, Giordano-Labadie F. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. *Allergy.* 2009;64:801–6.
- Manenti L, Vaglio A. Gabapentin for uraemic pruritus. *Nephrol Dial Transpl.* 2005;20:1278–9.
- Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, Enomoto T, Hashimoto T, Furuyama J, Hopkin JM, Morimoto K. Association between genetic variants of mast-cell chymase and eczema. *Lancet.* 1996;348:581–3.
- Marchionini A, Borelli S. Klimabehandlung der Neurodermitis disseminata. *Dtsch Med Wschr.* 1956;81:811–6.
- Marchionini A, Hausknecht W. Säuremantel der Haut und Bakterienabwehr. *Klein Wochenschr.* 1938;17:633–66.
- Marghescu S. Patch test reactions in atopic patients. *Acta Derm Venereol.* 1985;114:113–7.
- Marsella R, Girolomoni G. Canine models of atopic dermatitis: a useful tool with untapped potential. *J Invest Dermatol.* 2009;129:2351–7.
- Marsh DG, Meyers DA, Bias WB. The epidemiology and genetics of atopic allergy. *N Engl J Med.* 1981;305:1551–9.

- Marsh DG, Neely JD, Breazeale DR, et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. *Science*. 1994;264:1152–6.
- Marty P. La relation objectale allergique. *Rev Franc Psychoanal*. 1958;22:5–35.
- Massoumi R. The central role of Bcl-3 in atopic dermatitis. *J Invest Dermatol*. 2009;129:2088–90.
- Matzinger P. Memories are made of this? *Nature*. 1994;369:605–6.
- Maurer D, Fiebiger E, Reininger B, Wolff-Winiski B, Jouvin MH, Kilgus O, Kinet JP, Stingl G. Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals. *J Exp Med*. 1994;179:745.
- Maurer M, Church M, Gonçalo M, Sussman G, Sánchez-Borges M. Management and treatment of chronic urticaria (CU). *J Eur Acad Dermatol Venereol*. 2015; (29 Suppl 3):16–32.
- Maurer M, Rosén K, Hsin-Ju HJ, Saini S, Grattan C, Giménez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med*. 2013;368:2340–3.
- Mayaux MJ, Guihard-Moscato ML, Schwartz D, Benveniste J, Coquin Y, Crapanne JB, Poiterin B, Rodary M, Chevrel JP, Mollet M. Controlled clinical trial of homoeopathy in postoperative ileus. *Lancet*. 1988;8584:528–9.
- Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. *Zentralbl Bakteriol B*. 1978;167:375–90.
- Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, Gieler U. Treatment of head and neck dermatitis with ciclopiroxolamine cream – results of a double-blind, placebo-controlled study. *Skin Pharmacol Physiol*. 2006;19(3):153–9.
- McNally NJ, Williams HC, Phillips DR, et al. Atopic eczema and domestic water hardness. *Lancet*. 1998;352:527–31.
- Mee AS, Brown D, Jewell DP. Atopy in inflammatory bowel disease. *Scand J Gastroenterol*. 1979;14(6):743–6.
- Meerwaldt R, Odink RJ, Landaeta R, Aarts F, Brunekr FB, Gerritsen J, van Aalderen WM, Hoekstra MO. A lower prevalence of atopy symptoms in children with type 1 diabetes mellitus. *Clin Exp Allergy*. 2002;32:254–5.
- Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet*. 2006;367(9513):839–46.
- Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. *Br J Dermatol*. 1997;137:568–76.
- Melin L, Frederiksen T, Noren P, Swebilus BG. Behavioural treatment of scratching in patients with atopic dermatitis. *Br J Dermatol*. 1986;115(4):467–74.
- Mempel M, Hojka M, Schnopp C, Ring J, Abeck D. Colonization features of *Staphylococcus aureus* in children with atopic eczema. *Ann Dermatol Venereol*. 1998;125 Suppl 1:S63.
- Menz G, Kronenberger H, Lecheler J, Schulz K. Rehabilitation bei Asthma bronchiale. *Pneumologie*. 2007;61:710–20.
- Mercuriali H. De morbis cutaneis et omnibus corporis humani excrementis tractatus. Venetiis: Aput Iuntas; 1601.
- Merk HF, Bickers DR. *Dermatopharmatologie und Dermatopharmazie*. Berlin: Blackwell; 1992.
- Metzger H, Rivnay B, Henkart M, Kanner B, Kinet JP, Perez-Montfort R. Analysis of the structure and function of the receptor for immunoglobulin E. *Mol Immunol*. 1984;21:1167–75.
- Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Junger M, Bräutigam M. CASM-DE-01 study group: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology*. 2002;205:271–7.
- Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. *Dermatology*. 2004;208:365–72.
- Meyerson LW. A peculiar papulosquamous eruption involving pigmented nevi. *Arch Dermatol*. 1971;103:510–2.
- Mier PD. Earliest description of the atopic syndrome? *Br J Dermatol*. 1975;92:359.
- Mihm MC, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. *J Invest Dermatol*. 1976;67:305–12.
- Mildner M, Jin J, Eckhart L, Kezic S, Gruber F, Barresi C, Stremnitzer C, Buchberger M, Mlitz V, Ballaun C, Sterniczky B, Födinger D, Tschachler E. Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. *J Invest Dermatol*. 2010;130:2286–94.
- Milgrom H, Berger W, Nayak A, Gupta N, Pollard S. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). *Pediatrics*. 2001;108:36–45.
- Milingou M, Antille C, Sorg O, Saurat JH, Lubbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. *Arch Dermatol*. 2004;140(12):1542–4.
- Mitchell EB, Crow J, Chapman MD, Jouhal SS, Pope FM, Platts-Mills TAE. Basophils in allergen-induced patch test sites in atopic dermatitis. *Lancet*. 1982;1:127–30.
- Mitschenko AV, Lwow AN, Kupfer J, Niemeier V, Gieler U. Neurodermitis und Stress. *Hautarzt*. 2008;59:314–8.
- Mitsuyama K, Niwa M, Masuda J, Yamasaki H, Kuwaki K, Takedatsu H, Kobayashi T, Kinjo F, Kishimoto K, Matsui T, Hirai F, Makiyama K, Ohba K, Abe H, Tsubouchi H, Fujita H, Maekawa R, Yoshida H, Sata M, Kyushu ACP Study Group. Possible diagnostic role of antibodies to Crohn's disease peptide (ACP):

- results of a multicenter study in a Japanese cohort. *J Gastroenterol.* 2014;49(4):683–91. doi:10.1007/s00535-013-0916-9.
- Mittermann I, Reininger R, Zimmermann M, Gangl K, Reisinger J, Aichberger KJ, Greisenegger EK, Niederberger V, Seipelt J, Bohle B, Kopp T, Akdis CA, Spitzauer S, Valent P, Valenta R. The IgE-reactive autoantigen Hom s 2 induces damage of respiratory epithelial cells and keratinocytes via induction of IFN- γ . *J Invest Dermatol.* 2008;128:1451–9.
- Miyagaki T, Sugaya M. Erythrodermic cutaneous T cell lymphoma: how to differentiate this rare disease from atopic dermatitis. *J Dermatol Sci.* 2011;64:1–6.
- Miyake Y, Yokoyama T, Yura A, Iki M, Shimizu T. Ecological association of water hardness with prevalence of childhood atopic dermatitis in a Japanese urban area. *Environ Res.* 2004;94:33–7.
- Moffatt M, Cookson W. The genetics of asthma. Maternal effects in atopic disease. *Clin Exp Allergy.* 1998;28 Suppl 1:56–61.
- Moffatt MF, Hill MR, Cornelis J, Schou C, et al. Genetic linkage of T-cell α/δ complex specific IgE responses. *Lancet.* 1994;343:1597–600.
- Moffatt MF, Kabesch M, Lian L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. *Nature.* 2007;448:470–3.
- Möhrenschlager M, Ring J. Allergy to peanut oil – clinically relevant? *J Eur Acad Dermatol Venereol.* 2007;21:452–5.
- Möhrenschlager M, Schäfer T, Williams HC, von der Werth J, Krämer U, Behrendt H, Ring J. Übersetzung und Validierung der britischen Diagnosekriterien des atopischen Ekzems bei 8- und 9-jährigen Schulkindern in Augsburg. *Allergol J.* 1998;7:373–7.
- Möhrenschlager M, Beham A, Abeck D, Ring J. Atopic eczema in monozygotic twins with Dubowitz syndrome. *Br J Dermatol.* 1998;138:1091–2.
- Möhrenschlager M, Weidinger S, Huss-Marp J, Krämer U, Behrendt H, Ring J. Do gender-specific differences in eyelash length in 5- to 6-year old preschoolchildren with and without atopic eczema exist? Results from the MIRIAM study conducted in Augsburg, Germany. *Pediatr Dermatol.* 2005;22:576–7.
- Möhrenschlager M, Darsow U, Schnopp C, Ring J. Atopic Eczema: what's new? *J Eur Acad Dermatol Venereol.* 2006a;20:503–13.
- Möhrenschlager M, Schäfer T, Huss-Marp J, Eberlein-König B, Weidinger S, Ring J, Behrendt H, Krämer U. The course of eczema in children aged 5–7 years and its relation to atopy: differences between boys and girls. *Br J Dermatol.* 2006b;3:505–13.
- Möller H. Atopic winter feet in children. *Acta Derm Venereol.* 1972;52:401–5.
- Molin S, Vollmer S, Weiss EH, Ruzicka T, Prinz JC. Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. *Br J Dermatol.* 2009;161(4):801–7. doi:10.1111/j.1365-2133.2009.09245.x. Epub 2009 Apr 22.
- Morgan DB. A suggestive sign of allergy. *Arch Dermatol.* 1948;57:1050.
- Morgenstern V, Zutavern A, Cyrus J, Brockow K, Koletzko S, Krämer U, Behrendt H, Herbarth O, von Berg A, Bauer CP, Wichmann HE, Heinrich J, GINI Study Group; LISA Study Group. Atopic diseases, allergic sensitization and exposure to traffic-related air pollution in children. *Am J Respir Crit Care Med.* 2008;177:1331–7.
- Mossmann TR, Saat S. The expanding universe of T-cell subsets: Th1, Th2 and more. *Immunol Today.* 1996;17:138–46.
- Mostafa-Kara N, Pauwels A, Pinus E, Biuor M, Levy VG. Fatal hepatitis after herbal tea. *Lancet.* 1992;340:674.
- Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. *Dermatol Online J.* 2014;16:22608.
- Mrabet-Dahbi S, Maurer M. Does allergy impair innate immunity? Leads and lessons from atopic dermatitis. *Allergy.* 2010;65:1351–6.
- Muche-Borowski C, Kopp M, Reese I, Sitter H, Werfel T, Schäfer T, German Society for Allergology and Clinical Immunology (DGAKI); Society of German Allergologists (ADA); German Society for Pediatric and Adolescent Medicine (DGKJ); German Society of Dermatology (DDG); German Society of Pediatric Allergology (GPA). Allergy prevention. *J Dtsch Dermatol Ges.* 2010;8:718–24.
- Münch D. Music therapy in atopic eczema. In: Ring J, Przybilla B, Ruzicka T, editors. Handbook of atopic eczema. 2nd ed. Berlin/New York/Tokio: Springer; 2006. p. 565–9.
- Munkvad M. A comparative trial of Clinitar versus hydrocortisone cream in the treatment of atopic eczema. *Br J Dermatol.* 1989;121:763–6.
- Münzel K. Psychosoziale Belastung als Einflussfaktor bei der atopischen Dermatitis. In: Petermann F, Warschburger P, editors. Neurodermitis. Göttingen: Hogrefe; 1999.
- Münzel K, Schandry R. Atopisches Ekzem. Pathophysiologische Reaktivität unter standardisierter Belastung. *Hautarzt.* 1990;41:606–11.
- Murota H, Kitaba S, Tani M, Wataya-Kaneda M, Azukizawa H, Tanemura A, Umegaki N, Terao M, Kotobuki Y, Katayama I. Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases. *Allergol Int.* 2010;59:345–54.
- Murphy LA, Atherton DJ. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyl transferase levels to exclude patients at high risk of myelosuppression. *Br J Dermatol.* 2002;147:324–30.
- Murray CS, Rees J. Are subjective accounts of itch to be relied on? The lack of relation between visual analogue itch scores and actigraphic measures of itch. *Acta Derm Venereol.* 2011;91:18–23.
- Müseler A, Rakoski J, v. Zumbusch R, Henning M, Borelli S. Vergleichende hautphysiologische Untersuchung zur Wirksamkeit von Zinkschüttelmixtur bei akuter Neurodermitis. *Z Hautkr.* 1995;70:803–7.

- Mustakallio KK, Kiistala U, Piha HJ, Nieminen E. Epidermal lipids in Besnier's prurigo (atopic eczema). *Ann Med Exp Biol Fenn.* 1967;45:323–5.
- Nagelkerken L, Verzaal P, Lagerweij T, Persoon-Deen C, Berbee JFP, Prens EP, Havekes LM, Oranje AP. Development of atopic dermatitis in mice transgenic for human apolipoprotein C1. *J Invest Dermatol.* 2007;128:1165–72.
- Nahm D-H, Lee ES, Park H-J, Kim H-A. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. *Int Arch Allergy.* 2008;146:235–40.
- Nakano T, Shimojo N, Okamoto Y, Ebisawa M, Kurihara K, Hoshioka A, Yamaguchi K, Ito K, Fujisawa T, Kameda M, Suehiro Y, Ogura H, Shibata R, Suzuki S, Takahashi Y, Ikeda M, Kohno Y. The use of complementary and alternative medicine by pediatric food-allergic patients in Japan. *Int Arch Allergy Immunol.* 2012;159:410–5.
- Naldi L, Mercury SR. Chronic pruritus management: a plea for improvement – can itch clinics be an option? *Dermatology.* 2010;221:216–8.
- Napadow V, Li A, Loggia M, Kim J, Mawla I, Desbordes G, Schalock PC, Lerner EA, Tran TN, Ring J, Rosen BR, Kapchuk TJ, Pfab F. The imagined itch: brain circuitry supporting nocebo-induced itch in atopic dermatitis patients. *Allergy.* 2015;17:10.1111–12727, in press.
- Natter S, Seiberler S, Hufnagl P, Binder BR, Hirschl AM, Ring J, Abeck D, Schmidt T, Valent P, Valent R. Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. *FASEB J.* 1998;12:1559–69.
- Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. *J Allergy Clin Immunol.* 2006;118:930–7.
- Nemoto-Hasebe I, Akiyama M, Nomura T, Sandilands A, McLean WI, Shimizu H. Clinical Severity Correlates with Impaired Barrier in Filaggrin-Related Eczema. *J Invest Dermatol.* 2009;129:682–9.
- Nenoff P, Reinl P, Hausteil UF. *Der Hefepilz Malassezia.* Erreger, Pathogenese und Therapie. *Hautarzt.* 2001;52:73–86.
- Neuber K, Gerhard C, Held KR, Ring J. Dramatic improvement of nummular eczema after parenteral testosterone substitution in a patient with mixed gonadal dysgenesis. *Allergo J.* 1993;5:77–8.
- Neuber K, Steinrücke K, Ring J. Staphylococcal Enterotoxin B Affects in vitro IgE Synthesis, Interferon- γ , Interleukin-5 production in Atopic Eczema. *Int Arch Allergy Immunol.* 1995;107:179–82.
- Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. *Br J Dermatol.* 2000;143:385–91.
- Neumann C. Contact allergy and atopic eczema. In: Ruzicka T, Ring J, Przybilla B, editors. *Handbook of atopic eczema.* Berlin/New York: Springer; 1991.
- Niebel G. Verhaltensmedizinisches Gruppentraining für Patienten mit atopischer Dermatitis in Ergänzung zur dermatologischen Behandlung; Pilotstudie zur Erprobung von Selbsthilfestrategien. *Verhaltenmodifikation und Verhaltensmedizin.* 1990; 11:24–44.
- Niebel G. *Verhaltensmedizin der chronischen Hautkrankheiten.* Huber Verlag: Bern; 1995.
- Niggemann B, Reibel S, Wahn U. The atopy patch test (APT) – a useful tool for the diagnosis of food allergy in children with atopic dermatitis. *Allergy.* 2000;55:281–5.
- Niggemann B, Reibel S, Roehr CC, Felger D, Ziegert M, Sommerfeld C, Wahn U. Predictors of positive food challenge outcome in non-IgE-mediated reactions to food in children with atopic dermatitis. *J Allergy Clin Immunol.* 2001;108:1053–8.
- Nishioka K, Yasueda H, Saito H. Preventive effect of bedding encasement with microfine fibers on mite sensitization. *J Allergy Clin Immunol.* 1998;101: 28–32.
- Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. *J Allergy Clin Immunol.* 2015;135:324–36.
- Novak N. New insights into the mechanism and management of allergic diseases: atopic dermatitis. *Allergy.* 2009;64:265–75.
- Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. *J Allergy Clin Immunol.* 2003;112:252–62.
- Novak N, Allam JP, Bieber T. Allergic hyperreactivity to microbial components: a trigger factor of “intrinsic” atopic dermatitis? *J Allergy Clin Immunol.* 2003;112:215–6.
- Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J, et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. *Allergy.* 2007;62:766–72.
- Novak N, Bieber T, Hoffmann M, Fölster-Holst R, Homey B, Werfel T, Sager A, Zuberbier T. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. *J Allergy Clin Immunol.* 2012;130: 925–31.
- Novembre E, Cianferoni A, Lombardi E, Bernardini R, Pucci N, Vierucci A. Natural history of “intrinsic” atopic dermatitis. *Allergy.* 2001;56:453–4.
- Nowak D, Heinrich J, Jörres R. Prevalence of respiratory symptoms, bronchial hyperresponsiveness and atopy among adults: West and East Germany. *Eur Respir J.* 1996;9:2541–52.
- Nürnberg W. Stationäre Rehabilitation von Hauterkrankungen am Beispiel des atopischen Ekzems. *Hautarzt.* 2005;56:644–8.
- O'Driscoll J, Burden AD, Kingston TP. Potent topical steroid obtained from a Chinese herbalist. *Br J Dermatol.* 1992;127:543–4.
- Ochs HD, Oukka M, Torgerson TR. TH17 cells and regulatory T cells in primary immunodeficiency diseases. *J Allergy Clin Immunol.* 2009;123:977–83.
- Oepen J. Unkonventionelle diagnostische und therapeutische Methoden in der Umweltmedizin. *Gesundheitswesen.* 1998;60:420–30.

- Oh SH, Bae BG, Park CO, Noh JY, Park IH, Wu WH, Lee KH. Association of stress with symptoms of atopic dermatitis. *Acta Derm Venereol.* 2010;90:582–8.
- Ohman S, Johansson SGO. Immunoglobulins in atopic dermatitis with special reference to IgE. *Acta Derm Venerol (Stockh).* 1974;54:193–202.
- Ohtsuka T, Matsumaru S, Uchida K, et al. Time course of plasma histamine and tryptase following food challenges in children with suspected food allergy. *Ann Allergy.* 1993;71:139–46.
- Oji V, Eckl K-M, Aufenvenne K, Nätebus M, Tarinski T, Ackermann K, Seller N, Metz D, Nürnberg G, Fölster-Holst R, Schäfer-Korting M, Hausser I, Traupe H, Hennies HC. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. *Am J Hum Genet.* 2010;87:1–8.
- Olaiwan A, Chandresris MO, Fraïtag S, Lortholary O, Hermine O, Fischer A, de Prost Y, Picard C, Bodemer C. Cutaneous findings in sporadic and familial autosomal dominant hyper-IgE syndrome: a retrospective, single-center study of 21 patients diagnosed using molecular analysis. *J Am Acad Dermatol.* 2011;65:1167–72.
- Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plotz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. *Allergy.* 2005;60:693–6.
- Olesen AB. Diseases rarely associated with atopic eczema. In: Ring J, Przybilla B, Ruzicka T, editors. *Handbook of atopic eczema.* 2nd ed. Berlin/New York/Tokio: Springer; 2006. p. 144–9.
- Olesen AB, Ellingsen AR, Larsen ES, Larsen PO, Veien NK, Thestrup-Pedersen K. Atopic dermatitis may be linked to whether a child is first or second born and/or the age of the mother. *Acta Derm Venerol (Stockh).* 1996;76:457–60.
- Olesen AB, Ellingsen AR, Olesen H, Juul S, Thestrup PK. Atopic dermatitis and birth factors: historical follow-up by record linkage. *BMJ.* 1997;314:1003–8.
- Olesen AB, Juul S, Birkebaek N, Thestrup-Pedersen K. Association between atopic dermatitis atopic dermatitis and insulin-dependent diabetes mellitus: a case-control study. *Lancet.* 2001;357:1749–52.
- Olesen AB, Juul S, Thestrup-Pedersen K. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. *Acta Derm Venereol.* 2003;83:445–50.
- Oranje A, De Waard-van der Spek F. Atopic dermatitis and diet. *J Eur Acad Dermatol Venereol.* 2000;14:437–8.
- Orihara K, Nakae S, Pawankar R, Saito H. Role of regulatory and proinflammatory T-cell populations in allergic diseases. *WAO J.* 2008;1:9–14.
- Ortonne JP, Perrot H, Thivolet J. Étude clinique et statistique d'une population de 100 vitiligos: facteurs étiologiques et étude clinique. *Sem Hop Paris.* 1976;52:679–86.
- Owada Y, Takano H, Yamanaka H, Kobayashi H, Sugitani Y, Tomioka Y, Suzuki I, Suzuki R, Terui T, Mizugaki M, Tagami H, Noda T, Kondo H. Altered water barrier function in epidermal-type fatty acid binding protein-deficient mice. *J Invest Dermatol.* 2002;118(3):430–5.
- Ozkaya E. Adult-onset atopic dermatitis. *J Am Acad Dermatol.* 2005;52:579–82.
- Pajno GB, Vita D, Barberio E, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind placebo-controlled study. *J Allergy Clin Immunol.* 2007;120:164–70.
- Pallas S, Huss-Marp J, Ring J, Behrendt H, Eberlein B. Charakterisierung von Patienten mit umweltbezogenen Gesundheitsstörungen an einer dermatologisch-allergologischen Klinik. *Umweltmed Forsch Prax.* 2010;15:135–47.
- Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. *J Am Acad Dermatol.* 2001;44:S47–57.
- Paller AS, Lebwohl M, Fleischer AB, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized comparative studies. *J Am Acad Dermatol.* 2005;52:810–22.
- Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet.* 2006;38:441–6.
- Papoiu ADP, Wang H, Coghill RC, Chan Y-H, Yosipovitch G. Contagious itch in humans: a study of visual “transmission” of itch in atopic dermatitis and healthy subjects. *Br J Dermatol.* 2011;164:1299–303.
- Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. *Lancet.* 2012;380(9843):738–46.
- Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K, PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. *Br J Dermatol.* 2013;168(4):844–54.
- Park J, Kim B-J, Kwon J-W, Song YH, Yu J, Kim H-B, Lee S-Y, Kim WK, Jee HM, Kim KW, Kim K-E, Hong S-J, Shin Y-J. Patterns of psychosocial adaptation and allergic disorders in Korean schoolchildren. *Int Arch Allergy Immunol.* 2011;154:249–57.
- Paternoster L, Zhurov AI, Toma AM, Kemp JP, St Pourcain B, Timpson NJ, McMahon G, McArdle W, Ring SM, Smith GD, Richmond S, Evans DM. Genome-wide association study of three-dimensional facial morphology identifies a variant in PAX3 associated with nasion position. *Am J Hum Genet.* 2012;90:478–85.
- Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A randomized controlled evaluator-blinded trial

- of intravenous immunoglobulin in adults with severe atopic dermatitis. *Br J Dermatol.* 2002;147:518–22.
- Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, Hamelmann E. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. *J Allergy Clin Immunol.* 2013;132:601–7.
- Pepys J. Atopy. In: Gell PG, Coombs RRA, Lachmann PF, editors. *Clinical aspects of immunology.* 3rd ed. Oxford: Blackwell; 1975. p. 877.
- Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol.* 2008;158:801–7.
- Petermann F, Warschburger P, editors. *Neurodermitis.* Göttingen: Hogrefe; 1999.
- Petermann F, Gulyas AF, Nieband K, Warschburger P. Effects of allergen avoidance at high altitude on children with asthma or atopic dermatitis. *Pediatr Asthma Allergy Immunol.* 2004;17:15–24.
- Pfäb F, Huss-Marp J, Gatti A, Fuqin J, Athanasiadis GI, Irnich D, Raap U, Schober W, Behrendt H, Ring J, Darsow U. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema – a blinded, randomized, placebo-controlled, crossover trial. *Allergy.* 2010a;66:903–10.
- Pfäb F, Valet M, Sprenger T, Huss-Marp J, Athanasiadis GI, Baurecht HJ, Konstantinow A, Zimmer C, Behrendt H, Ring J, Tölle TR, Darsow U. Temperature-modulated histamine-itch in nonlesional skin in atopic eczema – a combined psychophysical and neuroimaging study. *Allergy.* 2010b;65:84–94.
- Pfäb F, Valet M, Napadow V, Tölle TR, Behrendt H, Ring J, Darsow U. Itch and the brain. *Chem Immunol Allergy.* 2012;98:253–65.
- Pflugshaupt C. Eigenwirkungen von Vehikeln. Systematik und Gedanken zur Vehikelwahl. *Dt Dermatol.* 1992;8:1144–55.
- Pichler W, Bircher AA, Wüthrich B. Spezialistenkommission der Schweizer Gesellschaft für Allergologie und Immunologie. Allergologie und Alternativmedizin. Stellungnahme zu paramedizinischen Verfahren, speziell Bioresonanz. *Schweiz Ärztezeitung, nachgedruckt in. Allergologie.* 1996;19:158–61.
- Piérard GE. What do you mean by dry skin? *Dermatologica.* 1989;179:1–2.
- Pilette C, Jacobson MR, Ratajczak C, Detry B, Banfield G, VanSnick J, et al. Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis. *Allergy.* 2013;68:312–21.
- Pion IA, Koenig KL, Lim HW. Is dermatologic usage of coal tar carcinogenic? A review of the literature. *Dermatol Surg.* 1995;21:227–31.
- Platts-Mills T, Mitchell E, Rowntree S, Chapman M, Wilkins S. The role of dust mite allergens in atopic dermatitis. *Clin Exp Dermatol.* 1983;8:233–47.
- Plaut M, Tinkle SS. Risks of smallpox vaccination: 200 years after Jenner. *J Allergy Clin Immunol.* 2003;112:683–5.
- Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J. Use of anti-interleukin-5 antibody in hypereosinophilic syndrome with eosinophilic dermatitis. *N Engl J Med.* 2003;349:2332–7.
- Plötz SG, Wiesender M, Todorova A, Ring J. What is new in atopic dermatitis/eczema? *Expert Opin Emerg Drugs.* 2014;19:9–18.
- Pluut OA, Bianco C, Jakasa I, Visser MJ, Krystek P, Larese-Filon F, et al. Percutaneous penetration of silver from a silver containing garment in healthy volunteers and patients with atopic dermatitis. *Toxicol Lett.* 2015;235:116–22.
- Prausnitz C, Kästner H. Studien über die Überempfindlichkeit. *Zentralbl Bakteriol Parasitenk Infekti-onskr Hygiene.* 1921;86:160.
- Premerlani M, Ludewig Y, Schnopp C, Ring J. Eczema school: practical approaches in an efficient module of tertiary prevention programs. In: Ring J, Przybilla B, Ruzicka T, editors. *Handbook of atopic eczema.* 2nd ed. Berlin/New York/Tokio: Springer; 2006. p. 576–81.
- Prescott S. Early origins of allergic disease: a review of processes and influences during early immune development. *Curr Opin Allergy Clin Immunol.* 2003;3:125–32.
- Prescott SL, MacAubas C, Smallcombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. *Lancet.* 1999;353:196–200.
- Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photophoresis. *Arch Dermatol Res.* 1994;287:48–52.
- Prochazka B. Sensibilität und Abgrenzung bei Neurodermitikern. Wiesen: Porsch; 1994.
- Proksch E, Jensen JM, Elias PM. Skin lipids and epidermal differentiation in atopic dermatitis. *Clin Dermatol.* 2003;21:134–44.
- Proksch E, Fölster-Holst R, Jensen M. Skin barrier function, epidermal proliferation and differentiation in eczema. *J Dermatol Sci.* 2006;43:159–69.
- Prucha H, Chen W, Traidl-Hoffmann C, Todorova A, Akdis C, Lauener R, Ring J. Atopic eczema and allergies: practical relevance for diagnostic work-up. *Community Based Med J.* 2013;2:15–24.
- Przybilla B, Ring J. Food allergy and atopic eczema. *Semin Dermatol.* 1990;9:220–5.
- Przybilla B, Enders F, Ring J, Winkelmann H. Stigmata of atopic constitution in patients with atopic eczema or atopic respiratory disease. *Acta Derm Venereol.* 1991;71:407–10.
- Przybilla B, Eberlein-König B, Rueff F. Practical management of atopic eczema. *Lancet.* 1994;343:1342–6.
- Pugh SM, Rhodes J, Mayberry JF, Roberts DL, Heatley RV, Newcombe RG. Atopic disease in ulcerative colitis and Crohn's disease. *Clin Allergy.* 1979;9(3):221–3.
- Purohit A, Duvernelle C, Melac M, Pauli G, Frossard N. Twenty-four hours of activity of cetirizine and

- fexofenadine in the skin. *Ann Allergy Asthma Immunol.* 2001;86:387–92.
- Purvis DJ, Thompson JM, Clark PM, et al. Risk factors for atopic dermatitis in New Zealand children at age 3,5 years of age. *Br J Dermatol.* 2005;152:742–9.
- Purwar R, Werfel T, Wittmann M. Regulation of IL-13 receptors in human keratinocytes. *J Invest Dermatol.* 2007;127:1271–4.
- Quaranta M, Knapp B, Garzorz N, et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. *Sci Transl Med.* 2014;6:244.
- Queille-Roussel C, Raynaud F, Saurat JH. A prospective computerized study of 500 cases of atopic dermatitis in childhood. *Acta Derm Venerol (Stockh).* 1985;114(Suppl):87–92.
- Raap U, Werfel T, Jaeger B, Schmid-Ott G. Atopische Dermatitis und psychischer Stress. *Hautarzt.* 2003;54:925–9.
- Raap U, Ikoma A, Kapp A. Neurophysiology of pruritus. *Hautarzt.* 2006;57:379–84.
- Rabinowitz LG, Esterly NB. Atopic dermatitis and ichthyosis vulgaris. *Pediatr Rev.* 1994;15:220–6; quiz 226.
- Rajka G. Itch and IgE in atopic dermatitis. *Acta Derm Venereol.* 1980;92:38–43.
- Rajka G. Essential aspects of atopic dermatitis. Berlin/New York/Heidelberg: Springer; 1989.
- Rajka G, Winkelmann RK. Atopic dermatitis and Sézary Syndrome. *Arch Dermatol.* 1984;120:83–4.
- Ramirez de Knott HM, McCormick TS, Kalka K, Skandamis G, Ghannoum MA, Schluchter M, Cooper KD, Nedorost ST. Cutaneous hypersensitivity to *Malassezia sympodialis* and dust mite in adult atopic dermatitis with a textile pattern. *Contact Dermatitis.* 2006;54:92–9.
- Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. *J Eur Acad Dermatol Venerol.* 1996;7(Suppl I):15–22.
- Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. *Qual Life Res.* 1998;7:399–407.
- Ravens-Sieberer U, Bullinger M. KINDL – Fragebogen zur Erfassung der gesundheitsbezogenen Lebensqualität bei Kindermund Jugendlichen – Revidierte Form – Manual. 2000.
- Rechardt E. An investigation in the psychosomatic aspects of Prurigo Besnier. Helsinki: Psych Clinic d. Univ Helsinki; 1970.
- Reekers R, Beyer K, Niggemann B, et al. The role of circulating food antigen-specific lymphocytes in food allergic children with atopic dermatitis. *Br J Dermatol.* 1996;135:935–41.
- Reese I, Werfel T (Hrsg). *Nahrungsmittelallergie – Diätetische Gesichtspunkte und aktuelle Positionspapiere.* 2 aktualisierte Auflage. Deisenhofen: Dustri Verlag; 2006.
- Reinhard T, Ruzicka T, Sundmacher R. Pathogenese, Klinik und Therapie der Augenbeteiligung bei Atopie. *Ophthalmologie.* 1999;96:473–88.
- Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. *J Allergy Clin Immunol.* 2001;107:445–8.
- Reitamo S. European Tacrolimus Ointment Study Group: 0.1 % Tacrolimus ointment twice a day is an effective treatment for adults with moderate to severe atopic dermatitis. *JEADV.* 2003;17:180.
- Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis results of a single-center randomized trial. *J Invest Dermatol.* 1998;111:396–8.
- Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Täieb A, Gratton D, Sauder D, Sharpe G, Smith C, Junger M, de Prost Y. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. *J Allergy Clin Immunol.* 2002;109(3):539–46.
- Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1 % tacrolimus ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol.* 2005;152:1282–9.
- Reitamo S, Ortonne JP, Sand C, Bos J, Cambazard F, Bieber T, Gronhoj-Larsen C, Rustin M, Fölster-Holst R, Schuttelaar M. Long-term treatment with 0.1 % tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. *Acta Derm Venereol.* 2007;87:406–12.
- Reitamo S, Remitz A. An update on current pharmacotherapy options in atopic dermatitis. *Expert Opin Pharmacother.* 2014;15:1517–24.
- Remy W, Rakoski J, Siebenwirth J, Ulm K, Wiesenauer M. Classical homeopathic treatment in atopic dermatitis. *Allergologie.* 1995;18:246–52.
- Renz H, Hahn C, Schuhmann B, Kerzel S, Nassenstein C, Braun A, Päch G, Virchow C, Nockher WA. Neurotrophins in allergic bronchial asthma. In: Lowenstein H, Bienenstock J, Ring J, editors. *From genes to phenotypes.* Goettingen: Hogrefe Huber; 2006. p. 133–6.
- Reuter J, Wölfe U, Weckesser S, Schempp C. Which plant for which skin disease? Part 1: atopic dermatitis, psoriasis, acne, condyloma and herpes simplex. *J Dtsch Dermatol Ges.* 2010;8:788–96.
- Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. *Lancet.* 2001;357(9273):2012–6.
- Ricci G, Patrizi A, Specchia F. Mite allergen (Der p 1) levels in houses of children with atopic dermatitis: the relationship with allergometric tests. *Br J Dermatol.* 1999;140:651–5.
- Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. *Br J Dermatol.* 2000;143:379–84.
- Ricci G, Patrizi A, Bendandi B, Menna G, Varotti E, Masi M. Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis. *Br J Dermatol.* 2004;150(1):127–31.

- Richter R, Ahrens S. Psychosomatische Aspekte der Allergie in Manuale allergologicum (Fuchs E, Schulz KH) Dustri-Verlag. München Deisenhofen. 1990;8:1–16.
- Richter R, Dahme B. Psychosomatische Aspekte des Asthma bronchiale. *Prax Klin Pneumol*. 1987;60:1–16.
- Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S, Carr D, Schierl R, Nowak D, von Mutius E. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. *Lancet*. 2001;358:1129–33.
- Rigopolous D, Gregoriou S, Charissi C, Kontochristopoulos G, Kalogeromitros D, Georgala S. Tacrolimus ointment 0,1 % in pityriasis alba: an open-label, randomized, placebo-controlled study. *Br J Dermatol*. 2006;155(1):152–5.
- Ring J. Anaphylaktische Reaktionen. Berlin: Springer; 1978.
- Ring J. Atopic dermatitis. A disease of general vasoactive mediator dysregulation. *Int Arch Allergy Appl Immunol*. 1979;59:233–9.
- Ring J. Angewandte Allergologie. Munich: MMW; 1982a.
- Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial monozygoten twins. *Br J Dermatol*. 1982b;107:597–602.
- Ring J. Was ist Atopie? In: Braun-Falco O, Burk G, editors. Fortschritte der praktischen Dermatologie und Venerologie. Berlin/Heidelberg/New York: Springer; 1983. p. 103–11.
- Ring J, Lutz J. Decreased release of lysosomal enzymes from peripheral leukocytes of patients with atopic dermatitis. *J Am Acad Dermatol*. 1983;8(3):378–85.
- Ring J. Erstbeschreibung einer "atopischen Familien-Anamnese" im Julisch-Claudischen Kaiserhaus: Augustus, Claudius, Britannicus. *Hautarzt*. 1985;36:470–4.
- Ring J. Endogenous versus exogenous eczema. *Semin Dermatol*. 1990;9:195–6.
- Ring J, editor. Epidemiologie allergischer Erkrankungen. Munich: MMV; 1991a.
- Ring J. Atopy: condition, disease, or syndrome? In: Ruzicka T, Ring J, Przybilla B, editors. Hand-book of atopic eczema. Berlin/Heidelberg/New York: Springer; 1991b. p. 3–8.
- Ring J, editor. Neurodermitis. Expertise zur gesundheitlichen Versorgung und Vorsorge bei Kindern mit atopischem Ekzem. Landsberg: Ecomed; 1998.
- Ring J. Allergy in practice. Berlin/Heidelberg/New York: Springer; 2005.
- Ring J, Kunz B. Unsaturated fatty acids in the treatment of atopic eczema. In: Ring J, Ruzicka T, Przybilla B (eds), Handbook of Atopic Eczema 2nd ed, Springer, Berlin, New York; 1991.
- Ring J, Behrendt H. Allergie-Entstehung und Immunglobulin E-Bildung: Rolle von Infektionen und Umweltschadstoffen? *Allergo J*. 1993;2:27–30.
- Ring J, Fröhlich HH. Wirkstoffe in der dermatologischen Therapie. Berlin: Springer; 1985.
- Ring J, Landthaler M. Hyper-IgE syndromes. *Curr Probl Dermatol*. 1989;18:79–88.
- Ring J, Merkel C. Hämatogenes Kontaktekzem (systemische Kontaktekzem): Was ist das? In: Wolff H, Thomas P, Prinz J, editors. Fortschritte prakt Dermatol Venerol 22 (Ruzicka T. Berlin: Springer; 2012. p. 125–8.
- Ring J, Thomas P. Histamine and atopic eczema. *Acta Derm Venereol*. 1989;144:70–7.
- Ring J, Mathison DA, O'Connor R. In vitro cyclic nucleotide responsiveness of leukocytes and platelets in patients suffering from atopic dermatitis. *Int Arch Allergy Appl Immunol*. 1981;65:1–7.
- Ring J, Palos E, Zimmermann F. Psychosomatische Aspekte der Eltern-Kind-Beziehung bei atopischem Ekzem im Kindesalter. Erziehungsstil, Familiensituation im Zeichentest und strukturierten Interview. *Hautarzt*. 1986;37:560–7.
- Ring J, Przybilla B, Schwab U, Steger O. Klinisches Spektrum der Überempfindlichkeitsreaktionen gegen Sulfite. *Allergologie*. 1987;10:100–6.
- Ring J, Kunz B, Bieber T, Vieluf D, Przybilla B. The "atopy patch test" with aeroallergens in atopic eczema (abstract). *J Allergy Clin Immunol*. 1989;82.
- Ring J, Brockow K, Abeck D. The therapeutic concept of "patient management" in atopic eczema. *Allergy*. 1996;51:206–15.
- Ring J, Darsow U, Gfesser M, Vieluf D. The 'atopy patch test' in evaluating the role of aeroallergens in atopic eczema. *Int Arch Allergy Immunol*. 1997;113:379–83.
- Ring J, Darsow U, Behrendt H. Role of aeroallergens in atopic eczema: proof of concept with the atopy patch test. *J Am Acad Dermatol*. 2001a;45:49–52.
- Ring J, Krämer U, Schäfer T, Behrendt H. Why are allergies increasing? *Curr Opin Immunol*. 2001b;13:701–8.
- Ring J, Krämer U, Oppermann H, Ranft U, Behrendt H. Influence of pertussis/pertussis vaccination on asthma and allergy prevalence in East and West Germany. *Allergy Clin Immunol Int J World Allergy Org*. 2004;16(Suppl 1):17–24.
- Ring J, Barker J, Behrendt H, et al. Review of the potential photocarcinogenicity of topical calcineurin inhibitors. Position statement of the European Dermatology Forum. *J Eur Acad Dermatol Venereol*. 2005;19(6):663–71.
- Ring J, Ruzicka T, Przybilla B, editors. Handbook of atopic eczema. 2nd ed. Berlin/New York: Springer; 2006.
- Ring J, Möhrenschrager M, Henkel V. The US FDA "black box" warning for topical calcineurin inhibitors. *Drug Saf*. 2008;31:185–98.
- Ring J, Abraham A, de Cuyper C, Kim K, Langeland T, Parra V, Pigatto P, Reunala T, Szczepanski R, Möhrenschrager M, Bräutigam M, Rossi AB, Meents-Kopecky E, Schneider D. Control of atopic eczema with pimecrolimus cream 1 % under daily practice conditions: results of a >2000 patient study. *J Eur Acad Dermatol Venereol*. 2009;22:195–203.
- Ring J, Bachert C, Bauer P, Czech W (eds) Whitebook Allergy in Germany 3rd ed. Urban Vogel, München 2010.
- Ring J, von Zumbusch M. Neurodermitis. Beck, München 2002.
- Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lippozencic J, Luger T, Oranje AP, Schwerfer T, Schwenisson T, Seidenari

- S, Simon D, Ständer S, Stingel G, Schaller Sza-lais, Szepletowski JC, Taïeb A, Werfel T, Wollenberg A, Darsow U. Guidelines for treatment of atopic eczema (atopic dermatitis). *J Eur Acad Dermatol Venereol.* 2012;26:1176–93 and 1045–60.
- Roberts IF, West M, Ogilvie D, Dillon MJ. Malnutrition in infants receiving cult diets: a form of child abuse. *Br Med J.* 1979;1:296–8.
- Rodriguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell BA, Heather J. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. *J Allergy Clin Immunol.* 2009;123:1361–70.
- Roduit C, Frei R, Loss G, Büchele G, Weber J, Depner M, Loeliger S, Dalphin ML, Roponen M, Hyvärinen A, Riedler J, Dalphin JC, Pekkanen J, von Mutius E, Braun-Fahrländer C, Lauener R, Protection Against Allergy–Study in Rural Environments study group. Development of atopic dermatitis according to age of onset and association with early-life exposures. *J Allergy Clin Immunol.* 2012;130:130–6.
- Roelofzen JHJ, Aben KKH, Oldenhof UTH, Coenraads P-J, Alkemade HA, van de Kerkhof PCM, van der Valk PGM, Kiemeneij LALM. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. *J Invest Dermatol.* 2010;130:953–61.
- Rokugo M, Tagami H, Usuba Y, Tomita Y. Contact sensitivity to *Pityrosporum ovale* in patients with atopic dermatitis. *Arch Dermatol.* 1990;126:627–32.
- Romanos M, Gerlach M, Wamke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. *J Epidemiol Community Health.* 2010;64:269–73.
- Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. *Photodermatol Photoimmunol Photomed.* 2008;24:19–23.
- Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol.* 2003;111(2):389–95.
- Rosenwasser L, Klemm D, Dresback J, Inamura H, Mascali J, Klinnert M, Borish L. Promoter polymorphism in the chromosome 5 gene cluster in asthma and atopy. *Clin Exp Allergy.* 1995;25 Suppl 2:74–8.
- Rost GA. Allergische Disposition und Status exsudativus. *Klin Wochenschr.* 1929;8:2009–13.
- Rost GA, Marchionini A. Asthma-Ekzem, Asthma-Prurigo und Neurodermitis als allergische Hautkrankheiten. *Würzb Abh Gesamtgeb Prakt Med.* 1932;27:10.
- Rothenberg ME, Klion AD, Roufousse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser L, Ring J, Griffin EF, Haig AE, Frewer PIH, Parkin JM, Gleich G. Treatment of patients with the hyper-eosinophilic syndrome with mepolizumab. *N Engl J Med.* 2008;358:1215–28.
- Ruzicka T. Atopic eczema between rationality and irrationality. *Arch Dermatol.* 1998;134:1462–9.
- Ruzicka T, Ring J. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema. *Acta Derm Venereol.* 1987;67:469–75.
- Ruzicka T, Ring J, Przybilla B, editors. Handbook of atopic eczema. 1st ed. Berlin/Heidelberg/New York: Springer; 1991. p. 429–34.
- Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S. A short-term trial of tacrolimus ointment for the treatment of atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. *N Engl J Med.* 1997;337(12):816–21.
- Rycroft RJG, Menné T, Frosch PJ, Benezra C. Textbook of contact dermatitis. 1st ed. Berlin: Springer; 1991.
- Rysted I. Work-related hand eczema in atopics. *Contact Dermatitis.* 1985;12:164–71.
- Rystedt I. Prognosis factors in atopic dermatitis. *Acta Dermatol Venereol.* 1985;65:206–13.
- Rystedt I. Long-term follow-up in atopic dermatitis. *Acta Dermatol Venereol [Suppl].* 1986;114:117–20.
- Sakaguchi S, Wing K, Miyara M. Regulatory T cells – a brief history and perspective. *Eur J Immunol.* 2000;37 Suppl 1:S116–23.
- Salob SP, Laverty A, Atherton DJ. Bronchial hyper-responsiveness in children with atopic dermatitis. *Pediatrics.* 1993;91:13–6.
- Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. *J Allergy Clin Immunol.* 2001;107:891–6.
- Sampson HA. The evaluation and management of food allergy in atopic dermatitis. *Clin Dermatol.* 2003;21:183–92.
- Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. *Ach Dermatol.* 2012;148:890–7.
- Sandstrom MH, Faergemann J. Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study. *Br J Dermatol.* 2004;150:103–10.
- Santamaria Babi LF, Picker LJ, Perez Soler MT, Drzimalla K, et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. *J Exp Med.* 1995;181:1935–40.
- Sanz ML, Maselli JP, Gamboa PM, Garcia-Aviles MC, Oehling A, Diéguez I, de Weck AL. Flow-cytometric basophil activation test. A review. *J Investig Allergol Clin Immunol.* 2002;12:143–54.
- Sapolsky RM. Stress, the aging brain, and the mechanisms of neuron death. Cambridge, MA: MIT Press; 1992.
- Sasagawa S. Studies on the dry form of eczema in childhood patchy pityriasisiform lichenoid eczema (Kitamura-Takahashi-Sasagawa) *Jpn. J Dermatol.* 1967;77:62–87.
- Saunders SP, Moran T, Floudas A, Wurlod F, Kaszlikowska A, Salimi M, Quinn EM, Oliphant CJ, Núñez G,

- McManus R, Hams E, Irvine AD, McKenzie AN, Ogg GS, Fallon PG. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. *J Allergy Clin Immunol.* 2015;pii: S0091-6749(15)01022-2. doi:10.1016/j.jaci.2015.06.045. [Epub ahead of print].
- Saurat JH. Eczema in primary immune deficiencies. Clues to the pathogenesis of atopic dermatitis with special reference of the Wiskott-Aldrich syndrome. *Acta Derm Venereol.* 1985;114:125–8.
- Saurat J-H, Woodley D, Helfer N. Cutaneous symptoms in primary immunodeficiencies. *Curr Probl Dermatol.* 1985;13:50–91.
- Sawada E, Yoshida N, Sugiura A, Imokawa G. Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanisms in atopic dermatitis. *J Dermatol Sci.* 2012;68:25–35.
- Saxon A, Diaz-Sánchez D. Air pollution and allergy: you are what you breathe. *Nat Immunol.* 2005;6:223–6.
- Schadewaldt H. Geschichte der Allergie. Bände 1–4, Munich: Düstri; 1980–1984.
- Schaefer J, Rustenbach SJ, Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. *Dermatology.* 2008;217:169–72.
- Schaeckel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. *Immunity.* 2002;17:289.
- Schäfer T. Evidence-based Medicine (EBM) und Allergie-Prävention. Gibt es Evidenzbasierte Empfehlung-lungen zur Prävention allergischer Krankheiten? *Allergo J.* 2002;11:312–9.
- Schäfer T, Ring J. The possible role of environmental pollution in the development of atopic dermatitis. In: Williams HC, editor. *Atopic dermatitis.* Cambridge: Cambridge University Press; 2000. p. 155–68.
- Schäfer T, Przybilla B, Ring J, Kunz B, Greif A, Überla K. Manifestation of atopy is not related to patients' month of birth. *Allergy.* 1993;48:291–4.
- Schäfer T, Vieluf D, Behrendt H, Krämer U, Ring J. Atopic eczema and other manifestations of atopy: results of a study in East and West Germany. *Allergy.* 1996;51:532–9.
- Schäfer T, Dirschedl P, Kunz B, Ring J, Überla K. Maternal smoking during pregnancy and lactation increases the risk for atopic eczema in the offspring. *J Am Acad Dermatol.* 1997a;36:550–6.
- Schäfer T, Nienhaus A, Haupt G, Vieluf D, Nagel S, Berger J, Ring J. Befunde der Hautuntersuchung und allergologischen Diagnostik. In: *Epidemiologische Untersuchungsprogramm Bille-Siedlung, Behörde für Arbeit, Gesundheit und Soziales (BAGS) der Freien und Hansestadt Hamburg (Hrsg.), Bd. 1.* Frankfurt/Berlin/Bern/New York/Paris/Wien: Peter Lang; 1997b.
- Schäfer T, Vieluf D, Berger J, Ring J. Epidemiologie von Insektengiftallergien. *Allergo J.* 1997c;6:4–6.
- Schäfer T, Heinrich J, Wjst M, Krause C, Adam H, Ring J, Wichmann HE. Indoor risk factors of atopic eczema in school children from East Germany. *Environ Res.* 1999;81:151–8.
- Schäfer T, Staudt A, Ring J. Entwicklung des Deutschen Instruments zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH). *Hautarzt.* 2001;52:492–8.
- Schäfer T, Riehle A, Wichmann HE, Ring J. Alternative medicine in allergies – prevalence, patterns of use, and costs. *Allergy.* 2002;57:694–700.
- Schäfer T, Krämer U, Behrendt H, Ring J. Epidemiologie des atopischen Ekzems. *Allergo J.* 2003a;12:430–8.
- Schäfer T, Ruhdorfer S, Weigl L, Wesner D, Heinrich J, Döring A, Wichmann HE, Ring J. Intake of unsaturated fatty acid and HDL cholesterol levels are associated with manifestations of atopy in adults. *Clin Exp Allergy.* 2003b;33:1360–7.
- Schäfer T, Borowski C, Diepgen T, et al. Evidenz-basierte und konsentrierte Leitlinie "Allergieprävention". *Allergo J.* 2004a;13:252–60.
- Schäfer T, Hölscher B, Ring J, Wichmann E, Heinrich J. Worm infestations reduce the risk for atopic eczema. *Allergo J.* 2004b;13:527–30 [in German].
- Schäfer T, Merkl J, Klemm E, Wichmann HE, Ring J. We and our pets: allergic together? *Acta Vet Hung (Separatum).* 2008;56:153–61.
- Schauber J, Dorschner RA, Coda AB, Büchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. *J Clin Invest.* 2007;117:803–11.
- Schauber J, Gallo RL. Antimicrobial peptides and the skin immune system. *JACL.* 2008;122:261–6.
- Scheewe S, Warschburger P, Clausen K, Skusa-Freemann B, Petermann F. *Neurodermitis-Verhaltenstrainings für Kinder, Jugendliche und Eltern.* Munich: MMW-Quintessenz; 1997.
- Schempp C, Emde M, Wölfl U. Dermatology in the Darwin anniversary. Part 1: evolution of the integument. *J Dtsch Dermatol Ges.* 2009;7:750–8.
- Scheynius A, Johansson C, Buentke E, Zargari A, Linder MT. Atopic eczema/dermatitis syndrome and Malassezia. *Int Arch Allergy Immunol.* 2002;127:161–9.
- Schlaud M, Atzpodien K, Thierfelder W. Allergic diseases. Results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2007;50:701–10.
- Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wüthrich B. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). *Allergy.* 2001;56:841–9.
- Schmid-Grendelmeier P, Fischer B, Wüthrich B. IgE to *Malassezia furfur*/M. symposiumalis. A serologic marker for the atopic eczema/dermatitis syndrome? *Allergy Clin Immunol Int.* 2002;14:140–2.

- Schmid-Grendelmeier P, Doe P, Pakenham-Walsh N. Tele dermatology in sub-Saharan Africa. *Curr Probl Dermatol.* 2003;32:233–46.
- Schmidt T, Abeck D, Boeck K, Mempel M, Ring J. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. *Acta Derm Venereol.* 1998;78:318–9.
- Schmidt-Ott G, Kuensebeck HW, Jaeger B, Werfel T, Frahm K, Ruitman J, Kapp A, Lamprecht F. Validity study for the stigmatisation experience in atopic dermatitis and psoriasis patients. *Acta Derm Venereol.* 1999;79:443–7.
- Schmidt-Ott G, Burchard R, Neiderauer HH, Lambrecht F, Kuensebeck HW. Stigmatisation and quality of life of patients with psoriasis and atopic dermatitis. *Hautarzt.* 2003;54:852–7.
- Schminke LF, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M, et al. Diagnostic approach to the hyper-IgE syndrome: immunologic and clinical key findings to differentiate hyper-IgE syndrome from atopic dermatitis. *J Allergy Clin Immunol.* 2010;126:611–7.
- Schmitt J, Meurer M, Klön M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema – a population-based study. *Br J Dermatol.* 2007a;158:351–9.
- Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol.* 2007b;21:606–19.
- Schmitt J, Csotonyi F, Bauer A, Meurer M. Determinants of treatment goals and satisfaction of patients with atopic eczema. *J Dtsch Dermatol Ges.* 2008;6:458–65.
- Schmitt J, Romanos M, Pfennig A, Leopold K, Meurer M. Psychiatric comorbidity in adult eczema. *Br J Dermatol.* 2009a;161:878–83.
- Schmitt J, Romanos M, Schmitt NM, Meurer M, Kirch W. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. *JAMA.* 2009b;301:724–6.
- Schmitt J, Kirch W, Meurer M. Effects of the introduction of the German “Praxisgebühr” on outpatient care and treatment of patients with atopic eczema. *J Dtsch Dermatol Ges.* 2009c;7:879–87.
- Schmitt J, Apfelbacher C, Chen CM, Romanos M, Sausenthaler S, Koletzko S, Bauer CP, Hoffmann U, Krämer U, Berdel D, von Berg A, Wichmann HE, Heinrich J. Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study (German Infant Nutrition Intervention plus). *J Allergy Clin Immunol.* 2010;125:404–10.
- Schmoeckel C, von Liebe V. [Acneiform exanthema caused by azathioprine] (Article in German). *Hautarzt.* 1983;34:413–5.
- Schneider I, Harangi F, Sebök B. Clinical and pathological aspects of atopic dermatitis. Budapest: Akademiai Kiado; 2011.
- Schnopp C, Ring J. Therapiestrategien bei atopischem Ekzem. *J Med.* 2003;3/4:16–20.
- Schnopp C, Holtmann C, Stock S, et al. Topical steroids under wet-wrap dressings in atopic dermatitis – a vehicle-controlled trial. *Dermatology.* 2002;204:56–9.
- Schnopp C, Grosch J, Ring J, Ollert M, Mempel M. Microbial allergen-specific IgE is not suitable to identify the intrinsic form of atopic eczema in children. *J Allergy Clin Immunol.* 2008;121:267–9.
- Schnuch A, Uter W, Reich K. Allergic contact dermatitis and atopic eczema. In: Ring J, Przybilla B, Ruzicka T, editors. *Handbook of atopic eczema.* 2nd ed. Berlin/New York/Tokio: Springer; 2006. p. 178–201.
- Schnyder UW. Neurodermitis – Asthma – Rhinitis. Eine genetisch-allergologische Studie. *Suppl ad Acta Genetica et Statistica* vol 10; *Int Arch Allergy.* 1960;17: (keine Seitenangabe).
- Schnyder UW, Borelli S. Neurodermitis constitutionalis sive atopica. In: Miescher G, Storck H, editors. *Entzündliche Dermatosen I, Handbuch der Haut- und Geschlechtskrankheiten, vol. 2/1.* Berlin/Heidelberg/New York: Springer; 1962. p. 228.
- Schnyder UW, Klunker W. Über das phänotypische familienpathologische Verhalten der Atopien. *Hautarzt.* 1957;8:510–1.
- Schoenecker I, Grübl A, Bartels P, Ulm K, Bauer CP. Klinische Effekte der Allergenreduktion durch Encasing – eine Metaanalyse. *Allergo J.* 2001;10:95–9.
- Schöni MH, Nikolaizik WH, Schöni-Afolter F. Efficacy trial of bioresonance in children with atopic dermatitis. *Int Arch Allergy Immunol.* 1997;112:238–46.
- Schöpf E, Mueller JM, Ostermann T. Stellenwert der adjuvanten Basistherapie bei chronisch-rezidivierenden Hauterkrankungen. *Neurodermitis atopica/Psoriasis vulgaris.* *Hautarzt.* 1995;46:451–4.
- Schram ME, Roekevisch E, Leeftang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *J Allergy Clin Immunol.* 2011;128:353–9.
- Schuh A, Nowak D. Evidence-based acute and long-lasting effects of climatotherapy in moderate altitudes and on the seaside. *Dtsch Med Wochenschr.* 2011;136:135–9.
- Schuh A, Kneist W, Schnizer W, Senn E, Streicher U. Änderungen der Schweiß- und peripheren Durchblutungsregulation. *Hautnah.* 1989;1:57–8.
- Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. *J Am Acad Dermatol.* 1993;28:719–23.
- Schultz Larsen F, Hanifin JM. Secular change in the occurrence of atopic dermatitis. *Acta Derm Venereol Suppl.* 1992;176:7–12.
- Schultz Larsen FV, Holm NV. Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. *Acta Derm Venereol Suppl.* 1985;114:159.
- Schultz Larsen F, Holm NV, Henningsen K. Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. *J Am Acad Dermatol.* 1986;15:487–94.

- Schultz-Larsen F. Atopic eczema. Etiological studies based on a twin population. Dissertation, Legefo-reningens, Copenhagen; 1985.
- Schultze-Werninghaus G. Should asthma management include sojourns at high mountain altitude? *Chem Immunol Allergy*. 2006;91:16–29.
- Schut C, Weik U, Tews N, Gieler U, Deinzer R, Kupfer J. Psychophysiological effects of stress management in patients with atopic dermatitis: a randomized controlled trial. *Acta Derm Venereol*. 2013;93:57–61.
- Schwanitz HJ. Diagnostik und Therapie von Handekzemen. *Dtsch Med Wochenschr*. 1992;117:343–8.
- Seidenari S, Belletti B, Schinri ME. Skin reactivity to sodium lauryl sulfate in patients with respiratory atopy. *J Am Acad Dermatol*. 1996;35:47–52.
- Selye H. A Syndrome Produced by Diverse Nocuous Agents. *Nature*. 1936;113:32.
- Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in wide-spread non-exudative atopic eczema. *Br J Dermatol*. 1992;126:179–84.
- Shenefelt PD. Hypnosis in dermatology. *Arch Dermatol*. 2000;136:393–9.
- Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. *Clin Exp Dermatol*. 2000;25:559–66.
- Siebenwirth J, Lütke R, Remy W, Rakoski J, Borelli S, Ring J. Wirksamkeit von klassisch-homöopathischer Therapie bei atopischem Ekzem. *Forsch Komplement Med*. 2009;16:315–23.
- Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. *Pediatrics*. 2015;135:597–606.
- Silberberg I, Baer I, Rosenthal SA. The role of Langerhans cells in contact allergy. I. An ultrastructural study in actively induced contact dermatitis in guinea pigs. *Acta Derm Venereol*. 1974;54:321–31.
- Silny W, Czarnicka-Operacz M. Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Dermatitis. Ergebnisse einer placebokontrollierten Doppelblindstudie. *Allergologie*. 2006;29:171–83.
- Simon FA. The allergen of human dander present in the skin of the general body surface. *J Invest Dermatol*. 1947;9:329–32.
- Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. *Allergy*. 2003;59:561–70.
- Simon D, Hösl S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. *J Allergy Clin Immunol*. 2008;121:122–8.
- Simon D, Bieber T. Systemic therapy of atopic dermatitis. *Allergy*. 2014;69:46–55.
- Simons E. Drug therapy. Advances in H1-antihistamines. *N Engl J Med*. 2004;351:2203–17.
- Simons FER, Johnston L, Simons KJ. Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. *Pediatr Allergy Immunol*. 2000;11:116–9.
- Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *J Allergy Clin Immunol*. 2014;134:818–23.
- Skudlik C, Schöne D, Disch R. Klimatherapie. *Allergologie*. 1999;22:12–4.
- Skudlik C, Weisshaar E, Wulfhorst B, et al. Multi-Center-Studie “Medizinisch-Berufliches Rehabilitationsverfahren Haut – Optimierung und Qualitätssicherung des Heilverfahrens (ROQ)” – Konzeption und Einbindung in das Stufenverfahren Haut. *J Dtsch Dermatol Ges*. 2009;7:122–6.
- Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nat Genet*. 2006;38:337–42.
- Sokel B, Kent CA, Lansdown R, Atherton D, Glover M, Knibbs J. A comparison of hypnotherapy and biofeedback in the treatment of childhood atopic eczema. *Contemp Hypnosis*. 1993;10:70–5.
- Sonkoly E, Muller A, Lauerma AI, Pivarski A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B. IL-31: a new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol*. 2006;117:411–7.
- Soumelis V, Liu YJ. Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. *Springer Semin Immunopathol*. 2004;25:325–33.
- Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, Scheewe S, Scheidt R, Schmid-Ott G, Schnopp C, Szczepanski R, Werfel T, Wittenmeier M, Wahn U, Gieler W. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. *BMJ*. 2006;332:933–8.
- Stachow R. Neurodermitis (atopische Dermatitis) Leitlinie der Fachgesellschaft Rehabilitation in der Kinder- und Jugendmedizin. AWMF-Leitlinie – Register Nr. 070/005, letzte Überarbeitung; 2002.
- Stalder JF, Sourisse M. La dermatite atopique et l’infection staphylococcique. *Ann Dermatol Venereol*. 1989;16:341–5.
- Stalder JF, Fleury M, Sourisse M, et al. Comparative effects of two topical antiseptics (chlorhexidine vs KMnO4) on bacterial skin flora in atopic dermatitis. *Acta Derm Venereol Suppl*. 1992;176:132–4.
- Stalder F, Taïeb A, ETFAD. Severity scoring of atopic dermatitis: the SCORACD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology*. 1993;186:23–31.
- Stalder JF, Bernier C, Ball A, De Raevé L, Gieler U, Deleuran M, Marcoux D, Eichenfield LF, Lio P, Lewis-Jones S, Gelmetti C, Takaoka R, Chiaverini C, Misery L, Barbarot S, Oriented Patient-Education Network in Dermatology (OPENED). Therapeutic patient education in atopic dermatitis: worldwide experiences. *Pediatr Dermatol*. 2013;30(3):329–34.
- Ständer M. Ein neuer Weg der Psoriasisbehandlung: Die Thermalsole Phototherapie (TSPT). *Dtsch Derm*. 1976;36:149–53.

- Ständer S, Zeidler C, Magnolo N, Raap U, Mettang T, Kremer AE, Weisshaar E, Augustin M. Clinical management of pruritus. *J Dtsch Dermatol Ges.* 2015;13:101–15.
- Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, Augustin M. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. *Dermatology.* 2010;221:229–35.
- Stangier U. *Hautkrankheiten und körperdysmorphe Störung. Fortschritte der Psychotherapie.* Göttingen: Hogrefe; 2001.
- Stangier U, Gieler U, Ehlers A. Autogenes Training bei Neurodermitis. *Z Allgemeinmed.* 1992;68:392–400.
- Stangier U, Gieler U, Ehlers A. *Neurodermitis bewältigen. Verhaltenstherapie, dermatologische Schulung, autogenes Training.* Berlin: Springer; 1996.
- Stauder A, Kovacs M. Anxiety symptoms in allergic patients: Identification and risk factors. *Psychosom Med.* 2003;65:816–23.
- Staudt A, Ring J, Schäfer T. Deutsches Instrument zur Erfassung der Lebensmittelqualität bei Hauterkrankungen (DIELH) – Analyse nach Erkrankungsgruppen und Domänen. *Allergo J.* 2002;11:445–6.
- Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov S, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. *J Neurosci.* 2003;23:6176–80.
- Steinke M, Fiocchi A, Kirchlechner V, et al. Perceived food allergy in children in 10 European nations. A randomized telephone survey. *Int Arch Allergy Immunol.* 2007;143:290–5.
- Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's translation). *Dtsch Med Wochenschr.* 1974;99:2386–92.
- Stiftung Warentest (Hrsg.). *Handbuch Die andere Medizin. Nutzen und Risiken sanfter Heilmethoden.* Berlin: Stiftung Warentest; 1994.
- Stingl G, Wolff-Schreiner EC, Pickler WJ, Gschnait F, Knapp W, Wolff K. Epidermal Langerhans cell bear Fc and C3 receptors. *Nature.* 1977;268:245.
- Stingl G, Katz SI, Klement L, Green I, Shevach EM. Immunological functions of Ia bearing epidermal Langerhans cells. *J Immunol.* 1978;121:2005–13.
- Storm van Leeuwen W, Bien Z, Varekamp H. Über die Hautreaktion mit Extrakten menschlicher Kopfhautschuppen bei allergischen Krankheiten. *Klin Wochenschr.* 1926;5:1023–5.
- Strachan DP. Hay fever, hygiene, and household size. *BMJ.* 1989;299:1259–60.
- Strachan DP. Allergy and family size: a riddle worth solving. *Clin Exp Allergy.* 1997;27:235–6.
- Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) preclinical pharmacologic profile and skin selectivity. *Semin Cutan Med Surg.* 2001;20:233–41.
- Suárez AL, Feramisco JD, Koo J, Steinhoff M. Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. *Acta Derm Venereol.* 2012;92:7–15.
- Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C, Krueger Y, Guttman-Yassky E. Intrinsic atopic dermatitis shows similar Th2 and higher Th17 immune activation compared with extrinsic atopic dermatitis. *J Allergy Clin Immunol.* 2013;132:361–70.
- Suetonius Gaius Tranquillus. *De vita caesarum. Libri VIII.* Ihm M, editor. Editio minor. Stuttgart: Teubner; 1958.
- Sugiura H, Maeda T, Uehara M. Mast cell invasion of peripheral nerve in skin lesions of atopic dermatitis. *Acta Derm Venereol.* 1992;90:613–22.
- Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. *J Invest Dermatol.* 1952;19:101–2.
- Sun XD, You Y, Zhang L, Zheng S, Hong Y, Li J, Gao XH. The possible role of TRPC6 in atopic dermatitis. *Med Hypotheses.* 2012;78:42–4.
- Susitaival P, Hannuksela M. The 12-year prognosis of hand dermatosis in 896 Finnish farmers. *Contact Dermatitis.* 1995;32:233–7.
- Synnerstad I, Fredrikson M, Ternesten-Bratel A, Rosdahl I. Low risk of melanoma in patients with atopic dermatitis. *J Eur Acad Dermatol Venereol.* 2008;22(12):1423–8. doi:10.1111/j.1468-3083.2008.02888.x. Epub 2008 Aug 14.
- Szczepanowska J, Reich A, Szepletowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. *Pediatr Allergy Immunol.* 2008;19:614–8.
- Szczepanski R, Gebert N, Hümmelink R, Könnig J, Schmidt S, Runde B, Wahn U. Ergebnis einer strukturierten Asthmaschulung im Kindes- und Jugendalter. *Pneumologie.* 1996;50:544–8.
- Szentivanyi A. The beta adrenergic theory of the atopic abnormality in bronchial asthma. *J Allergy.* 1968;42:203–32.
- Szentivanyi A, Heim O, Schultze P, Szentivanyi J. Adrenoceptor binding studies with 3 H (dihydroalprenolol) and 3 h (dihydroergocryptine) on membranes of lymphocytes from patients with atopic disease. *Acta Derm Venerol (Stockh).* 1980;92:19–21.
- Tada T. Regulation of reaginic antibodies information in animals. *Prog Allergy.* 1975;19:122.
- Tada T, Kubo S, Nakayama T. Self-tolerance: multiple strategies for peripheral unresponsiveness of T cell. In: Ring J, Behrendt H, Vieluf D, editors. *New trends in allergy IV.* Berlin/New York: Springer; 1997. p. 359–64.
- Taïeb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. *Contact Dermatitis.* 1999;41:177–80.
- Taïeb A, et al. *Dermatite atopique.* In: Wallach D, Tilles G, editors. *Histoire de la Dermatologie en France.* Toulouse: Privat; 2002.

- Talbot FB. Eczema in childhood. *Med Clinics North Am.* 1918;1:985–6.
- Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. *Lancet.* 1996;347:15–8.
- Tan HT, Ellis JA, Koplin JJ, Matheson MC, Gurrin LC, Lowe AJ, Martin PE, Dang TD, Wake M, Tang ML, Ponsonby AL, Dharmage SC, Allen KJ. Filaggrin loss-of-function mutations do not predict food allergy over and above the risk of food sensitization among infants. *Allergy Clin Immunol.* 2012;130:1211–3.
- Tanaka Y, Anan S, Yoshida H. Immunohistochemical studies in mite antigen-induced patch test sites in atopic dermatitis. *J Dermatol Sci.* 1990;1:361–8.
- Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. *Br J Dermatol.* 2009;161:1217–24.
- Temime P, Oddeze L. La chéilite exfoliatrice et la pulpité digitale keratosique craquelée récidivante peuvent être des manifestations atopiques. *Bull Soc Fr Dermatol Syphiligr.* 1970;77:150–6.
- Tengvall Linder M, Johansson C, Scheynius A, Wahlgren C. Positive atopy patch test reactions to *Pityrosporum orbiculare* in atopic dermatitis patients. *Clin Exp Allergy.* 2000;30:122–31.
- Terada N, Hamano N, Maesako KI, et al. Diesel exhaust particulates upregulate histamine receptor mRNA and increase histamine-induced IL-8 and GM-CSF production in nasal epithelial cells and endothelial cells. *Clin Exp Allergy.* 1999;29:52–9.
- Terhoorst D, Kalali BN, Ollert M, Ring J, Mempel M. The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. *Am J Clin Dermatol.* 2010;11:1–10.
- Tey HL, Yosipovitch G. Itch in ethnic populations. *Acta Derm Venereol.* 2010;90:227–34.
- Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, Flohr C, Hijnen D. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. *Curr Opin Allergy Clin Immunol.* 2015;15(5):453–60. doi:10.1097/ACI.0000000000000198.
- Thoma K. Topical vehicles: composition, principles of application and action. In: Ruzicka T, Ring J, Przybilla B, editors. *Handbook of atopic eczema.* Berlin/Heidelberg/New York: Springer; 1991. p. 364–74.
- Thomas KS, Dean T, Gilbert C, Sach TH, Koller K, Frost A, Williams HC; the SWET Trial Team. A randomized controlled trial of ion-exchange water softeners for the treatment of eczema in children (ISRCTN: 71423189). *PLoS Med* 2011;8:e1000395.
- Thum D, Seidl HP, Hein R, Ring J, Andres C, Mempel M. Current resistance patterns of *Staphylococcus aureus* towards topical antibiotics and relevant antiseptics in patients with atopic dermatitis and impetigo. *J Dtsch Dermatol Ges.* 2013;11:875–8.
- Thyssen JP, Carlsen BC, Johansen JD, Meldgaard M, Szeeci PB, Stender S, Menné T. Filaggrin null-mutations may be associated with a distinct subtype of atopic hand eczema. *Acta Derm Venereol.* 2010;90:528.
- Thyssen JP. The association between filaggrin mutations, hand eczema and contact dermatitis: a clear picture is emerging. *Br J Dermatol.* 2012;167:1197–8.
- Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. *J Dermatol Sci.* 2010;58:1–7.
- Traidl-Hoffmann C, Mariani V, Hochrein H, et al. Pollen-associated phytoprostanes inhibit dendritic cell IL12 production and augment helper type II cell polarization. *J Exp Med.* 2005;201:627–36.
- Traidl-Hoffmann C, Münster I, Ring J, Behrendt H. Impact of desloratadine on the crosstalk between human keratinocytes and leukocytes: implications for anti-inflammatory activity of antihistamines. *Int Arch Allergy Immunol.* 2006;140:315–20.
- Traidl-Hoffmann C, Jakob T, Behrendt H. Determinants of allergenicity. *J Allergy Clin Immunol.* 2009;123:558–66.
- Trautmann A, Akdis M, Kleemann D, Altnauer F, Simon HU, Graeve T, Noll M, Bröcker EB, Blaser K, Akdis CA. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. *J Clin Invest.* 2000;106:25–35.
- Troncone R, Merrett TG, Ferguson A. Prevalence of atopy is unrelated to presence of inflammatory bowel disease. *Clin Allergy.* 1988;18(2):111–7.
- Tudhope SJ, Catley MC, Fenwick PS, et al. The role of I[κ]B Kinase 2, but not activation of NF[κ]B, in the release of CXCR3 ligands from IFN- γ -stimulated human bronchial epithelial cells. *J Immunol.* 2007;179:6237–45.
- Tuft LA. Importance of inhaled allergen in atopic dermatitis. *J Invest Dermatol.* 1949;12:211–9.
- Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. *J Allergy Clin Immunol.* 1996;97:1064–70.
- Turpenen M. Absorption of hydrocortisone from the skin reservoir in atopic dermatitis. *Br J Dermatol.* 1991;124:358–60.
- Überla K, Dirschedl P, Gries A, Kunz B, Letzel H, Oed I, Ring J, Schotten K, Stickl H, Vogl-Voswinckel AE. Die Innenraumbelastung mit SO₂ und NO_x, allergische Symptome und die Keimbesiedelung der Gaumenmandeln bei 5-6-jährigen. Projektbericht der Arbeitsgruppe “Gesundheitsmonitoring in der Oberpfalz”. Inst. f. Med. Informationsverarbeitung, Biometrie und Epidemiologie, Munich; 1988
- UCB, Institute of Allergy. Allergic diseases as a public health problem. Brussels: European Allergy White Paper; 1997.
- Uehara M. Infraorbital fold in atopic dermatitis. *Arch Dermatol.* 1981;117:627–9.
- Uehara M. Clinical and histological features of dry skin in atopic dermatitis. *Acta Derm Venereol.* 1985;114:82–6.
- Uehara M, Kimura C. Descendant family history of atopic dermatitis. *Acta Derm Venereol.* 1993;73:62–3.

- Uehara M, Ofuji S. Patch test reaction to human dander in atopic dermatitis. *Arch Dermatol.* 1976;112:151–4.
- Uehara M, Sawai T. A longitudinal study of contact sensitivity in patients with atopic dermatitis. *Arch Dermatol.* 1989;125:366–8.
- Uehara M, Amemiya T, Arai M. Atopic cataracts in a Japanese population. *Dermatologica.* 1995;170:180.
- Uehara M, Sugiura H, Omoto M. Paternal and maternal atopic dermatitis have the same influence on development of the disease in children. *Acta Derm Venereol.* 1999;79:235.
- Undre NA, Moloney FJ, Ahmadi S, Stevenson P, Murphy GM. Skin and systematic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol.* 2009;160:665–9.
- Urbach E. *Klinik und Therapie der allergischen Krankheiten.* Wien: Maudrich; 1939.
- Valenta R, Seiberler S, Natter S, Mahler V, Mossabeh R, Ring J, Stingl G. Autoallergy: a pathogenetic factor in atopic dermatitis? *J Allergy Clin Immunol.* 2000;105:432–7.
- Van Bever HP, Docx M, Stevens WJ. Food and food additives in severe atopic dermatitis. *Allergy.* 1989;44:588–94.
- van den Bogaard EH, Bergboer JG, Vonk-Bergers M, van Vlijmen-Willems IM, Hato SV, van der Valk PG, Schröder JM, Joosten I, Zeeuwen PL, Schalkwijk J. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. *J Clin Invest.* 2013;123(2):917–27.
- van Leeuwen S. *Allergische Krankheiten, Asthma Bronchioli, Heufieber, Urticaria und Andere.* Berlin: Springer; 1926.
- Van Reijssen FC, Buijnzeel-Koomen CA, Kalthoff FS, et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. *J Allergy Clin Immunol.* 1992;90(2):184–93.
- Vandenplas Y, Hauser B, van den Borre C, et al. The long-term effect of a partial whey hydrolysate formula on the prophylaxis of atopic disease. *Eur J Pediatr.* 1995;154:488–494.
- Vanslow NA, Yamate M, Adams MS, Callies Q, Arbor A. The increased prevalence of atopic diseases in anhidrotic congenital ectodermal dysplasia. *J Allergy.* 1970;45:302–9.
- Verbov J. Juvenile plantar dermatosis (JPD). *Acta Derm Venereol Suppl.* 1989;144:153–4.
- Verbov J, Hart A. Severe varicella in a child with atopic eczema and ichthyosis. *Practitioner.* 1986;230:15–6.
- Vercelli D. Discovering susceptibility genes for asthma and allergy. *Nat Rev Immunol.* 2008;8:169–82.
- Verhagen J, Akdis M, Traidl-Hoffmann C, Schmid-Grendelmeier P, Hijnen DJ, Knol EF, Behrendt H, Blaser K, Akdis C. Absence of T-regulatory cell expression and function in atopic dermatitis skin. *Allergy Clin Immunol.* 2006;117:1176–83.
- Verhoef CM, van Roon JA, Vianen ME, Buijnzeel-Koomen CA, Lafeber FP, Bijlsma JW. Mutual antagonism of rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance. *Ann Rheum Dis.* 1998;57:275–80.
- Verhoeven EW, de Klerk S, Kraaimaat FW, van de Kerkhof PC, de Jong EM, Evers AM. Biopsychosocial mechanisms of chronic itch in patients with skin diseases: a review. *Acta Derm Venereol.* 2008;88:211–8.
- Vickers CF. The natural history of atopic eczema. Its incidence and course. *Acta Derm Venereol (Stockh).* 1980;92:113–5.
- Vickers CFH. The natural history of atopic eczema. *Acta Derm Venereol Suppl (Stockh).* 1989;92:113–5.
- Vieluf D, Korting HC, Braun-Falco O, Belohradsky BH. Eczematous skin lesions in X-linked immunodeficiency with hyper-IgM. In: Fritsch P, Schuler G, Hintner H, editors. *Immunodeficiency and skin, Current problems in dermatology*, vol. 18. Basel: Karger; 1989. p. 60–5.
- Vieluf D, Kunz B, Bieber T, Przybilla B, Ring J. “Atopy patch test” with aeroallergens in patients with atopic eczema. *Allergo J.* 1993;2:9–12.
- Vieluf D, Wieben A, Ring J. Oral provocation tests with food additives in atopic eczema. *Int Arch Allergy Immunol.* 1999;118:232–3.
- Vieths S, Holzhauser T, Erdmann S, et al. Neue Deklarationspflicht für Nahrungsmittelallergene in Lebensmitteln – Stellungnahme der Arbeitsgruppe Nahrungsmittelallergie der Deutschen Gesellschaft für Allergologie und Klinische Immunologie und des Ärzteverbandes Deutscher Allergologen. *Allergo J.* 2006;15:114–23.
- Vigo PG, Gircis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. *J Am Acad Dermatol.* 2006;55(1):168–70.
- Vocks E, Borelli S, Rakoski J. Climatotherapy in atopic dermatitis. *Allergologie.* 1994;17:208–13.
- Vocks E, Borelli S, Busch R, Dtingemann H, Ring J. Biometrische Studie zur Wetterabhängigkeit und Wetterempfindlichkeit beim atopischen Ekzem. *Acta Dermatol.* 2002;28:363–9.
- von Berg A, Koletzko S, Gruebl A, et al. The effect of hydrolysed cow’s milk formula for allergy prevention in the first year of life: The German Infant Nutritional Intervention Study, a randomized double-blind trial. *J Allergy Clin Immunol.* 2003;111:533–40.
- von Berg A, Filipiak-Pittroff B, Krämer U, et al. Preventive effect of hydrolyzed infant formula persists until age 6 years: Long-term results from the German Infant Nutritional Intervention Study (GINI). *Allergy Clin Immunol.* 2008;121:1442–7.
- Von Buboff D, Bausinger H, Matz H, Koch S, Hacker G, Takikawa O, Bieber T, Hanau D, de la Salle H. Human epidermal langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. *J Invest Dermatol.* 2004;123:298.
- von Ehrenstein OS, von Mutius E, Ili S, Baumann L, Bohm O, von Kries R. Reduced risk of hay fever and asthma among children of farmers. *Clin Exp Allergy.* 2000;30:187–90.

- von Eiff AW. Psychologie und Klinikstress. *Therapiewoche*. 1984;34:S7192–6.
- Von Hertzen L, Haahtela T. Prevention of allergic diseases. In: Pawankar R et al., editors. *Allergy frontiers: therapy and prevention*. Berlin/New York/Tokio: Springer; 2010. p. 447–64.
- Von Kobyletzki G, Freitag M, Herde M, Hoxtermann S, Stucker M, Hoffmann K, Altmeyer P. Photo-therapy of atopic dermatitis: comparison between conventional UVA1 phototherapy, UVA1 cold light phototherapy and combined UVA-UVB phototherapy. *Hautarzt*. 1999;50(1):27–33.
- von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. *Nat Rev Immunol*. 2010;10:861–86.
- von Mutius E, Martinez FD, Fritzsche C, et al. Prevalence of asthma and atopy in two areas of West and East Germany. *Am J Respir Crit Care Med*. 1994a;49:358–64.
- von Mutius E, Martinez FD, Fritzsche C, Nicolai T, Reitmeir P, Thiemann HH. Skin test reactivity and number of siblings. *Br Med J*. 1994b;308:692–5.
- von Mutius E, Weiland SK, Fritzsche C, Duhnen H, Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. *Lancet*. 1998;351:862–6.
- von Mutius E, Braun-Fahrlander C, Schierl R, Riedler J, Ehlermann S, Maisch S, Waser M, Nowak D. Exposure to endotoxin or other bacterial components might protect against the development of atopy. *Clin Exp Allergy*. 2000;30:1230–4.
- Von Pirquet C. *Allergy*. *MunchMed Wschr*. 1906;30:1457–8.
- von Sonnenburg F, Perona P, Schunk M, Sbornik M, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Rösch S, Baedeker N, Sobek V, Chaplin P. Safety and immunogenicity of the third generation smallpox vaccine IMVAMUNE® (MVA-BN®) in atopic dermatitis patients. (in prep).
- Voorhoorst R, Spieksma-Boezeman MIA, Spieksma FTM. Is a mite (*Dermatophagoides* sp.) the producer of the housedust allergen? *Allergie Asthma*. 1964;10:329–34.
- Vouch-Jourdain M, Barbarot S, Taïeb A, Diepgen T, Ambonati M, Durosier V, Sibaud V, Stalder JF. Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. *Dermatology*. 2009;218:246–51.
- Waersted A, Hjorth N. *Pityrosporum orbiculare* – a pathogenic factor in atopic dermatitis of the face, scalp and neck? *Acta Derm Venereol Suppl*. 1985;114:146–8.
- Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. *Br J Dermatol*. 1990;122(4):545–51.
- Wahn U, von Mutius E. Childhood risk factors for atopy and the importance of early intervention. *J Allergy Clin Immunol*. 2001;107:567–74.
- Wahn U, Wichmann HE. *Spezialbericht Allergien: Gesundheitsberichterstattung des Bundes*. Stuttgart: Statistisches Bundesamt; 2000. p. 1–147.
- Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hulstsch T, Graeber M, Cherill R, de Prost Y, for the Flare Reduction in Ekzema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics*. 2002;110:1–8.
- Waite DA, Eyles EF, Tonkin SI, O'Donnell TV. Asthma prevalence in Tokelauan children in two environments. *Clin Allergy*. 1980;10:71–5.
- Wakita H, Ohkuro M, Ishii N, Hishinuma I. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves. *Exp Dermatol*. 2015;24:215–6.
- Wallach D, Taïeb A, Tilles G, editors. *Histoire de la dermatite atopique*. Paris: Masson; 2004.
- Walzer M. Studies in absorption of undigested proteins in human beings: I. A simple direct method of studying the absorption of undigested protein. *J Immunol*. 1927;14:143–74.
- Wandtke F, Stanek KW, Götz M, Jarisch R. Bioresonanz – Allergietest versus Pricktest und RAST. *Allergologie*. 1993;16:144–5.
- Wang B, Rieger A, Kilgus O, Ochiai K, Maurer D, Födinger D, Kinet J, Stingl G. Epidermal Langerhans cells from normal human skin bind monomeric IgE via FcεRI. *J Exp Med*. 1992;175:1353–65.
- Wang JJ, Hsieh WS, Wu KY, Guo YL, Hwang YH, Jee SH, Chen PC. Effect of gestational smoke exposure on atopic dermatitis in the offspring. *Pediatr Allergy Immunol*. 2008;19:580–6.
- Warndorff JA. The response of sweat gland to acetylcholine in atopic subjects. *Br J Dermatol*. 1970;83:306 ff.
- Warnecke J, Wendt A. Anti-inflammatory action of pale sulfonated shale oil (ICHTHYOL pale) in UVB erythema test. *Inflamm Res*. 1998;47:75–8.
- Warner JO. Obesity and allergic disease: closely related epidemics of the 21st century. *Pediatr Allergy Immunol*. 2009;20:305–6.
- Warschburger P, Buchholz HAT, Petermann F. Psychological adjustment in parents of young children with atopic dermatitis: which factors predict parental quality of life? *Br J Dermatol*. 2004;150:304–11.
- Watkins CDB. Pityriasis alba: a form of atopic dermatitis. *Arch Dermatol*. 1961;83:915–9.
- Weber A, Lau S, Wahn U. Möglichkeiten und Nutzen der Innenraumallergenanalyse. *Allergo J*. 1997;6:139–44.
- Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. *J Allergy Clin Immunol*. 1997;100(4):536–43.
- Weidinger S, Klopp N, Wagenpfeil S, et al. Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. *J Med Genet*. 2004a;41:658–63.
- Weidinger S, Schäfer T, Malek B, von Schmiedeberg S, Schill WB, Ring J, Köhn FM. Association between atopy and cryptorchidism. *J Allergy Clin Immunol*. 2004b;114:192–3.
- Weidinger S, Klopp N, Rummeler L, Wagenpfeil S, Novak N, Baurecht HJ, et al. Association of NOD1

- polymorphisms with atopic eczema and related phenotypes. *J Allergy Clin Immunol.* 2005;116:177–84.
- Weidinger S, Mayerhofer A, Raemisch R, Ring J, Köhn FM. Prostate-specific antigen as allergen in human seminal plasma allergy. *J Allergy Clin Immunol.* 2006;117(1):213–5.
- Weidinger S, Rodriguez E, Stahl C, et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. *J Invest Dermatol.* 2007;127:724–6.
- Weidinger S, Gieger C, Rodriguez E, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. *PLoS Genet.* 2008a;4:e10001166. Epub 2008 Aug 22.
- Weidinger S, O’Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. *J Allergy Clin Immunol.* 2008b;121:1203–9.
- Weiland SK, von Mutius E, Hirsch T, et al. Prevalence of respiratory and atopic disorders among children in East and West of Germany five years after unification. *Eur Respir J.* 1999;14:862–70.
- Weinberg E, Fourie B, Allmann B, Toerien A. The use of cefadroxil in superinfected atopic dermatitis. *Curr Ther Res Clin Exp.* 1992;52(5):671–6.
- Werfel T. Allergenspezifische T-Zell-Antwort bei Ekzemerkrankheiten. Munich: Dustri-Verlag; 2000.
- Werfel T, Breuer K. Role of food allergy in atopic dermatitis. *Curr Opin Allergy Clin Immunol.* 2004;4(5):379–85.
- Werfel T, Kapp A. T-cells in atopic dermatitis. In: Leung D, Bieber T, editors. *Atopic dermatitis.* St. Louis: Marcel Dekker; 2002. p. 241–66.
- Werfel T, Reese I. *Diätetik in der Allergologie.* 2nd ed. Munich: Dustri; 2009.
- Werfel T, Morita A, Grewe M, et al. Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic lesions of atopic dermatitis. *J Invest Dermatol.* 1996;107:871–6.
- Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multicentre, randomized, dose-response study. *Allergy.* 2006;61:202–5.
- Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rancé F, Turjanmaa K, Worm M. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. *Allergy.* 2007;62(7):723–8.
- Werfel T, Aberer W, Augustin M, et al. Leitlinie Neurodermitis. AWMF reg. 013/027 AWMF online 2008,
- Werfel T, Erdmann S, Fuchs T, et al. Vorgehen bei vermuteter Nahrungsmittelallergie bei atopischer Dermatitis. *Allergo J.* 2008b;17:476–83, (AWMF Leitlinienregister Nr. 061/010, www.awmf-online.de).
- Werfel T, Lotte C, Scheewe S, Staab D, editors. *Manual Neurodermitisschulung.* Munich/Orlando: Dustri; 2008c.
- Werfel T, Aberer W, Augustin M, et al. Neurodermitis S2-Leitlinie. *J Dtsch Dermatol Ges.* 2009;7:s1–46.
- Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A, Erpenbeck VJ, Lösche C, Jung T, Krug N, Badorrek P, Hohlfeld JM. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. *J Allergy Clin Immunol.* 2015;136(1):96–103.e9. doi:10.1016/j.jaci.2015.04.015. Epub 2015 Jun 1.
- Weymayr C, Heissmann N. *Die Homöopathie-Lüge – so gefährlich ist die Lehre von den weißen Kügelchen.* Munich: Piper; 2012.
- Whitfield A. On the white reaction (white line) in dermatology. *Br J Dermatol.* 1938;50:71–82.
- Whitlock A. *Psychophysiologic aspects of skin disease.* Toronto: Saunders; 1976.
- Wichmann HE, Schlipkötter HW, Füllgraf G, editors. *Handbuch der Umweltmedizin, 3 Bände, 18. Ergänzungslieferung.* Landsberg: Ecomed; 1995–2000.
- Wiesenaue M, Gaus W, Häussler S. *Behandlung der Pollinosis mit Galphimia glauca.* *Allergologie.* 1990;13:359–63.
- Wilhelm KP, Scholermann A. Efficacy and tolerability of a topical preparation containing 10 % urea in patients with atopic dermatitis. *Akt Dermatol.* 1998;24(1–2):26–30.
- Wilkinson JD. Fusidic acid in dermatology. *Br J Dermatol.* 1998;139 Suppl 53:37–40.
- Willan R. *On cutaneous diseases.* London: Johnson; 1808.
- Williams HC, editor. *Atopic Dermatitis. The epidemiology, causes and prevention of atopic eczema.* Cambridge, UK: Cambridge University Press; 2000.
- Williams HC. *Clinical practice. Atopic dermatitis.* *N Engl J Med.* 2005;352:2314–24.
- Williams HC, Wüthrich B. The natural history of atopic dermatitis. In: Williams HC, editor. *Atopic dermatitis. The epidemiology, causes and prevention of atopic eczema.* Cambridge, UK: Cambridge University Press; 2000. p. 41–59.
- Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJA, Bingham EA, Finlay AY, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. *Br J Dermatol.* 1994a;131:383–96.
- Williams HC, Burney PGJ, Hay RJ, Strachan D, Hay RJ. The U.K. working party’s diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. *Br J Dermatol.* 1994b;131:397–405.
- Williams HC, Pembroke AC, Forsdyke H, Boodoo G, Hay RJ, Burney GJ. London-born black Caribbean children are at increased risk of atopic eczema. *J Am Acad Dermatol.* 1995;32:212–7.
- Williams HC, Burney PG, Pembroke AC, Hay RJ. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. *Br J Dermatol.* 1996;135:12–7.
- Winge MCG, Bilcha KD, Liedén A, Shibeshi D, Sandilands A, Wahlgren C-F, McLean WHI, Nordenskjöld M,

- Bradley M. Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis. *Br J Dermatol*. 2011;165:1074–80.
- Wise F, Sulzberger MB. Editor's remarks. In: *Yearbook of dermatology and syphilology*. Chicago: Year Book Medical; 1933.
- Wistokat-Wülfing A, Schmidt P, Darsow U, Ring J, Kapp A, Werfel T. Atopy patch test reactions are associated with T-lymphocyte mediated allergen-specific immune responses in atopic dermatitis. *J Allergy Clin Immunol*. 1998;101:196–7.
- Wohlrab W. Bedeutung von Harnstoff in der externen Therapie. *Hautarzt*. 1989;40(Suppl IX):35–41.
- Wohlrab W. Neurodermitis und Harnstoff. *Hautarzt*. 1992;43(Suppl XI):1–4.
- Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. *J Invest Dermatol*. 1996;106:446.
- Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. *J Allergy Clin Immunol*. 2001;107:219–525.
- Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. *J Allergy Clin Immunol*. 2003a;112:667–74.
- Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. *J Am Acad Dermatol*. 2003b;49(2):198–205.
- Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M. Proactive treatment of atopic dermatitis in adults with 0.1 % tacrolimus ointment. *Allergy*. 2008;63:742–50.
- Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai S, et al. EITAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol*, in press.
- Wong RC, Fairley JA, Ellis CN. Dermographism: a review. *J Am Acad Dermatol*. 1984;11:643–52.
- Woodfolk JA, Wheatley LM, Piyasena RV, Benjamin DC, Platts-Mills TAE. Trichophyton antigens associated with IgE antibodies and delayed type hypersensitivity: Sequence homology to two families of serine proteinases. *J Biol Chem*. 1998;273:29489–96.
- Worm M, Ehlers I, Sterry W, Zuberbier T. Clinical relevance of food additives in adult patients with atopic dermatitis. *Clin Exp Allergy*. 2000;30:407–14.
- Worm M, Forschner K, Lee HH, Roehr CC, Edenharter G, Niggemann B, Zuberbier T. Frequency of atopic dermatitis and relevance of food allergy in adults in Germany. *Acta Derm Venereol*. 2006;86(2):119–22.
- Wright RJ. Stress and atopic disorders. *J Allergy Clin Immunol*. 2005;116:1301–6.
- Wüthrich B. Zur Immunpathologie der Neurodermitis constitutionalis. Bern: Huber; 1975.
- Wüthrich B. Neurodermitis atopica sive constitutionalis. Ein pathogenetisches Modell aus der Sicht des Allergologen. *Aktuel Dermatol*. 1983;9:1–7.
- Wüthrich B. Neurodermitis atopica. *Wien Med Wochenschr*. 1989;139:156–65.
- Wüthrich B, editor. *The atopy syndrome in the third millennium*. Basel: Karger; 1999a.
- Wüthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. *Ann Allergy Asthma Immunol*. 1999b;83:464–70.
- Wüthrich B. Epidemiologie der Allergien in der Schweiz. *Ther Umsch*. 2001;58:253–8.
- Wüthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (“extrinsic”) and the nonallergic 8 “intrinsic”) AEDS. *J Invest Allergol Clin Immunol*. 2003;13:1–5.
- Wüthrich B, Schnyder UW. Eine wenig bekannte Ausdrucksform der Neurodermitis atopica: Das patchy pityriasiform lichenoid eczema (“Kitamura-Takahashi-Sasagawa”). *Akt Dermatol*. 1981;7:85–7.
- Wüthrich B, Frei PC, Bircher A, et al. Bioresonanz – diagnostischer und therapeutischer Unsinn. *Allergologie*. 2006;29:244–9.
- Wüthrich B, Schmid-Grendelmeier P, Schindler C, Imboden M, Bircher A, Zemp E, Probst-Hensch N and the SAPALDIA team: prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population. *Int Arch Allergy Immunol*. 2013;162:143–8.
- Yaghmaie B, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2013;131:428–33.
- Yamaguchi J, Aihara M, Kobayashi Y, Kambara T, Ikezawa Z. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. *J Dermatol Sci*. 1991;53:48–54.
- Yamamoto M, Haruna T, Ueda C, Asano Y, Takahashi H, Iduhara M, Takaki S, Yasui K, Matsuo Y, Arimura A. contribution of itch-associated scratch behavior to the development of skin lesions in Dermatophagoides farina-induced dermatitis model in NC/Nga mice. *Arch Dermatol Res*. 2009;301:739–46.
- Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. *J Am Acad Dermatol*. 2001;44(1):89–93.
- Yang Q. Acupuncture treatment of 139 cases of neurodermatitis. *J Tradit Chin Med*. 1997;17:57–8.
- Yin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. *J Invest Dermatol*. 2009;129:31–40.
- Yosipovitch G, Bernard JD. Chronic pruritus. *N Engl J Med*. 2013;368:126–63.
- Young SH, Rubin JM, Daman HR, editors. *Psychobiological aspects of allergic disorders*. New York: Praeger; 1986.

- Yun JW, Seo JA, Young WH, Koh HJ, Bae IH, Part YH, Lim KM. Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models. *J Invest Dermatol.* 2011;131:1576–9.
- Zachariae H, Cramers M, Herlin T, Jensen J, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. *Acta Derm Venereol Suppl.* 1985;114:48–54.
- Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchian V, Weidinger S, Mempel M, Ring J, Ollert M. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. *Acta Derm Venereol.* 2015. doi:10.2340/00015555-2165.
- Zollner TM, Wichelhaus TA, Hartung A, et al. Colonization with superantigen-producing *Staphylococcus aureus* is associated with increased severity of atopic dermatitis. *Clin Exp Allergy.* 2000;30:994–1000.
- Zuberbier T, Edenharter G, Worm M, et al. Prevalence of adverse reactions to food in Germany – a population study. *Allergy.* 2004;59:338–45.
- Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Giménez-Arnau A, Godse K, Gonçalves M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M, European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum, World Allergy Organization. The EAACI/GA(2)LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. *Allergy.* 2014;69:868–87.
- Zurbriggen B, Wüthrich B, Cachelin AB, Wili PB, Kägi MK. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. *Dermatology.* 1999;198:56–60.

Index

A

- Absence, 24, 25, 49–51, 74, 109, 120, 176
Acid mantle, 82–83, 124
Acrodermatitis enteropathica, 51
Acupuncture, 163, 164, 166, 167
Acute flare, 125–129, 141, 150, 151, 171
Acute therapy, 107, 126, 127, 140, 142, 143
Acyclovir, 57, 140
Adhesion factor, 97
Adrenergic, 5, 46, 100, 101, 105, 106, 159
Adstringentia, 148
Adult, 4, 9, 12–18, 23, 24, 31, 32, 34, 35, 37, 41, 50–54, 56, 61, 62, 64, 70, 102, 105, 106, 114, 115, 118, 126, 127, 144, 153
Aeroallergen, 12, 31, 108, 109, 111, 118–119, 127, 153, 170
Affection, 23, 102, 104
Air pollutant, 21, 84, 170–172
Airway disease, 19, 83, 108, 175, 176, 181
Alcohol, 117, 118, 121–123, 126, 136, 142, 147, 148, 171
Alefacept, 156
Allergen avoidance, 116, 172
Allergen dilution, 109
Allergen exposure, 10, 14, 23, 169, 170
Allergen extract, 95, 109, 113
Allergic diathesis, 6
Allergy, 1–6, 9–11, 14, 18, 20–22, 24, 33, 35, 37, 50, 52, 53, 55, 56, 62, 63, 74, 76, 89, 93, 95, 96, 100, 101, 104–106, 109–116, 119–121, 126, 130, 131, 138, 143, 147, 153, 155, 159, 164
Allergy burden, 23–25
Allergy diagnosis, 107, 108, 113, 114
Allergy protective factors, 172
Allergy risk, 169, 171
Alopecia areata, 54
Alternative procedures, 151, 152
Ammonium bituminosulfonate, 148
Anaphylaxis, 6–8, 18, 55, 63, 92, 114, 115, 140, 151, 171
Androgens, 18, 106
Angulus infectiosus, 33
Animal dander allergy, 119
Anthroposophic medicine, 165
Antibiotics, 133, 135, 137–140, 143, 154, 166, 171
Antibody, Monoclonal, 155–157
Anti-CD20-Antibody, 156–157
Antiemetics, 143
Antigen recognition, 88, 96
Antihistamines, 94, 127, 129, 140–143, 147, 149, 160
Anti-IgE-antibody, 54, 155–156
Anti-IL 4-R-antibody, 157
Anti-Interleukin 5, 157
Antimetabolite, 153
Antimicrobial, 83, 97, 124, 137–140, 148, 153
Antimycotic, 133, 137, 139–140, 143, 154
Antipruritic, 126–128, 135, 143–150, 153, 154, 160
Antiseptic, 113, 137–140
Anti-T-cell strategy, 156
Anti-TNF strategy, 156
Anxiety, 100–102, 104, 105
APT. *See* Atopy patch test (APT)
Arousal, emotional, 142
Arrhythmia, 142–143
Arthritis rheumatoid, 61, 63, 154, 156, 157
ASIT. *See* Immunotherapy, Allergen-specific
Association study, genome wide, 77
Astemizol, 142, 143
Asthma bronchiale, 7, 8
Atopic disease, 1, 2, 4, 5, 7, 8, 10, 12, 15, 18, 20–23, 45, 48, 54, 56, 60, 61, 63, 64, 69–71, 76–78, 87, 89, 94, 96, 109, 117, 119, 158, 169, 171
Atopic winter feet, 33, 36
Atopy, 4–9, 16–19, 21–23, 42–48, 52, 55, 57, 60–65, 69–72, 74–77, 84, 89, 90, 100, 107–109, 112, 114, 119, 170, 171
Atopy fold, 44–46, 48
Atopy ointment, 126
Atopy patch test (APT), 57, 63, 84, 85, 88, 90, 92, 94, 98, 109–113, 115, 116, 118, 120, 151
Atopy risk, 21, 69
Atrophy, 129–132, 134
Autoantibodies, 95–96, 145
Autogenic training, 160, 161
Autoimmune disease, 49, 92, 155–157
Autoimmune phenomenon, 13
Autonomic disturbance, 5, 6, 46, 47, 87, 100–101, 106
Avoidance, 21, 52, 95, 113, 114, 116–122, 169–175, 178, 181
Avoidance recommendation, 119
Axon reflex, 141
Azathioprine, 154, 155

B

Baby food, hypoallergenic, 20, 118, 121, 169, 173–174
 Bach flower therapy, 164, 166
 Bacterial, 57, 58, 63, 76, 98, 99, 137, 158
 Balneo PUVA therapy, 150, 151
 Bamboo hair, 52, 82
 Basic therapeutics, 20, 125, 147, 175
 Basic therapy, 20, 119, 121–126, 135, 137, 160
 Basophil activation, 114
 Bath ingredients, 125–126
 B-cell, 86, 89, 90, 92, 95, 106, 156
 Behavioral change, 107, 131
 Behavioral therapy, 160–162
 Besnier, 3, 31
 Beta blockade, 6
 Bioresonance, 163, 164, 166, 167
 Birbeck granule, 87, 88
 Bleach bath, 124, 138
 Blue (flower), 163
 Blue (light), 149, 150
 Blue (patches), 53
 Body mass index, correlation, 173
 Breast milk, 172, 173
 Bufexamac, 147, 148
 Burden, socioeconomic, 23–25

C

Calcineurin inhibitor, topical (TCI), 126–128, 133, 135–137, 147, 149
Candida infection, 33, 53, 57, 92, 96, 98, 140
 Candidate gene, 71, 75, 76
 Cannabinoid agonists, 126, 147, 149
 Capsaicin, 146, 147
 Casein hydrolysate, 173, 174
 Cataract, 56, 131
 Cat keeping, 21, 74, 96, 109, 111, 113, 118–120, 170, 171
 CD63, 114
 CD1a, 75, 88
 CD4+ cells, 89–90, 92
 CD 8 + cells, 89, 91–92
 Cell extract, 166
 Cells, 6, 17, 42, 50, 51, 53, 61, 63, 71, 75, 76, 79–81, 85–101, 105, 106, 111, 112, 114, 129, 135, 136, 140, 141, 143, 147, 150–152, 154–158, 166, 169, 170
 Cheilitis sicca, 33, 34, 42, 61
 Chemokines, 51, 71, 76, 91, 94, 96, 157–158
 Chlorhexidine, 137–139
 Cholinergic, 5, 46, 100, 105, 106, 141, 142
 Chronic inflammatory, 9
 CLA. *See* Cutaneous lymphocyte antigen (CLA)
 Climate change, 10, 14
 Climate therapy, 118, 150, 163, 167, 175–177
 Clioquinol, 137, 138, 140
 Coal tar, 148
 Colonization, microbial, 87, 91, 137
 Colorings, 115, 119, 137, 138
 Combination effects, 137

Communication therapy, 161
 Competence, social, 162
 Complication, 27, 51, 56–60, 63, 75, 99, 131–132
 Conditioning, 99, 120, 161
 Contact allergen, 113
 Contact allergy, 6, 35, 37, 50, 56, 63, 89, 90, 109–111, 113, 116, 131, 147
 Contact dermatitis, allergic, 38, 49, 50, 53, 55, 63, 88, 89, 111, 113, 155, 165
 Contact sensitization, 74, 139
 Coombs classification, 5, 6
 Corneocyte, 75, 80–82
 Corneodesmosome, 80–82
 Corneometer, 83
 Cornified envelope, 81
 Corticoderm, 132
 Cortisone, 6, 113, 130, 131, 134, 164
 Costs of disease, 23–25, 175
 Cotinin, 21, 84
 Cradle cap (crusta lactea), 40
 Cream, 118, 122–127, 136, 142, 147, 149, 150, 162, 181
 Crohn, 62, 156, 157
 Cromoglycate, 143
 Cross-reaction, 51, 96
 Crusta lactea (s. Cradle cap), 40
 Crusting, 29, 31, 65
 Cure, 15, 131, 162, 175
 Cutaneous lymphocyte antigen (CLA), 91
 Cyclosporin A, 135, 153–156
 Cystatin A, 82
 Cytokine cluster, 76
 Cytokines, 76, 79, 80, 87, 89, 91–96, 111, 135, 144, 152, 154–158, 170
 Cytomegalovirus infection (CMV), 60

D

Davos climate, 118, 149, 176, 177
 DC. *See* Dendritic cells (DC)
 Defense mechanisms, 97
 Definition, 4, 6–8, 13, 17, 69, 112
 Delayed blanch reaction, 44, 47, 100
 Delayed type hypersensitivity (DTH), 85, 87, 89, 156
 Dendritic cells (DC), 76, 80, 85, 87–92, 96, 98, 111, 112, 150, 151
 Dennie-Morgan atopy fold, 17, 44–46, 48
 Dentition, 53
 Dermatitis, 1–7, 11–15, 17, 19, 25, 27–30, 32–67, 69–77, 81, 83–109, 111–121, 123–127, 129–136, 139, 140, 142–148, 151–153, 155–165, 167, 170, 172–178, 181
 Dermatomyositis, 49, 51, 157
Dermatophagoides pteronyssinus, 51, 111, 113, 118, 119
 Dermatophyte, 98, 140
 Dermatoses, 27, 35, 52, 56, 89
 Dermographism, white, 44, 47, 48, 52, 53, 64, 100
 Desensitization, 161
 Desmosome, 80, 82
 Desquamation, 82, 83
 Detergent, 117, 118, 124, 138

- Diabetes mellitus, 23, 61, 63, 131
 Diagnostic criteria, 5, 15, 63–67
 Diagnostics, 5, 14, 42, 107–109, 114–116, 126, 162, 164, 177, 181
 Diaper Dermatitis, 48, 49
 Diary, 115, 116, 161
 Diathesis, 4, 6, 42, 48, 52, 65, 70, 114
 Diet, 20, 25, 52, 116, 118, 120, 121, 164, 167, 169, 172, 174
 Differential diagnoses, 11, 12, 35, 37, 38, 48–54, 56, 108
 Differentiation complex, epidermal (EDC), 71, 72, 74, 77
 Dirty neck, 37, 42
 Distraction techniques, 161
 Dog allergy, 21, 95, 96, 118, 120, 170, 171
 Dog keeping, 21, 170, 171
 Dose, 98, 111, 132–133, 141, 143, 147, 149–151, 153–157
 Dry, 2, 4, 33, 34, 36, 43–44, 48, 52, 64, 65, 74, 75, 77–85, 87, 109, 118, 121, 123–125, 127, 142, 147
 DTH. *See* Delayed type hypersensitivity (DTH)
 Dubowitz syndrome, 49, 52–53
 Dysesthesia, 23, 24, 51, 84, 136, 143
 Dyshidrosis, 33, 37, 50
 Dyshidrosis lamellosa sicca, 33
 Dysplasia, ectodermal, 54
 Dysregulation, autonomic, 6, 47, 76, 86, 87, 100–101
- E**
 Ear piercing, 75, 113, 171
 EBV. *See* Epstein-Barr-Virus (EBV)
 Ecchymosis, 130
 ECP. *See* Eosinophil cationic protein (ECP)
 Eczema
 herpeticum, 51, 57–59, 63, 89, 96, 98, 99, 115, 137, 140, 158
 infantum, 12, 13, 49
 molluscum, 60, 98
 verrucatum, 60, 65, 98
 Eczema Academy, 3, 5, 7
 Eczema flares, 94, 101, 102, 105, 107, 116–118, 125–129, 140–143, 150, 151, 160, 171
 Eczema nail, 33, 36, 38, 44
 Eczema overall, 119
 Eczema school, 2, 106, 107, 117, 162, 167, 177–179
 EDC. *See* Differentiation complex, epidermal (EDC)
 Educational program, 2, 106, 107, 117, 120, 121, 128, 161, 177–179
 Education style, 102, 104
 Efalizumab, 156
 Electroacupuncture, 164, 166
 Elicitor, 104, 119, 146, 167
 Emla, 147
 Emollient, 20, 113, 118, 119, 121, 124–127, 132, 133, 148
 Emulsion, 109, 122–125, 133, 137
 Emulsion bath, 123–125
 Encasing, 119
 Endogenous eczema, 3, 5, 100
 Enteropathy, gluten-sensitive, 55
 Environmental allergen, 5
 Environmental disease, 4
 Eosinophil, 71, 85, 90, 91, 93, 94, 96, 111, 141, 157
 Eosinophil cationic protein (ECP), 94
 Eosinophilia, 52, 53
 Epicutaneous test, 113
 Epidemiology, 1–25
 Epidermis, 2, 20, 29, 44, 72, 74–76, 79–82, 84, 87–89, 94, 97, 100, 104, 111, 122, 124, 125, 130, 136, 148–150
 Epooonychitis sicca, 33
 Epstein-Barr-Virus (EBV), 60
 Erosion, 30, 33, 42, 59, 98
 Erythema, 27, 29, 30, 33, 35, 42, 49, 51, 54, 65, 67, 79, 141, 149
 Erythematous, nummular, 37
 Erythroderma, 15, 38, 42, 51, 82
 E-selectin, 91
 Essential oils, 138
 Etheric, 148
 European task force on atopic dermatitis (ETFAD), 65, 66, 111
 Everolimus, 135
 Exacerbation, 20, 29, 55–57, 60, 94, 98, 105, 108, 111, 112, 114–116, 118, 119, 131, 133, 137, 140, 159, 177
 Excoriation, 30, 31, 33, 37, 43, 65
 Exposure, 7, 10, 14, 21–23, 36, 56, 72, 74, 84, 108, 112, 120, 136, 149, 151, 161, 169–171, 176
 Exposure study, 84
 Exsudative diathesis, 4
 Extensor side eczema, 15, 35, 36, 39, 64, 123
 Extrinsic, 5, 7, 16–18, 70, 74, 76, 88, 92, 112
 Eyebrow, scattering, 44
- F**
 Face, 15, 30, 37, 41, 46, 53, 54, 58, 95, 111, 118, 128, 131, 133, 137, 139, 147
 Factors, prognostic, 16, 22–23
 Family dynamics, 101, 104, 106, 178
 Family history, 101, 104, 106, 178
 Family studies, 69
 Fat, 122
 Fatty acid, unsaturated, 159
 Fibroblast, 80, 91, 135
 Filaggrin, 81–85
 Fine particles, 22, 120, 170–171
 Finger nail dystrophy, 44
 Finger tip eczema, 33, 36
 Finger tip rule, 127, 128
 Fish consumption, 172, 174
 Fissure, 33, 74, 81
 Flexural eczema, 64, 65
 Fold, infraorbital, 44–46, 48
 Food additive, 55, 108, 115, 116
 Food allergen, 12, 55, 56, 109, 113–115, 120
 Food allergy, 24, 52, 53, 55, 74, 114–116, 143, 155, 173

- Food IgG, 164
Foot eczema, 43, 50, 113, 150
Formaldehyde, 84, 85, 118
Foxp3, 92
Fusidic acid, 139
- G**
Gastroenteritis, eosinophil, 55
Gastrointestinal disease, 55
Gender, 18, 19
Gene association, 76, 77
Gene locus, 71, 72, 76–78
Genetics, 2, 4, 6, 9, 18, 21, 52, 53, 55, 69–77, 84, 86, 87, 107, 118, 146, 169, 181
Genital eczema, 35
Genodermatoses, 12, 49
Gentian violet, 137, 138
German Infant Nutritional Intervention Study (GINI) study, 20, 173
Gianotti-Crosti Syndrome, 37
Glucocorticosteroids, 56, 121, 125–137, 139, 141, 147, 149, 153, 165, 175
Glycerol, 125, 126
Graft-versus-host disease, 49, 51
Granuloma gluteale infantum, 131, 133
Grass pollen, 109, 110, 112, 113, 120, 151, 152
- H**
Hair disease, 54
Hair line, temporal, 44, 47, 48
Hair mineral analysis, 164
Halo eyes, 46
Halo periorbital, 44, 46, 48
Hand, 2, 5, 8, 15, 19, 20, 23, 29, 30, 37, 43–45, 48, 59–61, 65, 75, 95, 96, 107, 111, 113, 118, 120, 123, 130, 141, 148, 150, 175, 176
Hand eczema, 37–38, 43, 44, 50, 75, 175
Hanifin-Rajka criteria, 1, 5, 64, 66
Hay fever, 1, 5, 9, 11, 12, 14, 16, 18, 55, 64, 86, 109, 118, 151, 164, 166, 176
Head and neck dermatitis, 57, 98, 139, 140
Head, excoriation, 33
Hereditary, 6, 48, 52, 53, 69, 71
Herpes simplex infection, 57, 140
Herpeticum, eczema, 51, 57, 59, 63, 89, 96, 98, 99, 115, 137, 140, 158
Hertoghe sign, 46
High altitude, 109, 118, 121, 149, 153, 176–177
Histamine, 6, 93, 100, 101, 105, 114, 140, 141, 143, 144, 146, 150, 152, 153, 165, 171
Histamine receptor, 101, 141
Histamine-H 1 antagonists, 142
Histiocytosis X, 51
History, 1–6, 42, 55, 62, 64, 65, 69, 70, 84, 102, 103, 108, 109, 111, 112, 114–116, 122, 148, 159, 164, 169, 174, 175
HIV infection, 60
Homeopathy, 164–167
- Hormone, 18, 105, 106
Hostility, 102
House dust mite, 6, 51, 56, 82, 84, 85, 88, 90, 92, 95, 108, 109, 111, 113, 116, 118, 119, 121, 127, 145, 151–153, 170, 176
House dust mite extract, 109
Humidity, air, 119, 176, 177
Hydrolysate formula, 173
Hygiene hypothesis, 10, 14, 21, 23, 76, 158, 170, 171
Hypereosinophilia syndrome, 52
Hyper-IgE-syndrome, 49, 53–54
Hyperkeratosis, 35, 37
Hyperkeratotic, fissuring, 38
Hyperpigmentation, 34, 37, 42, 46
Hyperreactivity, bronchial, 6, 54, 83, 85
Hypersensitivity, 2, 4–8, 55, 64, 85, 89, 107, 114, 115, 117, 118, 156, 181
Hyposensitisation, 151, 165
- I**
Ichthyol, 125
Ichthyosis, 17, 37, 44, 45, 48, 52, 53, 64, 71–73, 75, 77
Imagination technique, 161
Immediate-type reaction, 5, 57, 98, 114, 115
Immune defect, 92
Immune deviation, 87, 89
Immune response, 17, 20, 76, 79, 87–89, 92, 95, 97, 133, 136, 152
Immune response adaptive, 76
Immune stimulation, 158
Immune system, 4, 10, 12–14, 23, 75, 80, 87, 88, 96, 97, 99, 100, 105, 170
Immuno globulin, 6–8, 60, 86–88, 153, 155, 157
Immunoglobulin E (IgE), 5–10, 15, 17, 18, 23, 48, 49, 51–55, 57, 62, 64, 65, 69–71, 73, 74, 76, 77, 86–89, 92–99, 101, 102, 105, 106, 109, 111, 112, 114–116, 140, 145, 151–156, 169
auto antibody, 95–96, 145
production, 8, 48, 76, 87, 89
receptor, high affinity, 76, 77, 88, 93, 94, 169
Immunopathy, 51
Immunophilin, 135, 153
Immunosuppression, 131, 149, 150, 153, 154
Immunotherapy, allergen specific (ASIT), 151–153, 165
Immuno tolerance, 91
Impetiginisation, 53, 57, 58, 115, 137–139
Impetigo, 49, 51, 57
Individual, 2, 3, 7, 14, 15, 19, 21, 23–25, 27, 42, 47, 50, 54–56, 59, 60, 62, 71, 77, 84, 85, 90, 97, 98, 101, 103, 107, 108, 113, 116–123, 126, 133, 142, 145, 146, 149, 159–162, 166, 167, 170, 172, 174, 175, 178
Indoor airpollutant, 84
Infant formula, 169, 173, 174
Infections, 10, 19, 33, 51–54, 57, 59, 60, 64, 76, 89, 92, 96–99, 104, 105, 108, 115, 131, 136, 138, 140, 171
Infectious disease, 12, 19–23, 51, 98, 166, 171
Infiltrate, inflammatory, 89, 90

- Inflammation, 15, 22, 57, 74, 87, 88, 90, 91, 93–96, 99, 101, 104, 109, 111, 113, 122, 123, 146, 156, 157, 159, 161, 164
- Inflammation marker, 94
- Inflammatory bowel disease, 77
- Inflammatory cell, 17, 96, 105, 135, 141, 147, 157
- Infliximab, 156
- Interdigital eczema, 51–53
- Interferon gamma, 63, 95, 157
- Interleukin 4, 6, 63, 76, 89, 91, 93, 95–97, 157
- Interleukin 5, 76, 89, 93, 94, 96, 157
- Interleukin 10, 89, 93
- Interleukin 31, 91, 95, 96, 144, 146
- Interleukin antibodies, 157, 158
- Intertrigo, retroauricular, 33
- Intestinal microbiome, 158
- Intradermal test, 109
- Intravenous, 57, 127, 129, 140–142, 155, 157
- Intrinsic, 5, 7–9, 16–18, 70, 73, 88, 92, 94, 98, 112
- In vitro allergy diagnostics, 108, 113, 114, 116
- Irritant, 38, 74, 84, 85, 116–118, 121, 161, 171, 175, 176
- Itch diary, 161
- Itch questionnaire, 116, 145
- Itch research, 144–146
- J**
- Jungle hypothesis, 10, 14, 19, 23, 170
- K**
- Kaposi's varicelliform eruption, 57
- Keratin filament, 72, 80, 81
- Keratinocyte, 72, 75, 76, 80–82, 90, 91, 94–97, 129, 135, 144, 145, 147, 154, 158
- Keratoconus, 56, 75
- Keratolytic, 54, 125
- Keratosis follicularis (pilaris), 54
- Ketotifen, 143
- KiGGS study, 9, 12, 62
- Kinesiology, 164, 166–167
- KLK7 mutation, 75
- Knee flexural eczema, 27, 29
- L**
- Lactobacillus, 20, 158
- Langerhans cell, 51, 80, 87–88, 93, 95, 136, 150
- Langerhans histiocytosis, 51
- Late cutaneous reaction, 109
- Leukotriene antagonist, 143
- Lewis triad, 141
- Lichen
 - nitidus, 37
 - planus, 27, 143
 - simplex chronicus, 4, 29, 49, 50
- Lichenification, 15
- Lichenoid, 36–37, 39
- Lid eczema, 31, 34, 45, 51, 56
- Life event, 19, 100, 104, 116, 145, 178
- Life style, 18, 100, 108, 146, 171, 177
- Light dermatosis, polymorphic, 56
- Light sensitivity, 131, 149
- Linear grooves, 44, 45
- Lip, dry, 33, 34
- Lipid layer, 81
- Lip licking eczema, 33
- Lipodystrophy, 132
- Living on a farm, 21
- Living room cleaning, 119
- Local anesthetics, 147
- Lotio, 122
- Lotio Alba, 122, 127
- Lotion, 118, 122, 123, 125, 147, 148
- Lower lip fissure, 34
- Lymphocyte, 80, 85, 87, 88, 91, 92, 94, 95, 101, 106, 111, 114, 135, 154, 156, 157
- Lymphocyte transformation, 114
- Lymphoepithelial Kazal typerelated inhibitor (LEKTI), 52, 75, 82
- M**
- Macrolactams, 135
- Major criteria (Hanifin Rajka), 64
- Malassezia furfur*, 52, 57, 96, 98, 99, 115, 139
- Mamillar eczema, 35, 37
- Marker, 8, 45, 55, 71–77, 88, 89, 92, 94, 96, 107, 114, 117, 156
- Mast cell, 6, 71, 75, 85, 86, 88, 92–94, 99, 106, 112, 135, 140, 141, 143, 150, 154
- Mast cell blocker, 143
- Maturation, 85, 89, 92
- Measles, 19, 136, 171
- Mediator release, 93, 105, 106
- Menthol, 148
- Mepolizumab, 157
- Metabolic disorder, 48
- Methicillinresistant *Staphylococcus aureus* (MRSA), 137–139
- Methotrexate, 154–155
- MHC II molecule, 88
- Minor criteria (Hanifin Rajka), 64
- MIRIAM study, 22
- Mite scabies, 51
- Model learning, 161
- Moisturising factor, 74, 81, 125, 126
- Molecular genetics, 2, 70–72, 76, 77, 107, 169
- Molluscum contagiosum, 60, 140
- Montelukast, 143
- Morbus, 37, 72
- Mother milk, 21, 172
- MRSA. *See* Methicillinresistant *Staphylococcus aureus* (MRSA)
- Mupirocin, 139
- Muscular atrophy, 132
- Music therapy, 178–179
- Mutation, 6, 52–54, 72–77, 81, 82, 85, 92, 95, 169
- MVA vaccine, 20, 97, 98

- Mycophenolate mofetil, 155
 Mycosis, 51, 88
 Mycosis fungoides, 51, 88
- N**
- Naevus, 62
 Nail changes, 44
 Nasal, 33, 46, 97, 115, 139
 Natural moisturizer, 74, 81, 125, 126
 Neck, dirty, 37, 42
 Neck eczema, 37, 42, 98
 Neonatal age, 12, 53, 82
 Nephrotic syndrome, 56
 Nerve fever, 57,
 Nervous system, 5, 46, 77, 87, 99–101, 105, 106, 141, 176, 177
 Netherton syndrome, 49, 52, 53, 71, 75, 77, 82, 136
 Neurodermitis, 3–5, 18, 65, 99, 117, 178
 Neurovegetative, 5
 Neutrophil activation, 89
 New therapy, 2, 155–160, 163
 Nickel allergy, 113
 Nitric oxide, 55
 Node, 59, 80, 86, 88, 100, 150
 Notalgia paresthetica, 147
 N-palmitoyl ethanolamine, 147
 Nummular eczema, 29, 37, 40, 106
 Nutrition, 10, 20, 25, 104, 107, 115, 121, 169–174, 178, 179
- O**
- Obesity, 118, 172
 Occlusion, 127
 Occupational impairment, 23
 Octenidin, 137, 138
 Ocular changes, 56
 Oedema, 2, 24, 29, 34, 46, 56, 65, 67
 Oil, 20–21, 118, 123–126, 138, 148
 Oil bath, 124–126
 Oil in water emulsion, 123
 Ointment, 2, 107, 121–128, 136, 139, 147, 162
 Oligosaccharide, 20, 158, 174
 Omalizumab, 155, 156
 Oozing, 3, 29, 33, 37, 58, 65, 115, 118, 137
 Otitis media, 56
- P**
- Paget, 35, 37
 Pajama, 119, 127
 Pallor facial, 44, 46, 48
 Papiloma virus, human (HPV), 60, 140
 Papule, 27, 29, 31, 33, 39, 51, 54, 65, 131
 Parasites, 10, 79, 82, 89, 170
 Paronychia, 33, 36
 Partner problems, 101
 Patches, 24, 29, 35, 53
 Patch Test, 6, 53, 63, 98, 109–111, 113, 116
 Patchy pityriasisiform lichenoid eczema, 36–37, 39
 Pathogen associated molecular pattern (PAMP), 87
 Pathophysiology, 2, 36, 52, 69–106, 115, 145, 181
 Patient empowerment, 107
 Patient exploration, 159
 Patient information flyer, 2, 116, 118, 130
 Patient management, 107
 Peanut oil, 20–21, 114, 115, 123, 125
 Pemphigoid bullous, 49, 51
 Peptide antimicrobial (AMP), 76, 80, 94–97, 149, 158, 159
 Periorbital shade, 46
 Perlèche, 33
 Personality pattern, 101, 106
 Pertussis vaccination, 19
 Pet keeping, 21, 23, 170, 171, 175
 Petrolatum, 110, 111, 122, 123, 126
 Phase triangle for topical therapy, 121, 123
 Phenylketonuria, 49, 52, 53
 Phosphodiesterase, inhibitors, 159
 Photocarcinogenicity, 136, 154
 Photopheresis, 150–151
 Phototherapy, 149, 151, 156
 pH value, 82, 83, 97, 124
 Phytotherapy, 164–165, 167
 Pimecrolimus, 133, 135–137, 143, 158
 Pitakinra, 157
 Pityriasis
 rubra pilaris, 42
 versicolor, 57, 98
 pityriasis, 35, 36, 38, 42, 57, 98, 136
 Placebo, 115, 142, 151, 152, 159–161, 166
 Plantar dermatosis juvenilis, 35
 Plaque lichenoid, 36, 39
 Plasma cell, 86, 89, 92, 96, 106, 157
 Plasmapheresis, 156
 Point prevalence, 9, 14
 Polidocanol, 125, 127, 147, 149
 Pollen avoidance, 120
 Pollen count, 120
 Pollen exposure, 36, 112, 120
 Pollen filter, 120
 Pollen surface, 22
 Pollutant exposure, 23
 Polyhexanid, 137–139
 Polyunsaturated fatty acid (PUFA), 20, 159, 172, 173
 Polyvidone iodine, 137, 138
 Pompholyx, 38, 50
 Potassium permanganate, 138
 Powder, 121, 123, 143
 Prebiotics, 20, 158, 174
 Predilection, 139
 Pregnancy, 12, 19–21, 23, 108, 130, 143, 146, 155, 158, 166, 170, 172–174
 Prevalence, 1, 2, 9–14, 17, 18, 20–24, 48, 50, 52, 54, 56, 57, 60–63, 70, 73, 84, 89, 95, 119, 124, 136, 170, 171, 173, 174
 Prevention, 2, 20, 21, 28, 98, 107, 118–121, 123, 124, 126, 159, 169–179, 181

Prick test, 17, 109, 112–115, 152
 Primary skin lesion, 4, 27–29, 42, 63
 Probiotics, 20, 158, 171, 172, 174
 Profilaggrin, 72
 Profilometry, 83
 Proinflammatory, 93, 94, 101, 135, 140, 170
 Protease, 52, 75, 77, 81–83, 85, 93
 Protease-activated receptor (PAR)² receptor, 75
 Protease inhibitor, 52, 75, 77, 81–83, 85
 Protein allergen, 7, 17, 110, 111
 Protein contact dermatitis, 55
 Protein kinase inhibitor, 158–159
 Provocation factor, 2, 107, 116–121, 126, 178
 Provocation test, oral, 6, 27, 108, 109, 113–116
 Prurigo, 3, 6, 15, 29, 31, 33, 42, 144, 146, 150
 Psoralen, 149, 150
 Psoriasin, 74
 Psoriasis, 1, 25, 27, 38, 49, 50, 55, 63, 66, 71, 72, 74, 88, 89, 97, 104, 144, 145, 148, 149, 154–158, 176
 Psychological, 99–106, 109, 115–116, 118, 124, 145, 159, 160, 162, 178, 181
 Psychopharmaceuticals, 143, 146, 160
 Psychosomatic, 16, 18–19, 23, 35, 99, 104, 105, 115, 145, 146, 159–163, 167, 177, 178, 181
 Psychotherapy, 160
 Pulpitis sicca, 33, 36
 Purpura, thrombocytopenic, 53, 157
 PUVA, 149–151

Q
 Quality control, 175, 178, 179
 Quality of life (QOL), 1, 23, 31, 116, 143, 145, 175, 178, 179
 Questionnaire, 9, 14, 83, 115, 116, 145

R
 Rapamycin, 135
 Reactivity, 4, 5, 8, 15, 46, 64, 85, 89, 92, 98–101, 106, 110, 142, 152, 156, 159, 176
 Reagin, atopic, 5, 6
 Rebound phenomenon, 132, 154
 Redness, 38, 47, 54, 131
 Reflex erythema, 141
 Regulatory T cell, 90, 92, 96, 101, 150, 155
 Rehabilitation, 25, 118, 175, 177
 Relaxation technique, 160, 161, 163, 167, 178
 Repair activity, 84
 Respiratory, 5, 7, 15, 16, 19, 21, 23, 33, 45–48, 52–54, 57, 60, 63, 70, 76, 83, 84, 95, 96, 114, 143
 Rhinoconjunctivitis, allergic, 46, 54, 56, 63, 118
 Risk group, 169, 174
 Rituximab, 156
 Rodents, 120
 Rosacea like perioral dermatitis, 131, 133, 134, 136

S
 Saline, 119, 146, 151
 Scabies, 35, 37, 49, 51–53, 144, 145
 Scaling, 29, 30, 35, 37, 38, 40, 42, 43
 School beginner, 28
 Scoring System for Atopic Dermatitis (SCORAD), 5, 29, 65–67, 95, 97, 138, 151–153, 178
 Scratching, 24, 27–29, 33, 37, 42, 45, 49, 50, 87, 95, 101, 109, 118, 127, 144–146, 149, 161
 Scrotal eczema, 35, 38
 Sea climate, 176
 Sebometer, 84
 Seborrhea, 122
 Seborrheic dermatitis, 12, 13, 48, 49, 52, 53
 Sebostasis, 43, 44, 48, 123
 Sebum production, 43
 Secondary, 27, 46, 53, 74, 86, 144, 171, 174–177
 Sedation, 142
 Self confidence, 1, 104, 162
 Seminal plasma, anaphylaxis, 55
 Sensitisation, 7, 12, 14, 16–18, 22, 65, 74–76, 102, 109, 112, 114–116, 119, 120, 137–139, 147, 151, 153, 174
 Sezary syndrome, 42, 51
 Sharply margined, 34, 40
 Shiny nails, 33
 Shock fragment, 6
 Shoe, 35, 50, 113
 Shower oil, 124, 126
 Side effects, 20, 49, 97, 118, 122, 127, 130–132, 134–137, 141–143, 150, 151, 154–157
 Signal transduction inhibition, 135, 158
 Silver nitrate, 138
 Silver textiles, 138
 Sirolimus, 135
 Skin, 1–9, 11, 14–16, 17, 18, 20, 21, 23–25, 27–33, 35, 37–39, 42–54, 56, 57, 59, 62–66, 69, 72–92, 94–100, 102, 104–109, 111–127, 129–141, 143–145, 147, 151–153, 155, 159–164, 171, 175–179, 181
 Skin associated lymphoid tissue (SALT), 79
 Skin barrier function, 18, 43, 52, 72–74, 81–85, 87, 104, 121–126, 160
 Skin care, 20, 21, 24, 117, 118, 120, 121, 123, 126, 133, 181
 Skin changes, 3, 27–31, 35–37, 39, 42, 45, 46, 49, 51–54, 57, 59, 75, 112, 118
 Skin cleaning, 124, 126, 171
 Skin disease, 1, 3, 9, 11, 23–25, 27, 38, 48–52, 54, 57, 63, 69, 82, 88, 99, 102, 104, 106, 107, 116, 124, 129, 130, 132, 143, 144, 149, 151, 155, 159, 160, 162, 163, 175, 176, 181
 Skin function, 77–85
 Skin roughness, 83, 85
 Skin test, 8, 64, 65, 95, 98, 108, 109, 115, 116, 164
 Skin type, 122, 123, 149
 Sleeplessness, 46
 Smallpox vaccination, 20, 60, 97–99, 140
 Soap, 84, 85, 118, 124

- Socioeconomic status, 18, 23
 Sodium chloride, 124–125
 Sole, hyperlinearity, 44, 45, 48
 Solid food, 172, 174
 Solvent, 64, 84, 117, 118
 SPINK5, 52, 71, 75, 77, 82
 Spreading oil bath, 124
 Staphylococcus aureus, 21, 29, 57, 63, 96, 97
 Steroid, 129–134, 136–139, 153, 154, 177
 Stigma of atopy, 17, 46, 48
 Stigmatisation, 23, 24
 Storage mites, 51, 119
 Stratum, 75, 79–82
 Stratum corneum, 72, 74, 75, 79–85, 96, 104, 125
 Stress, 7, 20, 23, 27–29, 56, 80, 87, 100–106, 108, 116–118, 145, 159–162, 171, 178, 181
 Striae distensae, 130–132
 Substance, vasoactive, 117, 118
 Sulfonates, 124, 125, 148, 149
 Sun allergy, 56
 Superantigen, 15, 91, 97, 99, 117
 Superinfection, 29, 33, 42, 58, 60, 115, 137, 140
 Surfactant, 124
 Sweating, 64, 84, 98, 100
 Symptoms, 7, 8, 11, 19, 27–67, 69, 71, 77, 84, 100–104, 106, 108, 109, 114, 115, 119, 125, 126, 131, 141, 143, 149, 151, 154, 174, 177, 178
 Syndets, 118, 124
 Syndrome of incombable hair, 54
- T**
 Tacrolimus, 135–137
 Tandem therapy, 125, 132, 134
 Tar, 148, 149
 T cell activation, 76, 154, 156
 T cell lymphoma, 42, 51, 53, 150, 151
 T cells, 17, 42, 50, 51, 53, 63, 76, 85–87, 89–92, 96, 97, 101, 111, 114, 135, 150, 151, 154–156, 169, 170
 Tea tree oil, 138
 Teleangiectasia, 130
 Terfenadine, 142
 Terminology, 3–5, 7, 16, 29, 63, 99, 123
 Textile, silver-coated, 138, 139
 Th1 and Th2 concept, 60, 89, 152
 T helper cell, 89, 90, 92
 Therapy, 2, 5, 53, 57, 63, 94, 106, 108, 113, 115, 116, 118, 119, 121–127, 130, 132–144, 146, 149–151, 153–155, 157, 158, 160–164, 166, 167, 175–179, 181
 Thymic stromal lymphopoietin (TSLP), 94, 95
 Thymus and activation regulated chemokine (TARC), 91, 94, 96, 158
 Thymus factor, 166
 TLR agonists, 158
 TNF receptor antagonist, 156
 Tobacco smoke, 10, 21–23, 72, 84, 108, 117, 170–172
 Tolerance development, 12, 167
 Toll-like receptor (TLR), 75, 76, 87, 94, 97, 158
 Topical calcineurin inhibitors (TCI), 126–128, 133, 135–137, 147
 Topicals, 4, 113, 121–144, 146–150, 153, 158, 177
 Toxin, 97
 Traditional Chinese Medicine (TCM), 164–165
 Traffic exposure, 23
 Transforming growth factor β (TGF- β), 89, 92
 Treatment. *See* Therapy
Trichophyton rubrum, 57
 Trichorrhesis invaginata, 52
 Triclosane, 138
 Truck traffic, 21
 Tumor necrosis factor (TNF), 90, 95, 156
 Twin study, 69, 70
 Type I reaction, 5, 63
 Type IV reaction, 89
- U**
 UK working party diagnostic criteria, 15, 64, 66
 Ulerythema ophryogenes, 54
 Unconventional procedures, 163–167, 178
 Unguentum emulsificans aquosum, 126
 Urea, 74, 81, 125, 126, 147, 154
 UV exposure, 56
- V**
 Vaccination, 10, 19, 20, 59–60, 97–99, 133, 136, 140, 166, 171
 Vaccination complication, 59
 Vacuum cleaning, 119, 120
 Vascular dilatation, 105, 141
 Ventilation, 120, 170
 Visual analogue scale (VAS), 65, 145
 Vitiligo, 56
 Volatile organic compounds (VOC), 10, 84, 85, 118, 171
 Vulvar eczema, 38
- W**
 WAO, definition of allergy, 7, 8
 Wart, 60, 65
 Water content, 83
 Water hardness, 124, 171
 Water-in-oil emulsion, 123, 137
 Water loss, transepidermal (TEWL), 43, 74, 83–85
 Weather change, 176, 177
 Wheal, 141
 Wiskott-Aldrich Syndrome, 46, 49, 53
 Wool hypersensitivity, 117
- Z**
 Zinc deficiency, 49, 51
 Zinc lotion, 122